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Abstract 
 
Pharmaceutical cocrystals have an important and influential role in the pharmaceutical 
industry through the formation of substitutional crystalline material to obtain the optimum 
physical properties of an active pharmaceutical ingredient (API) without changing its 
chemical properties. Pyrazinamide is anti-bacterial drug which is used to treat tuberculosis 
that infects the lung tissues. In this thesis, the ability of pyrazinamide to form co-crystals with 
different di-carboxylic acids through the formation of strong hydrogen bonds to form motifs is 
investigated. 
 
 Pyrazinamide cocrystals were synthesised through different methods using a variety of 
different solvents and different starting stoichiometric ratios. New cocrystals were formed 
between pyrazinamide and glutaric acid (1:1), pyrazinamide and adipic acid (4:1), 
pyrazinamide and pimelic acid (1:1), and pyrazinamide and sebacic acid (2:1). In all cases, X-
ray powder diffraction and NMR were used to characterise the new material formed with the 
crystal structures of these materials determined through single crystal X-ray diffraction. The 
crystal structure of a polymorph of azelaic acid was also determined through single crystal X-
ray diffraction analysis following attempted synthesis of a pyrazinamide:azelaic acid 
cocrystal.  
 
Other new products were characterised through X-ray powder diffraction, although further 
structural analysis was not carried out. These include adducts based on pyrazinamide:oxalic 
acid, pyrazinamide:malonic acid, pyrazinamide:maleic acid, pyrazinamide:isonicotinamide, 
nicotinamide:isonicotinamide and isonicotinamide:fumaric acid. Attempts to prepare adducts 
between pyrazinamide with histidine and nicotinamide only resulted in a mixture, as did the 
combination of L-dopamaine with succinic acid. 
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1.  Introduction 
 
1.1  Solid state chemistry   
 
The molecular crystalline solid state is a branch of materials chemistry with a wide range of 
applications that are often combined with crystal and crystallographic sciences
1
. The 
molecular solid state is the study of structure, synthesis and the physical properties of solid 
materials, with a focus on producing new materials based on a knowledge of structure and 
finding improved methods of characterisation
2,3,4
. The structure of a crystalline molecular 
material is important in the determination and understanding of physical properties and the 
role of elemental units or molecules in these materials
5,6
. This branch of chemistry has 
witnessed dramatic developments over the last few decades due to the increased impact on 
industry in the production of new products for larger markets such as pharmaceuticals, 
electronics, ceramics and dyes
6
.  
 
A crystal material is a solid body in which the atoms, molecules or ions are arranged in a 
regular manner such that a repeat unit runs in three-dimensional space
3,7
. Crystallisation is a 
process of formation of these crystals often from solution or a melt form
8
. A crystalline 
structure then enables diffraction to occur and hence the structure and properties of the 
material can be investigated using a crystallographic approach
9
. An amorphous material is a 
solid in which the atoms are not distributed or arranged in a regular distribution network with 
the atoms being arranged randomly without any crystallographic symmetry
3,10,11
. Non-
crystalline materials include glasses, gels, thin films and nanostructured materials
12
. These 
materials often display very different properties when compared to crystalline materials and 
hence can be used in different ways. 
 
In the field of organic solid state materials, crystalline entities can take various solid forms 
based around the compound of interest. These different forms can normally be categorised as 
crystalline or amorphous and whether they are polymorphs, solvates, hydrates, salts or 
cocrystals
3,10,13 
(figure 1.1). 
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Figure 1.1: Classification of organic solid state materials and their components (Taken from 
ref.3). 
 
In terms of crystalline materials, there are number of possible forms. Polymorphism is the 
ability of a solid crystalline material to display more than one crystalline structure or form 
3,14,15
. Despite being of the same chemical composition, polymorphic materials often have 
different physical properties such as solubility, melting point and bioavailability
5,13,16
.
 
This 
means that polymorphism can provide additional opportunities for the application of a 
material, whilst also providing problems in terms of purity control
16
. 
 
Other forms of organic solid materials such as salts, hydrates, solvates and cocrystals are all 
multicomponent crystalline materials
6
. A solvate is a crystalline material that contains solvent 
of crystallisation whilst a hydrate contains water as the solvent of crystallisation within the 
crystal structure framework. These are then also distinct in terms of physical properties from 
the pure anhydrous material. A cocrystal, or salt, also incorporates an additional component in 
the crystal structure and will be discussed in detail later
6
. 
 
1.1.2  Crystal and the pharmaceutical solid state  
 
One of the largest areas of interest for organic materials is in the drug development and solid 
form selection. Organic solid state chemistry plays an important role in this as crystalline 
molecular forms with therapeutic effect are considered an important formulation class of solid 
pharmaceutical materials
4,6,16
. The solid form chosen for an active pharmaceutical ingredient 
(API) affects the therapeutic activity and hence the value of many drugs on the market 
through the differences that formulation can make change to many physical properties such as 
solubility, dissolution, melting point and bioavailability
1-9
. APIs can be classed using the 
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Biopharmaceutical Classification System (BCS)
17 
depending on the solubility and 
permeability of the drug substance. The classification has four areas: (I) high solubility + high 
permeability; (II) low solubility + high permeability; (III) high solubility + low permeability; 
(IV) low solubility + low permeability
17
. 
 
The preferable area for most APIs is class (I) where the drug substance has high solubility and 
high permeability; i.e when the highest dose of the drug is highly soluble in 250 ml of water 
and therefore the bioavailability will be high. In addition, these substances have high level of 
permeability and their absorption rate is usually higher than excretion, for example 
paracetamol, metoprolol. A drug substance is considered to have a poor solubility and 
permeability in class (IV) when  more than 85% of drug substance is insoluble in 250 ml of 
water, is therefore also has poor bioavailability and usually is not well absorbed in the tissue, 
for example bifonazole. There are many physicochemical factors which are affect drug 
absorption including pKa, solubility, stability, particle size, polar-non polar surface area and 
crystal form; physiological factors include the absorption mechanism, gastric empty and 
intestinal transit time
17
. 
 
The Biopharmaceutical Classification System (BCS)
17
 acts as a tool to improve, simplify and 
speed up the drug development process and allows the prediction of the rate limit in the 
intestinal absorption process after oral administration. BCS can be used to characterise the 
drugs for which a drug product may be eligible for bioequivalence studies. The classification 
itself can be used to expand the regulatory application of the BCS and drug discovery and 
recommend methods for classifying drugs
17
. Overall, the BSC is also considered useful in 
saving costs within the drug development procedure. 
 
The solid state form of an active pharmaceutical ingredient (API) can be used to optimise the 
physical properties of the drug product without changing the chemical composition or 
affecting the pharmacological properties
2,6
. Physical properties often depend on amorphous 
form or polymorphic structure
7
 or on the salt/cocrystal form, all of which lead to different 
structures and hence different physical properties to improve the drugs activity
9,18
. New 
pharmaceutical cocrystal preparations provide a potential route to the development of 
innovative drugs from existing API products, and hence the interest in cocrystal research has 
been increased in the last decade due to pharmaceutical applications
2,4,18
. 
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The pharmaceutical ingredients with active coccrystals have different pharmaceutical 
properties and that depending on the second component in the cocrystal. Some of the 
cocrystals exhibit lower or higher melting point with comparison to their pure original 
components for example: The melting points of succinic acid and urea are 135.5 
o
C and 188.9 
o
C respectively while the melting point of the cocrystal of succinic acid-urea is 149.9 
o
C
15
. 
Such a cocrystal would then display the active chemical properties of succinic acid and urea 
individually in solution but in combination with display distinct cocrystal physical properties 
in the solid state
6,18
.
 
 
1.2  Cocrystals and salts 
 
The definition of a cocrystal has been the subject of debate in the scientific literature to reach 
the accepted form of definition
7,10,13,19
. According to Aakeroy, a cocrystal is structural 
crystalline solid material that consists of two or more equal constructing blocks (organic 
molecules that are solid at ambient temperature) that are in stoichiometric amounts
19,20
. 
Cocrystals are already used in many applications including pharmaceuticals, pigments, dyes, 
chemical processing and superconductors. However, one of the most potentially significant 
impacts will be through the
 
increased options for optimum solid form in the pharmaceutical 
industry where formulations are currently limited to salt form only
6,20
.   
 
Cocrystals and salts are both ordered crystalline materials but differ in terms of proton 
transfer between the two molecular components
3,21,22
. Figure 1.2 shows the possibility of 
cocrystal and salt formation between pyrazinamide and a carboxylic acid. If there is no proton 
transfer between the two components, the material formed will be a cocrystal (1) whereas 
proton transfer from the acid to the amide would result in a salt (2) (figure 1.2.). 
 
                             
                                           (1)                                                                          (2) 
Figure 1.2: Schematic example of an organic cocrystal pyrazinamide:carboxylic acid (1) or a 
salt (2). 
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Many crystalline materials are found in salt form in the pharmaceutical industry and these are 
considered as an alternative to cocrystals when the product has easily ionisable positions in 
the active pharmaceutical ingredients
7,23
. Conversely, cocrystals are often considered a vital 
option when no ionisable groups are present. Both cocrystals and salts are important in 
pharmaceutical development as both of them can give the advantages found in                                                                                                                                 
multicomponent structures
6
. There are many drugs on the market in the crystalline salt form 
of an API, such as hydrochloride salts and these are used to optimize the crystallinity, 
solubility and stability of the active pharmaceutical component
6,23
. 
The probability of forming a cocrystal or salt depends on the difference in pKa values of the 
components which indicate if proton transfer is likely between the acid and base coformers
11
. 
If ΔpKa = pKa (base) – pKa (acid) is greater than 2 or 3 in general a salt will be formed, 
whereas if ΔpKa is less than 0 the product is often predicted to be a cocrystal (figure 1.3). The 
prediction of a cocrystal or salt form based on ΔpKa is unreliable if ΔpKa lies between 0 and 
3 
23,24,25
. It is why when ΔpKa is sufficiently large that salt formation is highly likely24.  
 
                                             ΔpKa = pKa (base) – pKa (acid) 
Figure 1.3: The effect of ΔpKa values on cocrystal or salt formation25,26,27. 
 
The value of pKa (base) depends on the dissociation of the base and is constant for a 
particular species as defined as below
28
: 
 
                   BOH (base) B
+
 + OH
-
(salt), Ka (base) = [B
+
] * [OH
-
] / [BOH]; 
                                 pKa (base) = - log10 Ka (base) 
 
The value of pKa  (acid) depends on the dissociation of the acid and is constant for particular 
species as defined as below
28
: 
 
 HA (acid) H
+
 + A
-
 (salt), Ka= [H
+
] * [A
-
] / [HA]; 
                                  pKa = - log10 Ka (acid) 
 
This is a property of an acid or base in solution and describes the behaviour of a molecule in 
the medium. Hence, the extension to solid state is not always reliable, although there is a 
potential link through the nucleation phase and other limitations of some species of a mixed 
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salt and cocrystal when the hydrogen proton be shared between the base and acid or partially 
occupied two sites
25,27
. There are some factors which are affecting on the formation of salt-
cocrystal continuum such as solvent, stoichiometric ratio of coformers and temperature 
28,29,30
. 
                         
The proton location is not always a clear indicator of salt or cocrystal form as the proton can 
be shared across the two sites, not clearly bonded to either the acid or the base. Temperature 
can have an effect on the cocrystal-salt continuum as in the example of pentachlorophenol:4-
methylpyridine
25
. The position of the proton in pentachlorophenol:4-methylpyridine changes 
with temperature; the complex becomes more like a cocrystal at higher temperature as the 
proton moves closer to the oxygen of pentachlorophenol
25
. Neutron diffraction was used to 
locate the position of the hydrogen in between the donor and acceptor. At 20K the N-H and 
O-H distances were 1.208 Å and 1.309 Å respectively showing that the proton had migrated 
away from the phenol and towards the pyridine N, forming a salt. The complex showed a 
higher cocrystal nature at 200K where the N-H and O-H  distances were 1.306 Å and 1.228 Å, 
respectively
25,26
. This proton migration was shown to be a gradual process with the proton 
being  almost central within interaction at a temperature of  80K
25
. 
 
The choice of solvent during synthesis can also have an effect on the proton transfer and 
whether the product forms as either a salt or cocrystal. Different forms can also be produced 
using the same molecular coformers but variation of the stoichiometric ratio of the starting 
materials. In salt-cocrystal the hydrogen proton can partially occupy two sites and the 
physical effects: solvent, temperature and stoichiometric are also have effect for example: 
pentachlorophenol:4-methylpyridine
25
.
 
2,3-lutidine:fumaric acid is an example of a 
combination that can form cocrystal or salt forms through different stoichiometric amounts of 
starting materials
30
. A starting ratio of 1:1 coformers produces a 1:2 salt complex while a 2:1 
cocrystal form is obtained from a 2:1 ratio of starting materials
29,30
. 
 
The formation of a cocrystal or salt is depends on the hydrogen proton position between the 
acid and base which affects the physical properties of the crystal, Aakeroy
21,30
 has shown 
during investigations to materials structural determination of more than 80 crystalline 
materials produced from equal stoichiometric amounts of carboxylic acid and N-heterocycles 
shows that 45% form a salt which is a result of hydrogen proton transfer from the acid to base 
with unexpected stoichiometry compound or solvate included, while 5% form a cocrystal, 
which is result of no hydrogen proton transfer from the acid
21
. The result of 5% cocrystal in 
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the comparison to 45% salt shown positive advantages in structural prediction of cocrystal 
which is much easier than structural prediction of salt through converting carboxylic acid into 
carboxylic anion and that will provide more chances in producing new types of solid forms 
which have significant effect in developing of drugs and the possibility of design prediction in 
the pharmaceutical industry
21,30
. 
 
The first cocrystal to be reported and studied was quinhydrone in 1844 by Friedrich Wohler 
2,19
. The quinhydrone cocrystal consists of the two organic components, quinone and 
hydroquinone. Wohler synthesised this material whilst studying quinine, after mixing quinine 
and hydroquinone to produce a new cocrystal material which was synthesised by grinding a 
1:1 stoichiometric ratio of coformers
19,31
. Quinhydrone has been characterised and analysed 
through various methods during the last decades
19,31
. At the end of the 1800s and early in the 
1900s a variety of cocrystal materials were discovered, but in the absence of modern 
analytical and crystallographic techniques were described as organic molecular compounds. 
More detailed structural information on cocrystals was absent until the 1960s when a group 
began the study of cocrystal formation of 9-methyladenine with 1-methylthymine
32
. In 2009 
the Cambridge structural database (CSD) announced that cocrystals only account for 0.5 % of 
the crystal structure archive
33
. In 2014 the CSD web site published statistical figure shows that 
cocrystals account for more than 0.7 % of the cocrystal structure, so there significant potential 
for many more cocrystals to be discovered
34
. 
 
1.3  Cocrystal design 
 
Cocrystals are often discovered by using screening techniques or by cocrystallisation from 
solution containing the coformer components
33
. The components in cocrystal structures 
normally interact through hydrogen bonding
32
, as formation of strong intermolecular 
interactions between the different molecules enables the production of a multicomponent 
system rather than recrystallisation of individual components
4,9
. The additional interactions 
between the coformer molecules will produce cocrystal structures with specific physical and 
chemical properties which differ from that of the single components
14,33
.  
 
An example of a cocrystal based on a strong molecular synthon is shown below (figure 1.4). 
Succinic acid and urea form a strong hydrogen bond to produce a cocrystal structure of 
succinic acid: urea in a 1:1 ratio
6
. The carboxylic acid group forms a preferential interaction 
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with the amide group in the urea molecule to form an alternative heteromolecular 22R (8) ring 
as shown in (figure 1.4)
6
.
  
This heterosynthon is formed in preference to the combination of 
acid-acid and amide-amide rings that would be produced if the components were 
recrystallized as separate components.   
 
                                                                                                                                                                                    
 
Figure 1.4: Cocrystal structure of succinic acid-urea
6
. 
 
In most cases the combination of two components will not result in the formation of a 
cocrystal and hence the synthon approach is used in the design process to generate new 
cocrystal materials
35
. A synthon is a supramolecular building unit made of multiple molecules 
interacting through a strong and reliable hydrogen bond network
4-6
. The example of the 
succinic acid-urea cocrystal above displays the hydrogen bond synthon commonly found in 
acid-amide cocrystals (figure 1.4)
6,35
.  
 
As mentioned previously, cocrystal synthesis depends on the preferential formation of these 
supramolecular synthons rather than the formation of crystals by the interactions between 
molecules of the individual components. The synthons involved in cocrystal formation of 
acid-amide cocrystals are often based on acid-pyridine (I) (figure 1.5) in combination with 
amide-amide (II), acid-amide (III) or amide-pyridine (IV) depending on the stoichiometry of 
the components. The examples given in Figure 1.5 represent the behaviour that is commonly 
expected in isonicotinamide or nicotinamide with alkanedicarboxylic acid cocrystals
36
. 
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                                                                                                                                                                                (I) 
                                                                                              
                                                                                                                                                                               (II)                                                                                            
                                                                                                                       
(III) 
                                                                                                                                                                 
(IV) 
Figure 1.5: The hydrogen bonding synthons commonly found in acid-amide cocrystals formed 
between isonicotinamide and alkanedicarboxylic acids
36
.     
 
 
 
1.4   Cocrystal synthesis and characterisation 
 
There are a variety of methods employed for the synthesis of cocrystals although in many 
cases, the need for single crystal X-ray diffraction means that full cocrystal analysis requires 
formation by using slow solvent evaporation. This is the traditional method of synthesis and is 
based on slow evaporation from solution containing stoichiometric amounts of the 
components or cocrystal formers required
4,6
.   
 
Although this is the most common synthetic approach, cocrystallisation through solvent 
evaporation often requires the starting materials to have a similar solubility to prevent the 
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recrystallisation of the cocrystal coformers before the crystallisation process
4
. Complete 
dissolution of all starting materials is also needed to enable possible crystallisation of the 
cocrystal. The diagram below (figure 1.6) illustrates the coformer solubility effect on 
cocrystal formation through a ternary phase diagram
9,37
.
  
In figure 1.6,  A shows similar 
solubility between the coformers  related area A,B and D,E to produce cocrystal C in presence 
the solvent F  while ternary phase diagram B shows different solubility between the coformers 
related area A,B and D,E and the production of cocrystal C reduce significantly due to the 
difference in the solubility of coformers  of A,B and D,E in presence the solvent F 
9
.                   
 
                                   (A)                                                          (B) 
Figure 1.6: The crystallisation through solvent evaporation. Diagram (A) shows similar 
solubility between two coformers to form cocrystal, while Diagram (B) shows the different 
solubility between two coformers and the effect on the cocrystal formation. Area A acts as 
coformer 1 with the solvent, area B acts as coformer 1 with cocrystal, area C acts as 
cocrystal, area D acts as coformer 2 with cocrystal, area E acts as coformer 2 with the 
solvent, area F represents the solvent (Adapted from ref.9). 
 
The cocrystallisation  is consider to be another method to synthesis cocrystals, the solvent is 
important in any kind of crystallisation, the intermolecular interaction is change by changing 
solvent then change the solubility profile of components
6
. The crystallisation, by adding 
excess amount of one cocrystal to the former, may lead to the production of cocrystal
38,39
. 
 
1.4.1   Alternative synthesis methods  
 
Grinding
40
 is a common method for cocrystal synthesis and this method does not require the 
need for solvent
40
. Grinding can take the form of either dry or liquid assisted grinding and 
both these techniques have been used in producing cocrystals
41
. In dry grinding the motor and 
pestle are used and the cocrystal formers are mixed together manually inside the motor
37,42
. In 
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liquid assisted grinding (or solvent drop grinding) a small amount of the liquid (solvent) is 
used and added to the components mixture. The technique includes grinding stoichiometric 
amounts of components in presence of small amount of solvent to give more kinetic to the 
molecules of components and increase the control. Example of solvent drop grinding with 
different stoichiometries includes the synthesis of Meloxicam cocrystals through grinding 
meloxicam with naphthoic acid (1:1) in presences some drops of tetrahydrofuran. Meloxicam 
also form cocrystal with glutaric acid (1:1) and cocrystals of Meloxicam with fumaric acid 
(2:1) through solvent drop grinding synthesis
37,43
.
 
The dry grinding which is without solvent 
with different stoichiometries such as nicotinamide with 2-Chloro 4-nitrobenzoic acid (1:1) 
and the cocrystal formed is more stable than the pure compound of nicotinamide
44
. The 
advantages of the solvent drop grinding method are to increase the yield, control the 
formation of polymorphs and improve product crystallinity
37
. Melting is another method to 
produce cocrystal and this method is based on melting two components of cocrystal formers 
together and after that cooling them at room temperature, the cocrystal may be produced by 
melting such as the cocrystal of carbamazepine with nictotinamide
45
. 
 
Supercritical fluid technology
46
 is consider alternative method of synthesis can be used to 
generate pharmaceutical single pure cocrystals and that can be achieved by using different 
properties of supercritical fluids and that technique can be used to design and screening of 
cocrystals and can be used to produce cocrystal from materials that have thermal sensitivity 
and or an instable structure
47,48,49
.
 
The Supercritical fluid technology is used in crystal 
engineering to produce new cocrystal with different API to increase the rate of cocrystal 
formation such as producing pharmaceutical cocrystals of indomethacin with saccharine
48
.  
The slurry method is also used as a method of crystallisation and depends on the removal of 
the excess amount of solvent normally required for crystallisation, hence reducing the 
limitations encountered when the coformers have a big difference in solubility. The method 
includes isolation of the coformers in a small quantity of solvent such as the cocrystal of 
stanolone with L-tartaric acid
50,51
. 
 
1.4.2   Methods of characterisation 
 
 The structure of cocrystals can be characterised and analysed by many kinds of methods. The 
common method which was used to characterise cocrystal structure was by powder X-ray 
diffraction
52
. X-ray diffraction was used to detect the new cocrystals formed and if they were 
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cocrystal or not and to compare the new cocrystal formed with the original component 
pattern
53
. Single crystal X-ray diffraction was used to characterise single cocrystal and to 
obtain the cocrystal structure, but it may be difficult to use single crystal X-ray diffraction on 
some cocrystals which were formed from dry grinding
37
. 
 
NMR spectroscopy was used to characterise the new cocrystal formed and it has advantages 
in distinguishing the new cocrystal structures in comparison with similar structures
54
. From 
the NMR chart it was also possible to know the stoichiometric ratio of cocrystal molecule 
formed. Raman and FT-IR spectroscopy were considered spectroscopic methods that were 
commonly used to characterise a new cocrystal material formed through comparing known 
cocrystal formers so as to find the match cocrystal peak
53
. 
 
 The physical properties of cocrystals can be determined by using Thermogravimetric 
Analysis (TGA) and Differential Scanning Calorimetry (DSC) which are physical methods 
that were commonly used to characterise and measure the physical properties of crystalline 
materials such as:  melting point and enthalpy factors of cocrystals
53,55
. 
 
1.5  Pharmaceutical cocrystals  
The chemical and physical properties of drug can be optimized in pharmaceutical cocrystals. 
A pharmaceutical cocrystal is define as a single organic crystal in solid state that integrates 
two equal molecules one of them an active pharmaceutical ingredient (API) and the other a 
cocrystal former and the two molecules interact together through non-covalent interactions by 
hydrogen bonding
2,4,56
. The physical properties are dependent on the structure of the 
pharmaceutical cocrystal and its structure design which is important for new solid materials 
with specified chemical and physical properties. In the pharmaceutical industry cocrystal 
composition is used to create products with specific physiochemical properties such as 
solubility, stability and bioavailability without influencing the pharmacological properties. 
Pharmaceutical cocrystal technology was used to characterize and improve new forms of 
drugs and increase the number of API
2,4,56
. The scientists have proven that pharmaceutical 
cocrystals can improve the quality and performance of drugs that have poor solubility, on the 
other hand some pharmaceuticals do not show maximum activity due to poor physiochemical 
properties which are specified by unconditioned polymorphic or amorphous occurrence. 
Pharmaceutical cocrystals have been used in many drug applications such as aspirin, 
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paracetamol, isonicotinamide, carbamazepine, diclofenac, meloxicam and dopamine. The 
fundamental aim of a pharmaceutical cocrystal is to generate a cocrystal with specific 
physical properties that are very different from the active pharmaceutical ingredient by 
changing or breaking covalent bonds
2
. It is also important to consider the condition of a safe 
coformer with API. The Food and Drug Administration (FDA) classifies pharmaceutical 
cocrystals as ‘’API-excipient’’57. Generally Recognized As Safe (GRAS)58 is an FDA 
designation and distinguishes that a chemical or substance added to food or drug should be 
considered as safe by experts
58
. Examples include saccharin, nicotinamide and acetic acid, 
therefore it is possible to use citric acid as a safe coformer with pyrazinamide to form 
pharmaceutical cocrystals while benzoic acid would be considered unsafe and not suitable to 
use in combination with an API in a pharmaceutical product. 
 
The melting point is important and affects the solubility and stability of a cocrystal. The 
melting point of a new cocrystal is often very different than that compared with the 
coformers. If the melting point of the cocrystal is higher than the coformers, then it will also 
be more stable and less soluble
3,9,44
. The dicarboxylic acids exhibit different melting point 
values due to effect of chain length and different number of carbon atoms
36
. The melting point 
of a pharmaceutical product can be designed to improve the activity of an API by selection of 
coformers with a desired different range of melting point
13
.
 
The melting point of 
isonicotinamide:pimelic acid (1:1) cocrystal is higher than the melting point of pure pimelic 
acid and this (1:1) cocrystal has melting point lower than the melting point of 
isonicotinamide:azelaic acid (2:1), therefore both isonicotinamide cocrystals (2:1) and (1:1) 
have melting points which are higher than the melting points of component dicarboxylic acids 
and that is due to strong interactions bonds that formed between the molecules of 
isonicotinamide with dicarboxylic acids
36
.   
 
In the 1950s Higuchi and Kuramotor
59
 studied the complex composition of pharmaceutical 
cocrystals between pharmaceutical and macromolecules such as the complex of 
polyvinylpyrrolione (PVP) with a series of molecules such as sulfathiazole, procaine, sodium 
salicylate, benzyl penicillin, and caffeine
59
.     
 
1.5.1  Pharmaceutical cocrystal applications  
 
 Cocrystals have attractive interest in pharmaceutical research and development with different 
applications: 
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A) Pharmaceutical cocrystals of Carbamazepine (Tegretol): 
 
Carbamazepine (with the commercial name Tegretol) is a drug which is used as an 
anticonvulsant via oral administration. The drug has a low solubility and a low dissolution 
bioavailability therefore the drug is required at a high dosage, more than (100mg/day) for 
therapeutic effect. The active ingredient is also detrimentally affected by polymorphism and 
uncontrolled hydration
60
.  
  
The pharmaceutical cocrystal of carbamazepine:saccharin consists of carbamazepine and 
saccharin in a 1:1 stoichiometric ratio. The stability and solubility of the API increases in the 
saccharin1:1 cocrystal, significantly improving the bioavailability and solubility of the 
carbamazepine drug. Carbamazepine is a good example that can be used to explain how the 
active pharmaceutical ingredient can be incorporated into a pharmaceutical cocrystal and 
provide a more stable and soluble crystalline drug that does not form the hydrate. The 
molecules in the carbamazepine:saccharin cocrystal combining together through hydrogen 
bonding synthon between the molecules as shown in (figure 1.7)
61
. The cocrystal structure 
was obtained through single crystal X-ray diffraction.   
 
                                                                                                
Figure 1.7: Cocrystal structure of carbamazepine:saccharin 1:1 cocrystal through hydrogen 
bonding synthon
61
 
 
B)  Pharmaceutical cocrystals of fluoxetine hydrochloride (Prozac): 
 
Fluoxetine is antidepressant drug and was used in the market in the last decade; it is 
commercially available as a tablet, capsules and solution. The active ingredient in Prozac is 
fluoxetine HCl which is available in a salt crystalline solid form. However this form has poor 
solubility. The active ingredient can be cocrystallised so as to modify the physical properties 
with keeping the hydrochloride salt of the API. Cocrystals of fluoxetine HCl can be produced 
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by cocrystallisation with a series of chemical organic compounds such as benzoic acid (1:1), 
fumaric acid (2:1), succinic acid (2:1) through the evaporation techniques. It was found in the 
fluoxetine hydrochloride cocrystals that the carboxylic acid group in succinic acid is bonded 
with the chloride ion in fluoxetine hydrochloride and the two molecules of fluoxetine 
hydrochloride are bonded with succinic acid through hydrogen bonding (figure 1.8). The 
fluoxetine HCl: succinic acid cocrystal shows an increase in the solubility compared with the 
crystalline form of the drug while fluoxetine HCl:benzoic acid has shown a decrease in 
aqueous solubility. Powder X-ray diffraction and infra-red spectroscopy have been used to 
confirm the formation of this cocrystal
62
.                     HCL 
 
 
Figure 1.8: Cocrystal structure of  fluoxetine:succinic acid (2:1)
62
.  
 
C) Pharmaceutical cocrystals of meloxicam: 
 
Meloxicam is an anti-inflammatory drug which is poorly soluble in water and in organic 
solvents. Meloxicam (figure 1.9) forms cocrystals with succinic acid (2:1), fumaric acid (2:1) 
and maleic acid (1:1) produced by solvent drop grinding. These materials were analysed using 
X-ray powder, single crystal X-ray diffraction and IR spectroscopy to confirm the new 
cocrystal structure formation. These cocrystals show improvement in solubility and an 
increase in the bioavailability
43,63
. 
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     Figure 1.9: Chemical structure of meloxicam
43,63
. 
 
D)   Pharmaceutical cocrystals of diclofenac: 
Diclofenac is an anti-inflammatory analgesic drug and is extremely poorly soluble in water. It 
has the ability to form cocrytstals with three hydrogen bond acceptors and two hydrogen bond 
donors. Diclofenac produces cocrystals with aromatic compounds containing nitrogen such as 
2-aminopyrimidine and 2-amino-4, 6-dimethylpyrimidine
64
. These diclofenac cocrystals were 
obtained by solvent drop grinding of diclofenac with 2-aminopyrimidine and 2-amino-4, 6-
dimethylpyrimidine in a stoichiometric ratio of 1:1. X-ray powder diffraction and IR were 
used to analyse and confirm the cocrystal structure (figure 1.10)
64
. The cocrystal combination 
through hydrogen bonds synthon in diclofenac:2-amino pyrimidine.  
 
                                
Figure 1.10: Cocrystal structure of diclofenac:2-aminopyrimidine (1:1) connecting through  
three hydrogen bond synthons64. 
 
E)  Pharmaceutical cocrystals of acetazolamide: 
 
 Acetazolamide (figure 1.11) is an antiepileptic drug which is used for glaucoma treatment. 
This drug has the commercial name (Diamox). Acetazolamide has a low solubility in water 
and has a number of polymorphic forms. Solvent drop grinding and slow solvent evaporation 
were used to synthesise acetazolamide cocrystals with nicotinamide and 4-hydroxybenzoic 
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acid
65
. X-ray powder diffraction and IR-spectroscopy were used to characterise the cocrystals 
and Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis TGA were 
used for melting point measurements. 
 
    
Figure 1.11: The chemical structure of acetazolamide
65
. 
                    
F)  Pharmaceutical cocrystal of  2-chloro 4-nitrobenzoic acid: 
2-chloro 4-nitrobenzoic acid can be used for treatment of immunodeficiency diseases
44,66
, 
viral infection and anti-cancer
44
. The active pharmaceutical ingredient 2-chloro 4-nitrobenzoic 
acid forms cocrystal with nicotinamide in a stoichiometric ratio 1:1. The cocrystals were 
synthesised by slow solvent evaporation and solvent drop grinding. The cocrystal was 
characterised by using X-ray powder diffraction and the cocrystal structure was determined 
through single crystal X-ray diffraction. The cocrystal structure formed through hydrogen 
bonding of acid-pyridine between the two molecules (figure 1.12)
44,66
. It was found that the 
cocrystal has melting point higher than the melting point of the pure components and that 
confirming that the pharmaceutical cocrystal has more stability than that of the pure 
pharmaceutical components
44
. 
 
                                         
Figure 1.12: Cocrystal structure of 2-chloro 4-nitrobenzoic acid:nicotinamide (1:1)
 44,66
. 
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G)   Pharmaceutical cocrystal of dopamine: 
 
Dopamine is a drug which is used to treat Parkinson's disease. The Dopamine drug is 
available in salt form as dopamine hydrochloride or dopamine hydrobromide. Dopamine 
hydrobromide forms a cocrystal with 3,5-dinitrobenzoic acid in a stoichiometric ratio 1:1 
(figure 1.13). The cocrystal was synthesised by slow solution evaporation
67
. The cocrystal 
was characterised by using X-ray powder diffraction and the melting point determined by 
using Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC). 
 
 
Figure 1.13: Cocrystal structure of dopamine:3,5-dinitrobenzoic acid (1:1)
67
. 
 
 
H)  Pharmaceutical cocrystal of nicotinamide and isonicotinamide: 
 
Nicotinamide can be used for anti-inflammatory skin. Nicotinamide forms cocrystal with 
fumaric acid in a stoichiometric ratio 1:1
68
. Slow solvent evaporation method was used for 
synthesis and the cocrystal structure was characterised through powder X-ray diffraction and 
the cocrystal structure was determined through single crystal X-ray diffraction
68
. This 
structure includes one molecule nicotinamide and one molecule fumaric acid linked through 
acid-pyridine hydrogen bond (figure 1.14).  
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Figure 1.14: Cocrystal structure of nicotinamide:fumaric acid (1:1)
68
 . 
 
Isonicotinamide form cocrystals with carboxylic acids (Pimelic acid, subaric acid, azelaic acid 
and benzoic acid) in a stoichiometric ratio 1:1
36,69
. The cocrystals were synthesised by slow 
solution evaporation and methanol was used as solvent. All the cocrystals formed were 
characterised by using powder X-ray diffraction and the cocrystal structures were obtained 
through single crystal X-ray diffraction. The cocrystal structure of isoniotinamide:pimelic 
acid includes one molecule isonicotinamide and one molecule pimelic acid linked through 
acid-amide hydrogen bonds (figure 1.15).  
 
 
                      
Figure 1.15: Cocrystal structure of isonicotinamide:pimalic acid (1:1)
 36,69
.                                         
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1.6  Pharmaceutical polymorphism 
 
“Polymorph” is a word which is derived from two Greek words: “Polus” which means many 
and “morphs” which means shape70. Polymorph is a word that is used in crystallography and 
biology to describe the behaviour of a natural solid material and can occur in different forms. 
More specifically, it is the ability of a solid chemical compound to crystallise in more than 
one crystal arrangement with a different physical properties but with same chemical 
properties 
6,15,71
. This means that two polymorphic forms of a compound can display two 
distinct behaviours in terms of solid state based properties. 
 
The first discovery of polymorphism in organic solid materials was by Friedrich Wohler and 
Justus von Liebig when they discovered polymorphs of benzamide in 1832, during their 
experiments on a boiling solution of benzamide. After cooling the solution analysis of the 
resulting crystalline material identified three polymorphs of benzamide
72,73
. 
 
The polymorph phenomenon is not always clear to understand. In 2006 a new polymorph of 
maleic acid was discovered which was first crystallised and studied 124 years earlier
74,75
. 
Maleic acid is a solid organic chemical compound which is widely used in the chemical 
industry. The new polymorph of maleic acid was found when caffeine and maleic acid (2:1) 
were dissolved in chloroform and the solvent evaporated slowly from the solution
74. 
 
Polymorphs have different stabilities and can be changed from stable to unstable forms at a 
specific temperature. These differing stabilities can also affect the solubility and dissolution 
rate of the drug and hence the bioavailability in the body
76. Conditions which can determine 
which polymorph is present in the crystal solid material include: solvent effects, 
crystallisation temperature and stirring conditions
6,77
. Pharmaceutical polymorphs have 
different solubility and that affecting on the drug therapeutic activity and one polymorph may 
be more active than the other polymorph of the same drug. 
 
Polymorphs play a big role in the pharmaceutical industry and in developing active drug 
ingredients
6,77
. Drugs can usually be taken orally in crystalline solid form and the drug 
dissolution rate depends on the crystal form of the polymorph. It has been found that 
paracetamol (acetaminophen) exhibits polymorphism
78
 and has three forms; polymorph I 
(stable), polymorph II (metastable) and polymorph III (unstable)
79
. Polymorph I is 
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thermodynamically more stable than polymorph II at room temperature which in turn displays 
more favourable compression properties than polymorph I
77
. This is an important 
consideration as polymorph I is difficult to make into tablets and most of the paracetamol 
drug products on the market contain polymorph I mixed with agents to improve the 
compression properties
77,79
. Polymorph II however is costly in the crystallisation process 
during production
 80
. 
 
1.7  Pyrazinamide 
 
Pyrazinamide is an anti-tuberculosis
81
 drug which is used in combination with other drugs to 
kill the bacteria that cause tuberculosis
82
. It is white crystalline powder soluble in water 50 
mg/ml and methanol 13.8 mg/ml and ethanol 5.7 mg/ml and stable at room temperature with a 
melting point at 190 
o
C. Pyrazinamide (figure 1.16) contains an amide group and two 
heterocyclic (N) groups thus containing both strong hydrogen bond donors and acceptors. 
Those groups provide good potential for pyrazinamide to form cocrystals with dicarboxylic 
acids through acid-amide hydrogen bonds; N-H
.....
O=C in which the amide NH2 acts as a 
donor to the carboxyl C=O and OH
….
O=C in which the carboxyl OH acts as a donor. There is 
also opportunity for pyrazinamide to interact with carboxylic acids through the formation of 
strong acid-pyridine O-H
….
N (heterocyclic) hydrogen bonds in which the carboxyl OH acts as 
a donor to pyridine nitrogen which is acting as an acceptor. There is also the possibility for 
the formation of intramolecular hydrogen bonds between the amide and the neighbouring 
pyridine group forming a five-membered ring through strong N-H
.....
N (heterocyclic) 
interactions or the formation of a C-H
….
O=C hydrogen bond also generating a five-membered 
intramolecular ring on the opposite side of the molecule. These interactions act to stabilize the 
planarity and conformation of the pyrazinamide molecule.  
 
 
 
 
 
 
 
Anas. M. Al-Abachi                                                                                Introduction                                                                                                              
 
 Page 22 
 
                                                                        
(a)                (b)                               
                                                                                                                                           
                              (c)                                                                             (d)    
              
                                        (e)                                                                                          (f)          
 
Figure 1.16: Chemical structure of (a) Pyrazinamide showing, (b) possible intramolecular 
hydrogen bonds, (c, d) possible intermolecular interactions in formation of a crystal, (e, f) 
possible intermolecular interactions with pyrazinamide in formation of a crystal. 
 
 
1.8  Polymorphism of pyrazinamide 
 
A number of pyrazinamide polymorphs have been reported in the literature
76,83,84,85
, many of 
these papers report the study of similar forms or investigation of these forms at different 
temperatures
76
. Analysis of these literature sources reveals that pyrazinamide has four distinct 
polymorphic forms (α86 , β87, δ88 and γ89). These forms have been synthesised using a variety 
of methods including solvents drop grinding and solution crystallisation through solvent 
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evaporation from different solvents with varying polarity and hydrogen bonding. The 
literature shows that the α polymorph is the most stable commercial form76. 
The polymorphic behaviour of pyrazinamide (α86, β87, δ88, and γ89) has been studied using a 
variety of characterisation techniques including infrared spectroscopy, powder X-ray 
diffraction, Differential Scanning Calorimetry (DSC) and polarized light thermal microscopy. 
The IR spectra alone exhibit two main profiles in the N-H stretching vibration region that can 
be used to identify the polymorphs α, β and δ whose crystalline structures have pyrazinamide 
dimers where the dimer does not exist with the γ form76. However the most detailed 
information regarding these polymorphs can be obtained through X-ray diffraction study. The 
structures of all four polymorphs have been determined by single crystal X-ray diffraction and 
the hydrogen-bond networks and packing features are discussed below.  
 
 Crystallization of the α form83,86 (figure 1.17) takes place within the P21/n monoclinic space 
group with pyrazinamide dimers formed through complementary amide-amide hydrogen 
bonds. Hence the structure forms the expected centrosymmetric 22R (8) dimer formed by 
classical complementary N–H…..O=C interactions. The dimers are then held together in a 
ladder-type arrangement by the formation of complementary N–H.....N (heterocyclic) 
interactions forming an 22R (10) ring motif. This network is reinforced by formation of C-
H
.....
O interactions such that the carbonyl oxygen acts as a double acceptor. The second 
heterocyclic N forms a further weak intramolecular hydrogen bond with neighbouring 
pyrazinamide dimers through a C-H
…..
N (heterocyclic) interaction that links the ladders 
together. This structure (figure 1.17) highlights the formation of the interactions predicted in 
Figure 1.16 motif e. 
 
Figure 1.17: A view of the crystal structure of pyrazinamide α form.  
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The β form83,87 (figure 1.18) of pyrazinamide also crystallises in the P21/c monoclinic space 
group. The structure of this form also contains the expected amide dimer through amide-amid 
hydrogen bonds, forming the standard 22R (8) motif through complementary N-H
….
O=C 
interactions. The dimers are then held together through a ladder-type arrangement by the 
complementary C-H
…..
N (heterocyclic) interactions forming 22R (10) ring motif, the ring is 
reinforced by formation other N-H
…..
O=C. The second heterocyclic N forms a further weak 
intramolecular hydrogen bond with neighbouring rotated pyrazinamide dimers through a C-
H
…..
N (heterocyclic) interaction that links the ladders together. This structure (figure 1.18) 
highlights the formation of the interactions predicted in Figure 1.16 motif e. 
 
 
 
Figure 1.18: A view of crystal structure of pyrazinamide β form. 
        
 The δ form83,88 of pyrazinamide (figure 1.19) crystallises in the P-1 triclinic space group and 
forms one of the most simple packing diagrams. The centrosymmetric amide dimer is also 
present in this structure giving the expected 22R (8) motif through complementary N-H
….
O=C 
interactions. The dimers are then held together in a ladder-type arrangement by the formation 
of complementary C-H
.....
N (hetero) interactions between neighbouring dimers forming an 22R
(6) motif. These ladders are then linked to adjacent ones by further C-H
…..
N interactions 
forming another set of 
2
2R (6) motifs. This structure (figure 1.19) highlights the formation of 
the interactions predicted in Figure 1.16 motif e. 
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Figure 1.19: A view of crystal structure of pyrazinamide δ form.  
 
The γ form83,89 of pyrazinamide (figure 1.20) crystallises in the Pc monoclinic group space but 
unlike the other polymorphs there are no amide dimers present. The NH2 group is involved in 
interactions with two different adjacent molecules; one through formation of a N-H
….
O=C 
hydrogen bond linking together molecules in a vertical chain, the other through N-H
…..
N 
(heterocyclic) interaction forming an infinite chain in a horizontal direction. The other 
hydrogen bond C-H
…..
N forming spiral interaction. This structure (figure 1.20) highlights the 
formation of the interactions predicted in Figure 1.16 motif f. 
 
 
Figure 1.20: A view of crystal structure of pyrazinamide γ form. 
 
1.8.1  Crystal thermal stability of pyrazinamide polymorphs   
          
Thermal analysis has demonstrated that the α, β and δ forms give rise to the γ form on heating 
and that in the endothermic transition some super-heating is observed
76
 (the DSC peaks 
display irregular shape)
76,83
. The thermal analysis showed (figure 1.21)
 that form β changes to 
form polymorph γ when heated at 95 oC, whilst polymorph α and polymorph δ undergo 
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transitions to form polymorph γ at higher temperatures, 145 oC and 135 oC respectively. The 
other additional phase transition from form δ to form α on heating at 120 oC. The relative 
stability of the four pyrazinamide polymorphs γ> α> δ> β at 145 oC were derived from the 
experimental observations and polymorph γ is more stable and preferential formation 
structure without dimer at temperature values higher than 145 
o
C
76 
and the stability of  the 
four polymorphs were  α> δ> β > γ at 25 oC while the stability of the four polymorphs were  δ 
> α> β > γ at zero temperature76,83. It was noticed that the stability of the four pyrazinamide 
polymorphs depends on the changing in the temperature degree and the most stable 
polymorph form of pyrazinamide is α at room temperature. The thermal analysis study of 
pyrazinamide polymorphs helps to find out the relative stability of pyrazinamide polymorphs 
forms.  
 
 
                  
 
Figure 1.21: Thermal analysis of the pyrazinamide polymorphs
83
. 
 
 
1.9  Pharmaceutical cocrystals of pyrazinamide 
 
Pyrazinamide forms cocrystals with a number of molecular coformers including fumaric acid 
succinic acid, benzoic acid, malonic acid and glutaric acid. These structures contain a variety 
of structural motifs. 
 
A)  Pyrazinamide:fumaric acid and pyrazinamide:succinic acid 
 
Pyrazinamide forms cocrystals with fumaric
82
 and succinic acid
90
 both in a stoichiometric 
ratio 2:1. Both cocrystals were synthesised by slow solvent evaporation from methanol and 
the structures characterised by using single crystal X-ray diffraction. The cocrystal structures 
contain pyrazinamide dimers linked through N-H
…..
O=C hydrogen bonds. The cocrystals with 
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fumaric acid (A) and succinic acid (B) are formed through acid-pyridine hydrogen bonds 
(figure 1.22). Both cocrystal structures include one pyrazinamide per one half molecule acid 
linked through acid-pyridine strong hydrogen bonds while the pyrazinamide molecule is 
linked to another pyrazinamide molecule through amide-amide hydrogen bonds forming an 
2
2R (8) pyrazinamide dimer. 
 
 
(A) 
               
                                                                           (B) 
Figure 1.22: A view of the cocrystal structures of (A) pyrazinamide:fumaric acid 2:1 and (B) 
pyrazinamide:succinic acid (2:1) showing the hydrogen bonded structural motifs.     
                                                                                                                 
B)  Pyrazinamide:isoniazid dual drug 
 
Pyrazinamide forms cocrystal with isoniazed drug (1:1)
82
 dual drug cocrystal and synthesis by 
solvent drop grinding and characterised by powder X-ray diffraction. 
It was found that the combination of multi drugs of pyrazinamide and isoniazed with succinic 
acid acids or fumaric acid forms adduct cocrystal structures and characterised by powder X-
ray diffraction and single crystal X-ray diffraction (figure 1.23) 
The melting point of product obtained showed increase in the drug solubility and that will 
improve the drug activity. 
Anas. M. Al-Abachi                                                                                Introduction                                                                                                              
 
 Page 28 
 
 
 
                                        Pyrazinamide       Succinic acid               Isoniazed 
Figure 1.23: A view of the crystal structure proposed of drug-drug adduct of 
pyrazinamide:succinic acid:isoniazed linked through acid-pyridine hydrogen bonds 
 
 
C)  Pyrazinamide:2,5-dihydrobenzoic acid 
 
Pyrazinamide forms cocrystal with 2,5-dihydroxy benzoic acid
91
 in a stoichiometric ratio 1:1. 
The cocrystal was synthesised by solvent drop grinding and characterised by X-ray powder 
diffraction analysis. This structure was obtained through single crystal X-ray diffraction. The 
cocrystal structure contains acid-amide and acid-pyridine hydrogen bonds forming an 22R (8) 
ring (figure 1.24). 
 
Figure 1.24: A view of the cocrystal structure of pyrazinamide:2,5-dihydroxy benzoic acid 
(1:1) in chain showing the hydrogen bonded structural motifs. 
 
D) Pyrazinamide:malonic acid 
 
Pyrazinamide forms cocrystal with malonic acid 1:1
90
.The cocrystal was synthesised through 
slow solvent evaporation from methanol and characterised by X-ray powder diffraction 
analysis. This structure was obtained through single crystal X-ray diffraction (figure 1.25). 
The cocrystal structure contains acid-pyridine and acid-amide hydrogen bonds and forms an 
acid-amide dimer 
2
2R (8). 
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Figure 1.25: A view of the cocrystal structure of pyrazinamide:malonic acid 1:1 showing the 
hydrogen bonded structural motifs.   
 
 
E)  Pyrazinamide:glutaric acid 
 
Pyrazinamide form cocrystal with glutaric acid (1:1)
90
 through acid-amide dimer and acid-
pyridine in pyrazine. The cocrystal of pyrazinamide-fumaric acid was synthesised though 
slow solvent evaporation and characterised through powder X-ray diffraction and the 
cocrystal structure was obtained through single crystal X-ray diffraction (figure 1.26). The 
cocrystal structure includes acid-amide and acid-pyridine hydrogen bonds; together these 
hydrogen bonds forming an 22R (8) and 
2
2R (7) rings between pyrazinamide and glutaric acid 
molecules. 
 
 
Figure 1.26: A view of the cocrystal structure of pyrazinamide:glutaric acid showing the 
hydrogen bonded structural motifs. 
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1.10   Aims and objectives 
 
      The aim of the present work focuses on the following objective: 
1- Synthesis and determination of new binary cocrystals using solvent evaporation 
crystallization and solvent drop grinding methods using different solvents (methanol and 
ethanol) and different stoichiometric ratios. 
2- Attempt to synthesis new cocrystals from combination of pyrazinamide with a series of 
selected dicarboxylic acid such as: oxalic acid, oxamic, malonic acid, malieic acid, 
fumaric acid, succinic acid, glutaric acid, adipic acid, pimelic acid, subaric acid, azelaic 
acid, sebacic acid and with other molecules such as histidine, nicotinamide and 
isonictotinamide. 
The former molecules chosen for the above study have complementary donor and 
acceptor functional groups that can form potential supra-molecular bonds in the 
crystallisation   process. Pyridine ring and amide functional groups on pyrazinamide can 
form hydrogen bonds with carboxylic acid functional groups on dicarboxylic acid 
producing cocrystals or salts.  
3- Characterisation using powder X-ray diffraction data to confirm the formation of new 
material.  
4- Using NMR to identify the stoichiometric ratio of the new cocrystal material formed. 
6- Crystal structure determination using single crystal X-ray powder diffraction and powder 
X-ray diffraction methods. 
7- Discussion and analysis of new structures relative to each other and with other previously 
published work. 
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2 .  Experimental 
 
2.1   Synthesis by solvent evaporation crystallization 
 
0.1 g of pyrazinamide and equivalent stoichiometric molar ratio of dicarboxylic acid were 
dissolved separately in two conical flasks in 20 ml solvent at room temperature. The solutions 
were heated and stirred until all the starting materials were totally resolved. The solutions 
were hot filtered in another conical flask to remove any undissolved starting materials. The 
filtered solutions were combined in a further conical flask and left on the bench for 
crystallization at room temperature for up to two weeks. The material obtained from 
crystallization was filtered and dried by suction for half an hour. The experiments were 
repeated using a variety of different solvents (methanol, ethanol and ethyl acetate) and 
different stoichiometric ratios (1:1, 1:2 and 2:1). The time required for crystallization varied 
from one to two weeks depending on the length of the chain of acid coformer.  
This experimental procedure was used in the synthesis of all conformer combinations. The 
method was used also to cover other unsuccessful other combinations such as dopamine, 
histidine with dicarboxylic acids.  
 
2.2   Synthesis by solvent drop grinding 
 
0.1 g of pyrazinamide was ground with the equivalent stoichiometric molar ratio of 
dicarboxylic acid with a few drops of solvent (methanol, ethanol or ethyl acetate) added .The 
mixture was ground in a mortar and pestle for 30 minutes at room temperature.  
 
2.3   Powder X-ray diffraction data 
 
 All data were collected at room temperature using a Bruker D8 high resolution X-ray powder 
diffractometer in transmission mode. The crystalline samples were ground and placed in a flat 
disc of approximately 10mm diameter between transparent polyethylene tape. The wavelength 
used was λ= 1.5406 Å generated by the selected tube X-ray source (CuKα1). Powder X-ray 
diffraction data were recorded between either 5
o≤2θ≤60o or 5o≤2θ≤90o for 30 minutes. The X-
ray powder diffraction patterns data were collected in the form of a RAW file and that file 
converted to a UXD file for additional analysis. The UXD file was after that converted into 
XY format file through using Perl software for additional analysis through using the 
Microsoft office Excel software. 
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2.4   Single crystal X-ray diffraction data 
 
Single X-ray diffraction data  of Pyrazinamide:PimelicAcid 1:1 was collected and recorded 
by using diffractometer equipment and the data was collected by the EPSRC UK National 
Crystallography Service
92
 on a Rigaku AFC12 goniometer equipped with an enhanced 
sensitivity (HG) Saturn724+ detector mounted at the window of an FR-E+ Super Bright 
molybdenum rotating anode generator with HF Varimax optics. The data collection was 
driven and processed and an absorption correction was applied using CrystalClear-SM 
Expert
93
. The remaining datasets were measured on an Agilent Super Nova diffractometer 
using an Atlas detector and the data collections were driven and processed and absorption 
corrections were applied using CrysAlisPro
94
. All five structures were solved using ShelXS4 
and refined by a full-matrix least-squares procedure on F2 in ShelXL
95
. All non-hydrogen 
atoms were refined with anisotropic displacement parameters. In Pyrazinamide:AdipicAcid 
the hydrogen atoms bonded to N(7A), N(7B) and O(8), and in Pyrazinamide:SebacicAcid 
the hydrogen atoms bonded to N(7) and O(8) were located in the electron density and their 
positions refined freely, with their isotropic thermal parameters based on the equivalent 
isotropic thermal parameter of the parent atom (Uiso(H) = 1.2(Ueq(N) and Uiso(H) = 
1.5(Ueq(O)). In Azelaic Acid the hydrogen atoms bonded to O(1) and O(9) were located in 
the electron density and their positions and isotropic thermal parameters refined freely All 
other hydrogen atoms in all five structures were added at calculated positions and refined by 
use of a riding model with isotropic displacement parameters based on the equivalent 
isotropic displacement parameter (Ueq) of the parent atom. 
 
 
 
2.5   1H  NMR spectra  
 
0.05 g of a crystalline sample was dissolved in 2ml of dimethyl sulfoxide-d6 (DMSO) solvent 
in a 5mm diameter quad probe (NMR tube). The NMR data were recorded at 300.15 MHz by 
using Bruker AVIII300 spectrometer equipment. The data were analysed using the 
Mestrenova software
96
. 
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2.6   Crystallographic Data 
 
Crystal structure determination of compound Pyrazinamide:PimelicAcid 1:1: 
C5H5N3O:C7H12O4, Mr = 283.29, crystal dimensions: 0.42 x 0.16 x 0.02 mm, triclinic, space 
group: P-1, a = 5.3302(4) Å, b = 8.4201(6) Å, c = 15.5321(11) Å, α = 89.478(7)o, β = 82.760 
(7)
o, γ = 71.840(6)o, V = 656.75(9) Å3, Z = 2, ρcalcd = 1.433 Mg/m
3 ,μ = 0.113 mm-1, λMo-Kα = 
0.71075Å, T = 100(2) K, 2θmax = 54.96
o
, 7308 reflections measured, 2979 independent 
reflections (Rint = 0.0290), R1 = 0.0350 (observed reflections), wR = 0.1010 (all data), largest 
diff. peak and hole: 0.404 and -0.207 e.Å
-3
.  
 
Crystal structure determination of compound Pyrazinamide:GlutaricAcid 1:1: 
C5H5N3O:C5H8O4, Mr = 255.23, crystal dimensions: 0.15 x 0.10 x 0.03 mm, monoclinic, 
space group: P21/c, a = 11.3844(9) Å, b = 4.8251(7) Å, c = 21.9011(16) Å, β = 104.610 (9)o, 
V = 1164.1 (2) Å
3, Z = 4, ρcalcd = 1.456 Mg/m3, μ = 1.012 mm-1, λCu-Kα = 1.5418 Å ,T = 
100.00(10) K, 2θmax = 133.16
o
, 3397 reflections measured, 3397 independent reflections, R1 
= 0.0397 (observed reflections), wR = 0.1076 (all data), largest diff. peak and hole: 0.179 and 
-0.217 e.Å-3. The crystal was a non-merohedral twin with the domains related by 180
o
 about 
the direct axis [0 0 1] and the refined percentage domain ratio being 64:36. 
 
Crystal structure determination of compound Pyrazinamide:AdipicAcid 4:1: 
4(C5H5N3O):C6H10O4, Mr = 638.62, crystal dimensions: 0.20 x 0.09 x 0.06 mm, triclinic, 
space group: P-1, a = 5.1814(8) Å, b = 11.7163(16) Å, c = 12.2250(14) Å, α = 74.708 (11)o ,β 
= 87.314 (11)
o, γ = 85.212 (12)o, V = 713.13 (17) Å3, Z = 1, ρcalcd = 1.487 Mg/m
3 
, μ = 0.963 
mm
-1, λCu-Kα = 1.5418 Å, T = 100.00 (10) K, 2θmax = 140.106
o
, 4178 reflections measured, 
2666 independent reflections (Rint = 0.0348), R1 = 0.0623 (observed reflections), wR = 0.1780 
(all data), largest diff. peak and hole: 0.353 and -0.368 e.Å
-3. 
 
 
Crystal structure determination of compound Pyrazinamide:SebacicAcid 2:1: 
2(C5H5N3O):C10H18O4, Mr = 448.48, crystal dimensions: 0.35 x 0.20 x 0.10 mm, triclinic, 
space group: P-1, a = 5.1790(2) Å, b = 5.4406(2) Å, c = 19.2691(7) Å, α = 94.342 (3)o,  β = 
93.910(3)
o, γ = 94.681(3)o, V = 538.07(3) Å3, Z = 1, ρcalcd = 1.384 Mg/m
3 ,μ = 0.869 mm-1, 
λCu-Kα = 1.5418 Å, T = 100.00 (10) K, 2θmax = 140.116
o
, 5733 reflections measured, 2026 
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independent reflections (Rint = 0.0159), R1 = 0.0339 (observed reflections), wR = 0.0911 (all 
data), largest diff. peak and hole: 0.290 and -0.169 e.Å
-3. 
 
 
Crystal structure determination of compound Azelaic Acid 1:1: C9H16O4, Mr = 188.22, crystal 
dimensions: 0.14 x 0.13 x 0.03 mm, monoclinic, space group: P21/c, a = 5.4938(2) Å, b = 
9.4418 (3) Å, c = 18.8258(6) Å, β = 95.673 (3)o, V = 971.74 (6) Å3, Z = 4 , ρcalcd = 1.287 
Mg/m
3, μ = 0.838 mm-1, λCu-Kα = 1.5418 Å, T = 100.00 (10) K,  2θmax = 148.496
o
, 3622 
reflections measured, 1922 independent reflections (Rint = 0.0182), R1 = 0.0430 (observed 
reflections), wR = 0.1287 (all data), largest diff. peak and hole: 0.288 and -0.224 e.Å
-3. 
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3.  Results 
Pyrazinamide was used in this investigation as the API for co-crystallisation with a group of 
alkane dicarboxylic acids (table 3.1). Potential synthesis of cocrystal adducts was carried out 
with variation of acid chain length to form products using different solvents and different 
methods of synthesis in combination with different stoichiometric ratios (1:1, 1:2, 2:1). 
Pyrazinamide shows extensive polymorphic behaviour and has demonstrated the ability to 
form cocrystals with dicarboxylic acids through strong hydrogen bonds formed with the 
amide and pyridine groups. This increases the potential to form cocrystals with oxalic acid, 
oxamic acid, malonic acid, maleic acid, fumaric acid, succinic acid, glutaric acid, adipic acid, 
pimelic acid, subaric acid, azelaic acid and sebacic acid (as shown in table 3.1). Further 
investigation was carried out to assess the potential for pyrazinamide to form cocrystals with 
other amides such as isonicotinamide, nicotinamide and histidine (table 3.2).  
Other work was carried out to investigate the adduct formation behaviour of   isonicotinamide 
with nicotinamide to form new products with different stoichiometric ratios (1:1, 1:2, 2:1), 
and its behaviour in adduct formation with fumaric acid. Additional experiments were carried 
out to investigate any potential cocrystal formation by the API, L-dopamaine with succinic 
acid.  
X-ray powder diffraction was used as the primary method to confirm the formation of a new 
material. NMR nuclear magnetic resonance spectroscopy was used to identify the 
stoichiometric ratio of the cocrystal or adduct formed. Single crystal X-ray diffraction 
analysis was used to determine the crystal structures of any new material formed. This was 
carried out in the case of pyrazinamide with glutaric acid, adipic acid, pimelic acid, azelaic 
acid and sebacic acid. 
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Table 3.1. Molecular structures of the dicarboxylic acids used in this investigation.                                                                                        
               Coformer                 Chemical Structure 
 
 
Oxalic acid  
 
 
Oxamic acid 
 
 
 
Malonic acid 
 
 
 
Maleic acid 
 
 
 
Fumaric acid 
 
 
Succinic acid 
 
 
 
Glutaric acid 
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Table 3.1. Continued molecular structures of the dicarboxylic acids used in this investigation. 
 
 
 
 
 
 
               Coformer                                   Chemical Structure 
 
 
Adipic acid 
 
 
Pimelic acid 
 
 
 
Suberic acid 
 
 
 
Azelaic acid 
 
 
 
Sebacic acid 
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Table 3.2   Molecular structures of the amides and APIs used in this investigation. 
Coformer                   Chemical Structure  
 
 
 
Pyrazinamide 
 
 
 
 
Isonicotinamide 
 
 
 
Nicotinamide 
 
 
 
Histidine 
 
 
 
L-Dopaamine 
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3.1   Pyrazinamide and oxalic acid 
Pyrazinamide and oxalic acid were dissolved separately in methanol, the solutions combined 
in a 1:1 stoichiometric ratio and the solvent allowed to evaporate. The product was a white 
solid crystalline material obtained through the solvent evaporation crystallisation method. 
The X-ray powder diffraction pattern of the product formed was compared with data of the 
starting materials and with a number of simulated patterns from previously published 
pyrazinamide polymorphs
76,83,97,98
. The X-ray powder diffraction pattern of the product 
confirms that a new material has been formed (figure 3.1). The pattern also indicates that a 
small amount of oxalic acid starting material may be present (see peaks at 18º, 26º and 29º 2-
theta), but there is no indication of the presence of pyrazinamide polymorphs in the product. 
The crystal quality of this product was insufficient for single crystal X-ray diffraction and 
hence further structure investigation was not carried out. It is worth nothing that this figure 
confirms that the pyrazinamide used as a starting material is matches polymorph 
(α(PYRAZIN15))97.  
 
Figure 3.1: X-ray powder diffraction patterns of the product of pyrazinamide and oxalic acid 
crystallisation from methanol, the starting materials (pyrazinamide, oxalic acid), and 
common pyrazinamide polymorphs. 
1
H  NMR was unable to identify the presence of oxalic acid in the sample and hence characterisation 
of this product was not possible. 
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3.2   Pyrazinamide and oxamic acid 
Pyrazinamide was crystallised with oxamic acid (as described in the solution-mediated 
synthesis method), with methanol used as solvent to dissolve the starting materials in a 1:1 
stoichiometric ratio. The solvent evaporation crystallisation method was used for obtain the 
product which was a white solid. The X-ray powder diffraction pattern of the product formed 
was compared to the patterns of the starting materials and to a number of simulated patterns 
from previously published pyrazinamide polymorphs
76,83,97,98
. Figure 3.2 shows that the 
product formed is indeed a mixture of the oxamic acid starting material with polymorph 
(γ(PYRAZIN17))83  
 
Figure 3.2: X-ray powder diffraction patterns of the product of pyrazinamide and oxamic 
acid crystallisation from methanol, the starting materials (pyrazinamide, oxamic acid) and 
common pyrazinamide polymorphs. 
 
The 
1
H NMR of this product showed the presence of both pyrazinamide and oxamic acid, 
confirming that the resultant solid was a mixture of the two components in an approximate 
ratio 1:1 pyrazinamide (γ(PYRAZIN17))83 to oxamic acid (figure 3.3). 
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Figure 3.3: 
1
H NMR of the product of pyrazinamide and oxamic acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.87 (1H, s), 8.29 (1H, 
s), 8.72 (1H, s), 8.86 (1H, s), 9.19 (1H, s): oxamic acid 7.81 (1H, s), 8.13(1H, s). 
 
 
 
 
 
 
 
 
Anas. M. Al-Abachi                                                                                        Results                                                                                                               
 
 Page 42 
 
3.3   Pyrazinamide and malonic acid 
Pyrazinamide was combined with malonic acid in a 1:1 stoichiometric ratio using methanol 
as the solvent of crystallisation. The solvent evaporation crystallisation method was used for 
cocrystal synthesis and resulted in a new material that formed as a white solid. The X-ray 
powder diffraction pattern of the product is different to that of the starting materials but was 
also compared to a number of patterns simulated from previously published pyrazinamide 
polymorphs
76,83,97,98
. It can be seen from figure 3.4 that the product may contain a mixture of 
the polymorphs (δ(PYRAZIN16) and γ(PYRAZIN17))98,83. The quality of new product was 
not suitable for single crystal X-ray diffraction analysis and further investigation was not 
carried out. As the product was clearly a mixture, it was also deemed not suitable for NMR. 
The cocrystal structure of pyrazinamide:malonic acid (1:1)
90
 was published by another 
research group after this work had been carried out. The X-ray powder diffraction pattern of 
product formed was compared with the simulated pattern of the pyrazinamide: malonic acid 
that was published. The patterns displayed no match with the published structure and hence 
the cocrystallisation in this work was unsuccessful. 
 
Figure 3.4: X-ray powder diffraction patterns of the product of pyrazinamide and malonic 
acid crystallisation from methanol, the starting materials (pyrazinamide, malonic acid), 
common pyrazinamide polymorphs and SX Simulated pattern of published structure of 
pyrazinamide and malonic acid. 
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3.4   Pyrazinamide and maleic acid 
Pyrazinamide was crystallised with maleic acid, using methanol used as solvent in a 1:1 
stoichiometric ratio. The product formed as a dark yellow solid using solvent evaporation 
method for synthesis. The X-ray powder diffraction pattern of the product formed was 
different to that of the starting materials confirming the formation of new material. The X-ray 
powder diffraction pattern of the product was also compared with a number of simulated 
patterns from previously published pyrazinamide polymorphs
76,83,97,98
. Figure 3.5 shows that 
the product contains some excess maleic acid (see peaks at 17º, 25º and 28º 2-theta) possibly 
mixed with polymorph (γ(PYRAZIN17))83 but also with some new unknown product present.  
 
Figure 3.5: X-ray powder diffraction pattern of the product of pyrazinamide and maleic acid 
crystallisation from methanol, the starting materials (pyrazinamide, maleic acid) and 
common pyrazinamide polymorphs. 
 
The 
1
H MNR analysis (appendix a-1) showed a pyrazinamide:maleic acid stoichiometry of 
1:1 but this is inconclusive as the product is clearly a mixture of a number of materials. 
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3.5   Pyrazinamide and fumaric acid 
Pyrazinamide and fumaric acid were dissolved in methanol and the solutions combined for 
cocrystal synthesis as in previous experiments in a 1:1 stoichiometric ratio. The product 
formed was a white solid, obtained through the solvent evaporation method for 
crystallisation. The X-ray powder diffraction pattern of the product formed was compared 
with the starting materials and with the simulated powder pattern of the previously published 
of pyrazinamide:fumaric acid (2:1)
82
 cocrystal structure. This confirmed that the product 
obtained was identical to the previously published pyrazinamide:fumaric acid cocrystal 
structure although the sample also contained a small excess of fumaric acid (see peaks at 24º, 
26º and 29º 2-theta)  (figure 3.6).  
 
Figure 3.6: X-ray powder diffraction patterns of the products of pyrazinamide and fumaric 
aid crystallisation from methanol, the starting materials (pyrazinamide, fumaric acid), 
common pyrazinamide polymorphs and SX Simulated pattern of published structure of 
pyrazinamide and fumaric acid. 
Analysis of the 
1
H NMR showed a pyrazinamide:fumaric acid proportion of 1:1; however 
this is not agreement with the PXRD result in which a 2:1 stoichiometry is confirmed. This 
anomaly may however be explained by the presence of excess fumaric acid in the product 
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that may by coincidence increase the NMR ratio of the components from 2:1 to 1:1 (figure 
3.7). 
 
Figure 3.7: 
1
H NMR of the product of pyrazinamide and fumaric acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.83 (1H, s), 8.29 (1H, 
s), 8.72 (1H, t), 8.90 (1H, d), 9.19 (1H, d): fumaric acid 6.65 (2H, s). 
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3.6  Pyrazinamide and succinic acid 
Pyrazinamide and succinic acid were dissolved separately in methanol for crystallisation, the 
solutions combined in a 1:1 stoichiometric ratio and the solvent allowed to evaporate. The 
product was a white solid crystalline material obtained through the solvent evaporation 
crystallisation method. The X-ray powder diffraction pattern of the product formed was 
compared with starting materials and with the simulated powder pattern of previously 
published of pyrazinamide:succinic acid cocrystal structures (2:1)
90
. This confirmed that the 
product formed was mixture and showed no match with the simulated powder pattern of 
previously published of pyrazinamide:succinic acid cocrystal and the product also contain an 
excess of succinic acid (figure 3.8). 
 
Figure 3.8: X-ray powder diffraction patterns of the products of pyrazinamide and succinic 
aid crystallisation from methanol, the starting materials (pyrazinamide, succinic acid), 
common pyrazinamide polymorphs and SX Simulated pattern of published structure of 
pyrazinamide and succinic acid. 
Analysis of the 
1
H NMR showed a pyrazinamide:succinic acid proportion of 3:2 confirming 
that the resultant solid was a mixture of the two components (figure 3.9 ). 
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Figure 3.9: 
1
H NMR of the product of pyrazinamide and succinic acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.83 (1H, s), 8.29 (1H, 
s), 8.72 (1H, t), 8.90 (1H, d), 9.19 (1H, d):succinic acid  2.40 (3H, s). 
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3.7   Pyrazinamide and glutaric acid 
Pyrazinamide and glutaric acid were dissolved in methanol in the solution combined in a 1:1 
stoichiometric ratio and the solvent allowed to evaporate for crystallisation. The product was 
a white solid. The X-ray powder diffraction pattern of this product was different to that of the 
starting materials confirming the formation of a new material. The powder diffraction pattern 
of the product was also compared to a number of simulated patterns from previously 
published pyrazinamide polymorphs
76,83,97,98
. It can be seen from figure 3.10 that the product 
does not contain any trace of either of the starting materials but is mixed with a negligible 
amount of polymorph (γ(PYRAZIN17))83. 
 
Figure 3.10: X-ray powder diffraction patterns of the product of pyrazinamide and glutaric 
acid crystallisation form methanol, the starting materials (pyrazinamide, glutaric acid), 
and common pyrazinamide polymorphs. 
 
1
H NMR indicated that the new material prepared from crystallisation of a 1:1 
stoichiometric starting ratio also contains the molecular coformers in a 1:1 stoichiometric 
ratio (figure 3.11). 
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Figure 3.11: 
1
H NMR of the product of pyrazinamide and glutaric acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.83 (1H, s), 8.29 (1H, 
s), 8.72 (1H, t), 8.92(1H, d), 9.19(1H, d) :  glutaric acid 1.71 (2H, t), 2.26 (4H, q). 
 
3.7.1  Crystal structure determination from single crystal X-ray diffraction data 
Once the bulk product was identified as a new solid material with a 1:1 ratio of components, 
the sample was submitted for single crystal analysis. This crystal structure determination 
confirmed that the stoichiometric ratio of the pyrazinamide and glutaric acid adduct was 
indeed 1:1 and that a neutral cocrystal of pyrazinamide:glutaric acid had been formed (no 
proton transfer had taken place between the components). Further crystallographic details of 
this structure determination are given in Table 3.3. 
Figure 3.12 shows the asymmetric unit of this cocrystal structure containing one glutaric acid 
molecule and one pyrazinamide molecule linked through two hydrogen bonds. The atom 
labelling used for subsequent discussion is also shown in the figure.  
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Table 3.3. Crystal data and structure refinement of pyrazinamide:glutaric acid 1:1. 
Identification code  Pyrazinamide_Glutaric Acid 
Empirical formula  (C5H5N3O), (C5H8O4) 
Formula weight  255.23 
Temperature  100.00(10) K 
Wavelength  1.5418 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 11.3844(9) Å α= 90.00 °. 
 b = 4.8251(7) Å β= 104.610(9)°. 
 c = 21.9011(16) Å γ = 90.00 °. 
Volume 1164.1(2) Å3 
Z 4 
Density (calculated) 1.456  Mg/m3 
Absorption coefficient 1.012 mm-1 
F(000) 536.0 
Crystal size 0.15 x 0.1 x 0.03 mm3 
Theta range for data collection 12.98 to 133.16°. 
Index ranges -13 ≤ h ≤ 13, -5 ≤ k ≤ 5, -22 ≤ l ≤ 26 
Reflections collected 3397 
Independent reflections 3397 [R(int) = 0.0000, R(sigma) = 0.0256] 
Completeness to theta = 67.684° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.970 and 0.859 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3397 / 0 / 166 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0397, wR2 = 0.1037 
R indices (all data) R1 = 0.0491, wR2 = 0.1076 
Extinction coefficient n/a 
Largest diff. peak and hole 0.18 and -0.022 e.Å-3 
 
Notes: The crystal was a non-merohedral twin with the domains related by 180 degrees about the direct axis [0 0 
1] and the refined percentage domain ratio being 64:36. 
___________________________________________________________________________ 
Anas. M. Al-Abachi                                                                                        Results                                                                                                               
 
 Page 51 
 
 
Figure 3.12: The asymmetric unit in the crystal structure of pyrazinamide:glutaric acid (1:1) 
showing the atom numbering scheme and the strong hydrogen bonds between the two 
molecular components. Hydrogen bonds are shown as dotted lines. 
 
The basic supramolecular structure motif within the asymmetric unit (figure 3.12) is formed 
by the pyrazinamide molecule linked to a glutaric acid molecule through two strong hydrogen 
bonds; N-H.....O=C in which the amide nitrogen N(7) acts as a donor via H(7A) to the 
carboxyl oxygen O(9), and O-H
….
O=C in which O(8) acts as a donor via H(8) to the amide 
oxygen O(7) as acceptor  table 2.These combine to form a 22R (8) hydrogen bond ring (table 
3.4).  
The formation of an intramolecular N-H
…
N hydrogen bond within the pyrazinamide 
molecule in which the amide nitrogen N(7) acts as a donor via H(7B) to N(4) further 
stabilizes the conformation of the pyrazinamide within the asymmetric unit this 
intramolecular interaction is not shown in Figure 3.12. 
The asymmetric units are linked together into an infinite chain by two further hydrogen 
bonds; a strong acid-pyridine interaction O-H
…
N in which O(12) acts as a donor via H(12) to 
the pyridine nitrogen N(1) and a weak C-H
…
O=C interaction in which C(2) in the 
pyrazinamide acts as a donor via H(2) to the oxygen O(13) in the glutaric acid. Together 
these hydrogen bonds form a 2
2R (7) ring such that a supramolecular chain of alternating 
2
2R
(7) and 
2
2R (8) rings are generated through alternating acid-amide and acid-pyridine motifs 
(figure 3.13).  
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Table 3.4: Intermolecular and intramolecular hydrogen bond distances (Å) and angles (
o
) 
within the pyrazinamide:glutaric acid (1:1) cocrystal.  
D-H-A                      d(D-H)              d(H
……
A)               d(D
……
A)                   <(DHA) 
N(7)-H(7A)
….
O(9) 
N(7)-H(7B)
....
N(4)   
N(7)-H(7B)
….
O(9)
i
          
O(8)-H(8)
….
O(7)   
O(12)-H(12)
….
N(1)
ii
  
C(2)-H(2)
….
O(13)
i
 
C(3)-H(3)
….
O(13)
iii
 
C(9)-H(9A)
….
O(8)
i
 
C(11)-H(11A)
…..
O(7)
i
                  
0.88 
0.88 
0.88 
0.84 
0.84 
0.95 
0.94 
0.99 
0.98
1.98 
2.32 
2.17 
1.79 
1.88 
2.58 
2.97 
2.55 
2.825 
2.849(16) 
2.701(2) 
2.851(16) 
2.616(15) 
2.727(16) 
3.252(2) 
3.571(2) 
3.382 
3.214 
168 
105 
133 
166 
178 
127 
122 
141 
104 
Symmetry code: i) 1-x,2-y, (ii) x-1,-y, z-1/2; (iii) x+1,-y, z+1/2 
 
 
Figure 3.13: A view of the pyrazinamide:glutaric acid (1:1) cocrystal structure showing the 
alternating acid-amide and acid-pyridine rings in the chain. Hydrogen bonds are shown as 
thin light blue lines. 
Within each of these chains the pyrazinamide molecules adopt the same orientation and face 
the same direction. These hydrogen bonded chains are then cross-linked to a neighbouring 
parallel chain via an additional N-H
….
O=C intermolecular hydrogen bond donated by N(7) 
through H(7B) to O(9) of a glutaric acid on the neighbouring chain. This complementary 
hydrogen bond interaction results in the formation of an 
2
4R (8) ring between the chains which 
run in opposite but parallel directions (figure 3.14). This is reinforced by a weak hydrogen 
bond intermolecular hydrogen bond C(3)-H(3)
….
O(13) in which H(3) on the pyrazinamide 
ring is donated by C(3) to O(13) of the glutaric acid (table 3.4).  
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Figure 3.14: A view of the pyrazinamide:glutaric acid cocrystal structure (1:1) showing the 
intermolecular hydrogen bonds between opposing chains. 
Each of these ribbons is linked to another by two weak C-H
….
O hydrogen bonds in which 
C(9) in the glutaric acid molecule acts as a donor via H(9A) to the oxygen O(8) as acceptor in 
the neighbouring glutaric acid molecule, and secondly in which C(11) in the glutaric acid 
molecule acts as a donor via H(11A) to the pyrazinamide oxygen O(7) (figure 3.15). All 
strong hydrogen bonding donor and acceptor sites in both molecules are involved in the 
hydrogen-bonded network in this structure. 
 
Figure 3.15: Diagram of the pyrazinamide:glutaric acid cocrystal structure (1:1) showing 
the combination of ribbons linked by C-H
….
O interactions to form an infinite sheet. 
Table 3.5 gives information regarding the geometry within the pyrazinamide:glutaric acid 
molecules. In the pyrazinamide, the bond lengths of C(7)-N(7) and C(7)-O(7) are 1.3192(19) 
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and 1.488(17) respectively and confirm the orientation of the amide group . In the acid, the 
bond lengths of C(8)-O(8) and C(8)-O(9) are 1.3221(17) and 1.2227(18); C(12)-O(12) and 
C(12)-O(13) are 1.3291(18) and 1.214(18) respectively, showing a clear distinction between 
the C=O and C-O(H) components of the carboxylic acid functional group, hence confirming 
that there is no proton transfer between the neutral components in this cocrystal structure.  
The torsion angles within the pyrazinamide molecule N(4)-C(5)-C(7)-N(7) and C(6)-C(5)-
C(7)-N(7) are 2.13(2) and -177.63(13) respectively and show a slight deviation from 
planarity. The molecule is partially stabilized in this conformation by the intramolecular N-
H
….
N which would result a planner conformation, but other intermolecular interactions also 
effect this geometry and causes slight distortion. 
The conformation of the glutaric acid is however far from expected. There is only one of the 
backbone angles C(8)-C(9)-C(10)-C(11) that is close to planar. All others, including the 
relationship between the carbon backbone and the carboxylic acid groups is significantly 
distorted. The result is that the angle between the planes of the two carboxylic groups is -
71.04(17) and 153.15(12)
o
. The orientation of the protonated oxygen on both ends is the same 
and the molecule then acts as a ‘bent’ molecule linker in the cocrystal structure. This type of 
unconventional conformation is not unusual for diacids with odd chain length. 
 
Table 3.5: Selected intramolecular bond lengths and torsion angles within the pyrazinamide: 
glutaric acid (1:1) cocrystal. 
Pyrazinamide Bond Lengths        (Å)                    Acid Bond Lengths         (Å) 
C(7)-N(7) 
C(7)-O(7) 
1.3192(19) 
1.2488(17)    
C(8)-O(8) 
C(8)-O(9) 
C(12)-O(12) 
C(12)-O(13)   
1.3221(17) 
1.2227(18) 
1.3291(18) 
1.214(18)                                                                                                                
Pyrazinamide Torsion Angles        (
o
) Acid Torsion Angles         (
o
) 
N(4)-C(5)-C(7)-N(7) 
N(4)-C(5)-C(7)-O(7) 
C(6)-C(5)-C(7)-O(7) 
C(6)-C(5)-C(7)-N(7)   
 
 2.13(2) 
-178.54(13) 
 1.70(2)   
-177.63(13) 
  
 
C(8)-C(9)-C(10)-C(11)  
C(9)-C(10)-C(11)-C(12) 
C(10)-C(11)-C(12)-O(12)  
O(8)-C(8)-C(9)-C(10) 
O(8)-C(8)-C(12)-O(12) 
O(8)-C(8)-C(12)-O(13)     
O(9)-C(8)-C(9)-C(10)         
-177.22(12) 
-68.44(17) 
173.80(12) 
 61.34(16) 
-71.04(17) 
 153.15(12)           
-117.84(16)                                                                                                                                                                                                                                            
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The synthesis of this pyrazinamide:glutaric acid adduct was also attempted using different 
methods of synthesis and the resulting X-ray powder diffraction patterns were compared with 
each other. The X-ray powder data of the material obtained from solvent evaporation matches 
that of the material obtained through solvent drop grinding with both of these patterns 
matching that of the simulated powder diffraction pattern from the single crystal structure of 
pyrazinamide:glutaric acid (1:1) (figure 3.16). Please note that the crystal structure in this 
work was determined at low temperature (100 k) and hence some peak positions will be 
shifted. 
Following the completion of this work and determination of the pyrazinamide:glutaric acid 
(1:1) cocrystal structure reported here, a paper was published in the literature by Luo et al
90
.  
also reporting this crystal structure. It can be seen from Figure 3.16 that the powder 
diffraction pattern matches the structure in this work. (the differences in peak positions arise 
from the Luo et al. structure being determined at 293 k.) 
 
Figure 3.16: X-ray powder diffraction patterns of products obtained through different 
methods of synthesis and the simulated powder diffraction patterns from the single crystal 
structure of the pyrazinamide:glutaric acid (1:1) cocrystal. From both this work and 
published structure.(Luo et al.)
90 
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dipic acidaPyrazinamide and 3.8    
Pyrazinamide was combined with adipic acid using methanol as a solvent to dissolve the 
starting materials in a 1:1 stoichiometric molar ratio. The solvent evaporation method was 
used for crystallisation and the new material formed as a white crystalline solid. The powder 
diffraction pattern of the product was compared with that of the starting materials and 
patterns simulated from previously published
 
pyrazinamide polymorphs
76,83,97,98
. The X-ray 
powder diffraction pattern of the product material confirms the formation of a new material 
(figure 3.17) but the sample may also contains an excess of adipic acid starting material (see 
peaks at 21º, 25º and 31º 2-theta) and there may be some pyrazinamide polymorph (β 
(PYRAZIN18))
76
 present. 
 
Figure 3.17: X-ray powder diffraction patterns of the product of pyrazinamide and adipic 
acid crystallisation from methanol, the starting materials (pyrazinamide and adipic acid) and 
common pyrazinamide polymorphs. 
 
From the powder diffraction data, the bulk material formed is clearly a mixture. 
1
H NMR of 
the product formed by crystallisation of 1:1 starting materials shows a resulting 2:3 
stoichiometric ratio of pyrazinamide and adipic acid (figure 3.18).  
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Figure 3.18: 
1
H NMR of the product of pyrazinamide and adipic acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.83 (1H ,s), 8.29 
(1H, s), 8.72 (1H, t), 8.92(1H, d), 9.19(1H, d) : adipic acid  1.51(6H, q), 2.22(6H, t), 12.08 
(2H, s). 
 
3.8.1 Crystal structure determination from single crystal X-ray diffraction data 
A small amount of the product was submitted for single crystal analysis and the crystal 
structure of a new pyrazinamide: adipic acid cocrystal was determined. The stoichiometric 
ratio of the pyrazinamide:adipic acid adduct was found to differ significantly from the NMR 
result above. This crystal structure determination confirmed that the ratio of the conformers 
within the adduct was indeed 4:1 pyrazinamide: adipic acid. This contradiction between the 
two techniques is to be expected as PXRD showed the presence of adipic acid in the mixed 
bulk material hence significantly increasing the proportion of adipc acid with respect to the 
pure cocrystal structure identified by single crystal diffraction. This crystal structure also 
confirmed that a neutral cocrystal of pyrazinamide: adipic acid had been formed and that no 
proton transfer had taken place between the two molecular components. The crystallographic 
details of this structure are given in Table 3.6. 
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Table 3.6. Crystal data and structure refinement of pyrazinamide:adipic Acid 4:1. 
Identification code  Pyrazinamide_AdipicAcid 
Empirical formula  4(C5H5N3O), C6H10O4 
Formula weight  638.62 
Temperature  100.00(10) K 
Wavelength  1.5418 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 5.1814(8) Å α= 74.708(11)°. 
 b = 11.7163(16) Å β= 87.314(11)°. 
 c = 12.2250(14) Å γ = 85.212(12)°. 
Volume 713.13(17) Å3 
Z 1 
Density (calculated) 1.487 Mg/m3 
Absorption coefficient 0.963 mm-1 
F(000) 334 
Crystal size 0.200 x 0.090 x 0.060 mm3 
Theta range for data collection 7.516 to 70.053°. 
Index ranges -6<=h<=5, -13<=k<=14, -14<=l<=10 
Reflections collected 4178 
Independent reflections 2666 [R(int) = 0.0348] 
Completeness to theta = 67.684° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9445 and 0.8308 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2666 / 0 / 223 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0623, wR2 = 0.1642 
R indices (all data) R1 = 0.0731, wR2 = 0.1780 
Extinction coefficient n/a 
Largest diff. peak and hole 0.353 and -0.368 e.Å-3 
 
Notes: There are four pyrazinamide molecules for every acid. The acid is located on an inversion centre such 
that only half the molecule is crystallographically unique. The hydrogen atoms bonded to N(7A), N(7B) and 
O(8) were located in the electron density and their positions refined. The remaining hydrogen atoms were fixed 
as riding models. The Uiso of all hydrogen atoms are based on Ueq or the parent atoms. 
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Figure 3.19 shows the atom labelling and the hydrogen bonds present in the asymmetric unit 
of this cocrystal structure. It contains two pyrazinamide molecules to one half adipic acid 
molecule linked through hydrogen bonds.  
 
 
Figure 3.19: The asymmetric unit in the crystal structure of pyrazinamide:adipic acid (4:1) 
showing the atom numbering scheme. Strong hydrogen bonds are shown as dotted lines. 
Atom labels with superscript denote the crystallographically equivalent half adipic acid 
molecule. Atom labels ‘A’ and ‘B’ denote the two crystallographically inequivalent 
pyrazinamide molecules. 
 
The basic supramolecular structure motif within the asymmetric unit (Figure 3.19) is formed 
by two pyrazinamide molecules and one half adipic acid molecule that is located on an 
inversion centre to create the complete molecule. There is a strong acid-pyridine interaction 
O-H
…
N in which O(8) in the adipic acid acts as a donor via H(8) to the pyridine nitrogen 
N(1) in the pyrazinamide molecule, this is reinforced by a weak hydrogen bond C-H
…
O in 
which C(6A) in pyrazinamide acts as donor via H(6A) to O(9) in adipic acid. These combine 
to form a 
2
2R (7) hydrogen bond ring. The two pyrazinamide molecules are linked to each 
other through complementary strong hydrogen bonds N-H
…
O in which the amide nitrogen 
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N(7A) or N(7B) acts as a donor via H(7A2) or H(7B2) to amide oxygen O(7B) or O(7A) 
respectively. These combine to form the common 22R (8) hydrogen bond ring found in most 
pyrazinamide structures. There are two N-H
….
N intra hydrogen bonds in pyrazinamide 
molecules influences on the planarity of pyrazinamide molecule; N-H
…
N in which the amide 
nitrogen N(7A) or N(7B) acts as a donor via H(7A) or H(7B) to the pyridine nitrogen N(4A) 
or N(4B)  respectively table 3.7.  
 
The pyrazinamide dimer within each asymmetric unit is then linked to the adjacent unit via 
additional three sets of hydrogen bonds. N-H
….
O in which the amide nitrogen N(7A) acts as a 
donor via H(7A1) to the amide oxygen O(7B) to form a complementary 24R (8) ring. Two 
distinct C-H
….
N interactions are formed in which C(3A) acts as a donor via H(3A) to the 
pyridine nitrogen N(1B) while C(6B) acts as a donor via H(6B) to the other heterocyclic 
nitrogen N(4A), together forming a 22R (6) ring. Finally, these units are linked together into an 
infinite chain through the adipic acid lying on an inversion centre (figure 3.20). 
 
Table 3.7: Intermolecular hydrogen bond distances (Å) and angles (
o
) within pyrazinamide: 
adipic acid 
D-H-A                        d(D-H)              d(H
……
A)               d(D
……
A)                   <(DHA) 
N(7A)-H(7A1)
….
O(7B)
ii
     
N(7A)-H(7A2)
....
O(7B)  
N(7A)-H(7A1)
….
N(4A) 
N(7B)-H(7B1)
….
N(4B)       
N(7B)
1
-H(7B1)
….
N(4B)iv        
N(7B)-H(7B1)
....
O(7A)      
O(8)-H(8)
....
N(1A)              
C(2A)-H(2A)
....
O(8)           
C(2B)-H(2B)
….
O(9)
iii
           
C(3A)-H(3A)
….
N(1B)
ii
          
C(3B)-H(3B)
….
O(7A)        
C(6A)-H(6A)
….
O(9) 
C(6B)-H(6B)
….
N(4A)               
0.89                      
0.92 
0.89                     
0.91                     
0.90 
0.90 
0.91                       
0.89             
0.95 
0.95 
0.95 
0.95 
0.95 
2.28 
2.08 
2.40                  
2.31 
2.55 
1.87 
1.83
2.38 
2.43 
2.63 
2.39 
2.53 
2.39 
3.026(2) 
2.998(3) 
2.768(3)                       
2.732(3)                       
3.183(3) 
2.784(3) 
2.711(3) 
3.297(3) 
3.356(3)                       
3.451(3) 
3.325(3) 
3.226(3) 
3.269(3) 
140 
175 
105 
107 
126 
176 
173 
163 
165 
144 
170 
130 
154 
Symmetry code: i) –3+x,1+y,2+z, (ii )3-x,-y,-z, (iii) x,y,1+z,(iv) –x+3,-y,-z+1 
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Figure 3.20: A view of the pyrazinamide:adipic acid (4:1) cocrystal structure showing the 
hydrogen bonded acid-pyridine rings, pyrazinamide dimers and linking hydrogen bonded 
rings to form an infinite chain. Hydrogen bonds are shown as thin light blue lines. The 
pyrazinamide molecules A and B are indicated.  
These hydrogen bonded chains are then cross-linked to a neighbouring parallel chain via four 
intermolecular hydrogen bonds on the neighbouring chain; three weak C-H
….
O  in which 
C(2A) in pyrazinamide acts as a donor through H(2A) to oxygen O(8) in a adipic acid as 
acceptor; C-H
….
O in which C(2B) in pyrazinamide acts as a donor through H(2B) to oxygen 
O(9) in adipic acid as acceptor; C-H
….
O in which C(3B) in pyrazinamide acts as a donor 
through H(3B) to oxygen O(7A) in pyrazinamide as acceptor and finally a strong hydrogen 
bond N-H
....
N in which the amide nitrogen N(7B) in pyrazinamide acts as a donor through 
H(7B1) to the pyridine N(4B) in the neighbouring pyrazinamide dimer (figure 3.21). 
 
Figure 3.21: A view of the pyrazinamide:adipic acid (4:1) cocrystal structure showing the 
intermolecular hydrogen bonds between opposing supramolecular chains. 
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This results in the formation of an extended hydrogen bonded sheet in which all strong 
hydrogen bond donors and acceptors are used in the complex hydrogen-bonded network. 
The bond lengths and torsion angles within the pyrazinamide:adipic acid cocrystal are given 
in (table 3.8). The bond lengths in pyrazinamide C(7A)-N(7A) and C(7A)-O(7A) are 
1.334(3) and 1.235(2) respectively, confirming the orientation of the amide group. In the 
acid, the bond lengths C(8)-O(8) and C(8)-O(9), again show a clear distinction between the 
C=O and C-O(H) components of the carboxylic acid functional group, hence confirming that 
there is no proton transfer between the components in this cocrystal structure. 
 
The torsion angles within the pyrazinamide molecule (A) [N(4A)-C(5A)-C(7A)-N(7A) and 
C(6A)-C(5A)-C(7A)-N(7A)] are -0.91(3) and 179.33(2) respectively and show that molecule 
(A) is planar. However, the torsion angles of molecule (B) [N(4B)-C(5B)-C(7B)-N(7B) and 
C(6B)-C(5B)-C(7B)-N(7B)] are 9.80(3) and -168.51(2) respectively showing that molecule 
(B) is slightly distorted in terms of the conformation of the the amide group. Both molecules 
are stabilised by the intramolecular N-H
….
N interaction, but the amide group in molecular B 
is also involved in an intermolecular N-H
….
N interaction that may explain the required 
distortion of this molecular conformation. 
The torsion angles within the adipic acid molecule show that overall the molecule is planar as 
expected in this type of acid with an inversion centre and even chain length. 
 
Table 3.8: Selected intramolecular bond lengths and torsion angles within the pyrazinamide: 
adipic acid (4:1) cocrystal. 
Pyrazinamide Bond Lengths       (Å)                    Acid Bond Lengths         (Å) 
 C(7A)-N(7A) 
 C(7A)-O(7A) 
 C(7B)-N(7B) 
 C(7B)-O(7B) 
1.334(3) 
1.235(2) 
1.331(3) 
1.240(2) 
C(8)-O(8) 
C(8)-O(9) 
 
1.324(3) 
1.209(3) 
 
 Pyrazinamide Torsion Angles      (º) Acid Torsion Angles         (º) 
 N(4A)-C(5A)-C(7A)-N(7A)  
 C(6A)-C(5A)-C(7A)-N(7A)   
 N(4B)-C(5B)-C(7B)-N(7B)  
 C(6B)-C(5B)-C(7B)-N(7B) 
 
-0.91(3) 
 179.33(2) 
 9.80(3) 
-168.51(2) 
 
O(8)-C(8)-C(9)-C(10) 
O(9)-C(8)-C(9)-C(10) 
C(8)-C(9)-C(10)-C(10)
1   
C(9)-C(10)-C(10)
1
-C(9)
1
  
O(8)-C(8)-C(8)
1
-O(8)
1 
                                                                                                    
O(9)-C(8)-C(8)
1
-O(9)
1
      
-179.39(19) 
 0.44(3) 
 -174.20(2) 
 180.00 
180.00
-180.00 
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The synthesis of this pyrazinamide: adipic acid adduct was also attempted using different 
methods of synthesis. The X-ray powder data of the material obtained from solvent 
evaporation was compared with that obtained through solvent drop grinding and both of these 
patterns were compared with the simulated powder diffraction pattern from the single crystal 
structure of pyrazinamide:adipic acid (4:1) (figure 3.22). The (4:1) crystal structure was 
determined at low temperature and hence some peak positions are shifted relative to room 
temperature of powder diffraction patterns. As expected, the original pattern from evaporation 
shows a mixture of adipic acid and the single crystal structure although there is also some 
preferred orientation distorting the relative intensities. The material obtained by grinding 
shows a mixture of cocrystal, with both adipic acid and pyrazinamide starting materials. 
 
 
Figure 3.22: X-ray powder diffraction patterns of products obtained through different 
methods of synthesis and the simulated powder diffraction pattern from the single crystal 
structure of the pyrazinamide:adipic acid (4:1) cocrystal.  
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3.9   Pyrazinamide and pimelic acid 
Pyrazinamide was crystallised with pimelic acid in this case using a range of different 
solvents for synthesis (methanol, ethanol, isopropanol and ethyl acetate) in combination with 
a number of different stoichiometric starting ratios (1:1, 1:2 and 2:1). All products formed as 
white solids and were obtained through the solvent evaporation crystallisation method. The X-
ray powder diffraction patterns of three materials formed were compared with those data from 
the starting materials and a number of simulated powder patterns from previously published 
pyrazinamide polymorphs
76,83,97,98
. It can be seen from Figure 3.23 that the powder patterns of 
all three products are inconclusive except that they contain differing amounts of new product 
mixed with both pimelic acid (see peaks at 19º, 23º and 27º 2-theta) and pyrazinamide 
polymorphs (α(PYRAZIN15, δ(PYRAZIN16))97,98. 
The X-ray powder patterns for pyrazinamide:pimelic acid in stoichiometric ratio 1:2 and 2:1 
match that of pyrazinamide: pimelic acid (1:1) with excess stating material also present in the 
mixture.  
 
Figure 3.23: X-ray powder diffraction patterns of the products of pyrazinamide and pimelic 
acid crystallisation from methanol in different stoichiometric ratios (1:1 and 1:2), the 
starting materials (pyrazinamide, pimelic acid) and other common pyrazinamide polymorphs. 
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The bulk product is clearly a mixture but 
1
H NMR indicated that the new material prepared 
from crystallisation of a 1:1 ratio of starting materials, also contains the molecular coformers 
in a 1:1 stoichiometric ratio (figure 3.24). 
 
Figure 3.24: 
1
H NMR of the product of pyrazinamide and pimelic acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.83 (1H, s), 8.29 (1H, 
s), 8.72 (1H, t), 8.92(1H, d), 9.19(1H, d): pimelic acid 1.25(2H, q), 1.51(4H, q) 2.22(4H, t) 
 
3.9.1 Crystal structure determination from single crystal X-ray diffraction data 
Once the bulk product was identified as containing a small amount of new unidentified 
material, the sample was submitted for single crystal analysis. This crystal structure 
determination confirmed that the stoichiometric ratio of the pyrazinamide and pimelic acid 
adduct was indeed 1:1, and that a neutral cocrystal of pyrazinamide:pimelic acid had been 
formed in which no proton transfer had taken place between the components. Further 
crystallographic details of this structure determination are given in Table 3.9. 
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Table 3.9. Crystal data and structure refinement of pyrazinamide:pimelic acid 1:1. 
 
Identification code  Pyrazinamide_Pimelic acid 
 Empirical formula  (C5H5N3O), (C7H12O4) 
Formula weight  283.29 
Temperature  100.15 K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.3302(4)  Å α= 89.478(7)°. 
 b = 8.4201(6) Å β=82.760(7)°. 
 c = 15.5321(11) Å γ =71.840(6)°. 
Volume 656.75(9) Å3 
Z 2 
Density (calculated) 1.433 Mg/m3 
Absorption coefficient 0.113 mm-1 
F(000) 300.0 
Crystal size 0.42 × 0.16 × 0.02 mm3 
Theta range for data collection 7.46 to 54.96 °. 
Index ranges -6 ≤ h ≤ 6, -10 ≤ k ≤ 10, -20 ≤ l ≤ 20 
Reflections collected 7308 
Independent reflections 2979 [R(int) = 0.0290, R(sigma) = 0.0228] 
Completeness to theta = 67.684° 99.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.998 and 0.954 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2979 / 0 / 183 
Goodness-of-fit on F2 1.062  
Final R indices [I>2sigma(I)] R1 = 0.0350, wR2 = 0.0984 
R indices (all data) R1 = 0.0381, wR2 = 0.1010 
Extinction coefficient n/a 
Largest diff. peak and hole                           0.40 and -0.21 e.Å-3 
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Figure 3.25 shows the asymmetric unit of this cocrystal structure containing one 
pyrazinamide molecule and one pimelic acid molecule linked through hydrogen bonds. The 
atom labelling used for subsequent discussion is also shown below. 
 
Figure 3.25: The asymmetric unit in the structure of the pyrazinamide:pimelic acid (1:1) 
showing the atom numbering scheme and the strong hydrogen bond between the two 
molecular components. Hydrogen bonds are shown as dotted lines. 
The basic supramolecular structure motif within the asymmetric unit (figure 3.25) is formed 
by the pyrazinamide molecule interacting with the pimelic acid molecule through a strong 
hydrogen bond O-H
….
N in which O(8) in the carboxyl oxygen acts as a donor via H(8) to the 
pyridine nitrogen N(1). This is reinforced by a weak hydrogen bond C-H
…
O in which C(2) in 
pyrazinamide acts as donor via H(2) to O(9) in the pimelic acid (table 3.10). As in previous 
structures, there is an intramolecular hydrogen bond formed between N(7) and N(4) via 
H(7B) within the pyrazinamide molecule, stabilising the conformation. 
Table 3.10: Intermolecular hydrogen bond distances (Å) and angles (
o
) within the 
pyrazinamide:pimelic acid (1:1) cocrystal. 
D-H-A                        d(D-H)              d(H
……
A)               d(D
……
A)                   <(DHA) 
N(7)-H(7A)
….
O(15) 
N(7)-H(7B)
….
O(15)
ii
   
N(7)-H(7B)-N(4)  
O(8)-H(8)
….
N(1)
    
O(14)-H(14)
….
O(7)
iii
           
C(12)-H(12B)
….
N(4)
  
C(2)-H(2)
….
O(9)    
C(3)-H(3)
….
O(9)
  
C(9)-H(9A)
….
 O(7) 
    
                                                                     
 
0.88 
0.88 
0.88 
0.84 
0.84 
0.99 
0.95 
0.95 
0.99 
  2.09 
  2.57 
  2.36 
  1.91 
  1.81 
  2.69 
  2.51 
  2.55 
  2.56 
2.938(12) 
3.011(12) 
2.727 
2.751(12) 
2.643(11) 
3.472 
3.187 
3.359 
3.367  
162 
112 
105 
178 
168 
135 
127 
142 
138 
Symmetry code: i) +X,-1+Y,1+Z; (ii) -X,2-Y,-Z; (iii) +X,1+Y,-1+Z 
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The asymmetric units are linked together into an infinite chain by two further strong hydrogen 
bonds; a strong acid-amide interaction N-H
.....
O=C in which the amide nitrogen N(7) acts as a 
donor via H(7A) to the carboxyl oxygen O(15) and O-H
….
O=C in which O(14) acts as a donor 
via H(14) to the amide oxygen O(7) as acceptor. Together these hydrogen bonds form a 22R (7) 
ring such that a supramolecular chain of alternating 22R (7) and 
2
2R (8) rings are generated 
through alternating acid-amide and acid-pyridine motifs (figure 3.26). Within each of these 
chains the pyrazinamide molecules adopt the same orientation and face the same direction. 
 
Figure 3.26: A view of the pyrazinamide:pimelic acid (1:1) cocrystal structure showing the 
alternating acid-amide and acid-pyridine rings. 
These hydrogen bonded chains are then cross-linked to a neighbouring parallel chain via three 
additional hydrogen bonds. One strong hydrogen bond, N-H
….
O=C, is donated by the amide 
nitrogen N(7) through H(7B) to O(15) on pimelic acid in the neighbouring chain. The 
complementary nature of this hydrogen bond results in the formation of an 24R (8) ring 
between the chains which run in opposite but parallel directions (figure 3.27). Two weak 
hydrogen bonds then act to reinforce this structure; C-H
….
N is formed by C(12) via H(12B) 
from pimelic acid to the heterocyclic N(4) and C-H
….
O by donation of H(3) to the pimelic 
acid O(9). 
 
Figure 3.27: Diagram of pyrazinamide:pimelic acid crystal structure (1:1) showing the 
intermolecular interactions between two adjacent chains. 
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Each ribbon is linked to another ribbon by a further C-H
…
O hydrogen bond in which C(9) in 
the pimelic acid molecule acts as a donor via H(9A) to oxygen O(7) in the neighbouring 
pimelic acid molecule which in this case acts as the acceptor (figure 3.28). This forms an 
infinite hydrogen bonded sheet of molecules lying parallel to the [0,-1,1] plane.  
All strong hydrogen bonding donor and acceptor sites are involved in the hydrogen-bonding 
network in this structure. 
 
Figure 3.28: A view of the pyrazinamide:pimelic acid cocrystal structure showing the infinite 
molecular sheet. 
The bond lengths within the pyrazinamide:pimelic acid cocrystal are given in Table 3.11. The 
bond lengths of C(7)-N(7) and C(7)-O(7) are 1.326(13) and  1.241(12) respectively and 
confirm the orientation of the amide group. In the acid, the bond lengths of C(8)-O(8) and 
C(8)-O(9) are 1.337(12) and 1.211(13); C(14)-O(14) and C(14)-O(15) are 1.325(12) and 
1.217(13) respectively showing a clear distinction between the C=O and C-O(H) components 
of the carboxylic acid functional group, hence confirming that there is no proton transfer 
between the neutral components in this cocrystal structure. 
The torsion angles within the pyrazinamide molecule N(4)-C(5)-C(7)-N(7) and C(6)-C(5)-
C(7)-N(7) are 6.77(13) and -175.28(9) respectively show a slight deviation from planarity. 
The molecule is partially stabilized in this conformation by the intramolecular N-H
….
N, but 
other intermolecular interactions are likely to effect this conformation. 
The torsion angles within the pimelic acid molecule show some distortion from planarity 
arising again from interactions formed between the components. The torsion angles defining 
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the acid groups O(8)-C(8)-C(9)-C(10) and C(12)-C(13)-C(14)-O(14) show that this 
conformation as is expected, as do the components of the carbon backbone C(9)-C(10)-
C(11)-C(12) and C(11)-C(12)-C(13)-C(14). The other angles C(8)-C(9)-C(10)-C(11) and 
C(10)-C(11)-C(12)-C(13) are -72.02(11) and 70.18(11) respectively and result in the overall 
conformation of the pimelic acid being distorted. The relationship between the two acid 
groups then differs significantly from planarity, again giving a ‘bent’ flexible linker within 
the cocrystal, not uncommon in diacids of odd chain length.  
 
Table 3.11: Intermolecular and intramolecular hydrogen bond distances and torsion angles 
within the pyrazinamide:pimelic acid cocrystal. 
Pyrazinamide Bond Lengths        (Å)                    Acid Bond Lengths         (Å) 
C(7)-N(7) 
C(7)-O(7) 
 1.326(13)    
 1.241(12)    
 C(8)-O(8) 
 C(8)-O(9) 
 C(14)-O(14) 
 C(14)-O(15)   
  1.337(12) 
  1.211(13)    
  1.325(12)                                                                                                            
  1.217(13)                                                                                                        
Pyrazinamide Torsion Angles        (
o
) Acid Torsion Angles         (
o
) 
N(4)-C(5)-C(7)-N(7) 
N(4)-C(5)-C(7)-O(7) 
C(6)-C(5)-C(7)-O(7) 
C(6)-C(5)-C(7)-N(7)  
 
 6.77(13) 
-172.48 
 5.48(14)        
-175.28(9)         
   
O(8)-C(8)-C(9)-C(10) 
O(9)-C(8)-C(9)-C(10) 
O(9)-C(8)-C(14)-O(14) 
O(8)-C(8)-C(14)-O(15) 
O(9)-C(8)-C(14)-O(15) 
C(8)-C(9)-C(10)-C(11) 
C(9)-C(10)-C11)-C(12)       
C(10)-C(11)-C(12)-C(13) 
C(11)-C(12)-C(13)-C(14) 
C(12)-C(13)-C(14)-O(14) 
C(12)-C(13)-C(14)-O(15) 
 178.24(8) 
 -2.54(15) 
  170.40 
  154.82 
  -2.38 
-72.02(11) 
 -179.92(8)                                                      
 70.18(11)   
 174.49(8) 
-174.50(9) 
 4.55(15) 
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The X-powder diffraction patterns of the products obtained through different methods of 
synthesis were compared with the simulated powder pattern from the crystal structure 
determined by single crystal X-ray diffraction to confirm if this structure is representative of 
the bulk. Figure 3.29 shows that the bulk material is not a good match with that from the 
single crystal analysis. This is a similar conclusion to the initial experimental observation that 
the crystal selected for structure determination was atypical of other parts of the bulk sample. 
Although there is some similarity between the samples obtained by solvent evaporation and 
solvent-drop grinding, it is clear that both are mixtures containing different proportions of 
product, starting materials and polymorphic form. 
 
 
Figure 3.29: X-ray powder diffraction patterns of the products of pyrazinamide and pimelic 
acid crystallisation from methanol through different method of synthesis, the starting 
materials (pyrazinamide, pimelic acid), common pyrazinamide polymorphs and the simulated 
pattern from the single crystal structure. 
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Different solvents (methanol, ethanol, propanol and ethyl acetate) were also used for 
attempted synthesis of the cocrystal of pyrazinamide:pimelic acid with the aim of obtaining 
the pure material Figure 3.30 shows the products obtained by solvent evaporation from 
different solvents. The results obtained from all solvents are similar, with that from propanol 
and ethyl acetate being the most similar. None of these have produced the pure bulk 
cocrystalline material, hence highlighting the difficulties that are encountered with the prolific 
polymorphic behaviour of pyrazinamide. 
 
 
Figure 3.30: X-ray Powder diffraction patterns and single x-ray powder diffraction pattern of 
the products of pyrazinamide and pimelic acid from different solvents, the starting materials 
(pyrazinamide, pimelic acid) and common pyrazinamide polymorphs. 
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3.10   Pyrazinamide and subaric acid  
Pyrazinamide and subaric acid were dissolved in methanol in a 1:1 stoichiometric starting 
ratio and the solvent evaporation method was used for crystallisation. The product formed 
was a white solid. The X-ray powder diffraction pattern of product formed is clearly a match 
to a combination of the patterns of the starting materials, confirming that this is a mixture of 
the starting materials and there is no new material has been formed (figure  3.31). 
 
 
Figure 3.31: X-ray powder diffraction pattern of the product of pyrazinamide and subaric 
acid crystallisation from methanol, the starting materials (pyrazinamide, subaric acid) and 
common pyrazinamide polymorphs. 
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3.11   Pyrazinamide and azelaic acid 
Pyrazinamide was crystallised with azelaic acid and methanol used as solvent for synthesis in 
a 1:1 starting stoichiometric ratio. A new product was obtained through the solvent 
evaporation method as a white solid. The X-ray powder diffraction pattern of this product 
(figure 3.32) shows the presence of both a new material and a significant amount of the 
pyrazinamide starting material (see peaks at 15º, 17º and 26 2-theta) or polymorph 
(α(PYRAZIN15))97.  
 
 
Figure 3.32: X-ray powder diffraction pattern of the product of pyrazinamide and azelaic 
acid crystallisation from methanol, the starting materials (pyrazinamide, azelaic acid) and 
other common pyrazinamide polymorphs.  
 
The bulk product is a mixture, 
1
H NMR indicate that the new material formed from 
crystallisation of 1:1 contains molecular coformers in a 1:1 stoichiometric ratio of starting 
materials of pyrazinamide and azelaic acid (figure 3.33). 
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Figure 3.33: 
1
H NMR of the product of pyrazinamide and azelaic acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.83 (1H, s), 8.29 (1H, 
s), 8.72 (1H, t), 8.92(1H, d), 9.19(1H, d) azelaic acid 1.23 (8H, s), 1.47 (5H, t), 2.21 (5H, t). 
 
3.11.1  Crystal structure determination from single X-ray diffraction data 
Once the bulk product was identified as containing a new material through X-ray powder 
diffraction, the sample was submitted for single crystal analysis. The crystal structure 
determination confirmed that the new material formed was not an adduct of the two 
components but was an unpublished polymorph of azelaic acid and hence the pyrazinamide 
detected in the NMR was starting material only. Further crystallographic details of this 
structure determination are given in Table 3.12. 
Figure 3.34 shows the asymmetric unit and the atom labelling used in this crystal structure of 
azelaic acid. The crystal structure polymorph of azelaic acid was published from 1967 at 
room temperature (CDS: AZELAC10)
99
. 
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Table 3.12.  Crystal data and structure refinement of azelaic acid. 
Identification code  Azelaic Acid 
Empirical formula  C9H16O4 
Formula weight  188.22 
Temperature  100.00(10) K 
Wavelength  1.5418 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 5.4938(2) Å α= 90°. 
 b = 9.4418(3) Å β= 95.673(3)°. 
 c = 18.8258(6) Å γ = 90°. 
Volume 971.74(6) Å3 
Z 4 
Density (calculated) 1.287 Mg/m3 
Absorption coefficient 0.838 mm-1 
F(000) 408 
Crystal size 0.140 x 0.130 x 0.030 mm3 
Theta range for data collection 6.657 to 74.248°. 
Index ranges -6<=h<=6, -10<=k<=11, -22<=l<=21 
Reflections collected 3622 
Independent reflections 1922 [Rint = 0.0182] 
Completeness to theta = 67.684° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.89788 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1922 / 0 / 126 
Goodness-of-fit on F2 1.171 
Final R indices [I>2sigma(I)] R1 = 0.0430, wR2 = 0.1254 
R indices (all data) R1 = 0.0480, wR2 = 0.1287 
Extinction coefficient n/a 
Largest diff. peak and hole 0.288 and -0.224 e.Å-3 
 
Note: The hydrogen atoms bonded to O(1) and O(9) were located in the electron density and freely refined. All 
other hydrogen atoms were fixed as riding models.  
 
[This polymorph was originally published before in 1967
79
 as a structure determined from data collected at 
room temperature with a final R factor (based on observed data) of 9 % (CSD AZELAC10)]. 
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Figure 3.34: The asymmetric unit in the crystal structure polymorph of azelaic acid showing 
the atom numbering scheme. 
The basic supramolecular structure motif within the asymmetric unit (figure 3.34) is formed 
by one molecule of azelaic acid. 
Table 3.13: Intermolecular hydrogen bond distances (Å) and angles (
o
) within the azelaic acid 
 
D-H-A                      d(D-H)              d(H
……
A)               d(D
……
A)                   <(DHA) 
O(1)-H(1)
….
O(2)
i
       0.89(3)                  1.76(3)           2.656(18)                177(3) 
O(9)-H(9)
….
O(10)
ii
       0.94(3)                  1.73(3)           2.667(17)                175(3) 
C(8)-H(8B)
…
O(2)                0.990                     2.67               3.338                       124.64             
___________________________________________________________________________ 
Symmetry code: i) x-1,y+1,z  ii) x+3,y+1,z+1 
 
The asymmetric units are linked together into an infinite chain by hydrogen bonds (Table 
3.13) O-H
...
O in which O(1) acts as a donor via H(1) and O(2) acts as an acceptor and the 
other hydrogen bond O-H
….
O  in which O(9) acts as a donor via H(9) and O(10) acts as an 
acceptor. Together these hydrogen bonds form a 
2
2R (8) ring such that a supramolecular chain 
of alternating 
2
2R (8) rings are generated through acid-acid motifs (figure 3.35).   
 
Within each of these chains the azelaic acid molecules adopt the same orientation and face 
the same direction. These hydrogen bonded chains are cross-linked to another neighbouring 
parallel chain via an additional two week hydrogen bonds; C-H
....
O in which C(8) in azelaic 
acid molecule acts as a donor via H(8B) to oxygen O(2) as acceptor in the neighbouring 
azelaic acid molecule and the other hydrogen bond in which O(1) in the azelaic acid act as a 
donor via H(1) to O(10) as acceptor in the other neighbouring azelaic acid molecule. The 
complementary hydrogen bond results in the formation of an 
2
4R (8) ring between the chains 
running in opposite but parallel directions (figure 3.36) 
Anas. M. Al-Abachi                                                                                        Results                                                                                                               
 
 Page 78 
 
 
Figure 3.35: A view of the crystal structure polymorph of azelaic acid showing the 
alternating acid-acid rings through hydrogen bonds in the molecules. 
      
Figure 3.36: Diagram of the crystal structure polymorph of azelaic acid showing the 
intermolecular hydrogen bonds between the molecules in two chains.  
 
Table 3.14: Hydrogen bonds (Å) and torsion angles (
o
) in azelaic acid polymorph. 
 Bond Lengths        (Å)                     Acid Angles          (
o
) 
C(1)-O(2)   
C(1)-O(2) 
C(9)-O(9)      
C(9)-O(10)    
1.323(2) 
1.223(2) 
1.318(2) 
1.228(2) 
 C(1)-C(2)-C(3)-C(4) 
 C(3)-C(4)-C(5)-C(6) 
 C(2)-C(3)-C(4)-C(5) 
 C(6)-C(7)-C(8)-C(9) 
 O(1)-C(1)-C(2)-C(3)  
 O(1)-C(1)-C(9)-O(9)      
 O(1)-C(1)-C(9)-O(10) 
174.32(14) 
174.41(14) 
179.48(14) 
177.87(14) 
179.34(14) 
133.70 
-67.98 
 
The bond lengths within the azelaic acid are given in Table 3.14. The bond lengths of C(1)-
O(1) and C(1)-O(2) are 1.323(2) and 1.223(2); C(9)-O(9) and C(9)-O(10)  are 1.318(2) and  
1.228(2) respectively showing a clear distinction between the C=O and C-O(H) components 
of the carboxylic acid functional group.  
The torsion angles within the azelaic acid molecule of the carbon backbone C(1)-C(2)-C(3)-
C(4) and C(3)-C(4)-C(5)-C(6); C(2)-C(3)-C(4)-C(5) and C(6)-C(7)-C(8)-C(9) are 174.32 and 
174.41(14); 179.48(14) and 177.97(11) respectively, show that is close to planar. The other 
angles of carboxylic acid groups O(1)-C(1)-C(9)-O(9) and O(1)-C(1)-C(9)-O(10) are 133.70 
and -67.98 respectively, show that carboxylic acid groups are significantly distorted. The 
Anas. M. Al-Abachi                                                                                        Results                                                                                                               
 
 Page 79 
 
relationship between the acid groups and carbon backbone is differs from planarity, giving a 
‘bent’ flexible linker within other azelaic acid molecules. This type of conformation is not 
unusual for diacids with odd chain length. 
 
The X-ray powder diffraction pattern of pyrazinamide:azelaic acid formed was compared 
with single crystal simulated pattern of  azelaic acid polymorph structure formed  at 100 k 
and also compared with a number of simulated patterns of previously published azelaic acid 
polymorphs
79
. The simulated pattern of azelaic acid polymorph formed is matching the 
simulated pattern of previously published polymorph (α(AZELAC10))99 and some peaks are 
shifted being generated at a low temperature (figure3.37). The bulk powder pattern shows a 
match to the simulated single crystal pattern of azelaic acid formed but there are also a 
number of differences in peaks that arise from the bulk sample being a mixture with 
pyrazinamide starting material. These different peaks are match the peaks of powder pattern 
of pyrazinamide starting material. The azelaic acid polymorph formed was high quality 
determined at low temperature (100 k).  This figure confirms that the azelaic acid used as a 
starting material is matches azelaic acid polymorph (β(AZELAC10))99. 
 
Figure 3.37:  X-ray powder diffraction pattern of the product azelaic acid polymorph, the 
starting materials (pyrazinamide, azelaic acid), common azelaic acid polymorphs and the 
simulated pattern from the single crystal structure. 
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3.12   Pyrazinamide and sebacic acid 
Pyrazinamide and sebacic acid were dissolved in methanol and combined for crystallisation 
in a 1:1 stoichiometric ratio. The solvent evaporation method was used for synthesis. The 
new product formed was a yellow solid crystal. The X-ray powder diffraction pattern of this 
product is different to those of the starting materials, confirming the formation of new 
material. The powder diffraction pattern of product formed was also compared with a number 
of simulated patterns from previously published pyrazinamide polymorphs
76,83,97,98
. It can be 
seen from the figure 3.38 that the product may contain small amount of sebacic acid starting 
material (see peaks 24º 2-theta) in a mixture with the new product. 
 
Figure 3.38: X-ray powder diffraction pattern of the product of pyrazinamide and sebacic 
acid crystallisation from methanol, the starting materials (pyrazinamide, sebacic acid) and 
other common pyrazinamide polymorphs. 
The bulk material looks like it is a mixture and this may effect interpretation of the NMR.   
1
H NMR indicated that the new product formed from crystallisation of a 1:1 ratio of starting 
materials show a resulting 2:1 stoichiometric ratio of pyrazinamide and sebacic acid (figure 
3.39). 
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Figure 3.39: 
1
H NMR of the product of pyrazinamide and sebacic acid (1:1) starting ratio 
using DMSO as a solvent. 
1
H NMR 300MHz (DMS0-d6): pyrazinamide 7.86 (1H, s), 8.27 (1H, 
s), 8.72 (1H, t), 8.85 (1H, d), 9.19 (1H, d): sebacic acid 1.25 (4 H, s), 1.56 (2H, q), 2.24 (2H, 
t).  
 
3.12.1  Crystal structure determination from single crystal X-ray diffraction data 
A small amount of yellow crystalline product was submitted for single crystal analysis and 
the crystal structure of a new pyrazinamide:sebacic acid cocrystal was determined. This 
established that the stoichiometric ratio of the pyrazinamide and sebacic acid in this material 
was 2:1. The crystal structure also confirmed that a neutral cocrystal has been formed in 
which no proton transfer had taken place between the two molecular components. The sample 
itself was found to contain both yellow crystals and a small amount of colourless crystalline 
material that was identified as sebacic acid. Further crystallographic details of this structure 
determination are given in Table 3.15.   
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Table 3.15. Crystal data and structure refinement for pyrazinamide:sebacic acid 2:1. 
Identification code  Pyrazinamide_Sebacic Acid 
Empirical formula  2(C5 H5 N3 O), C10 H18 O4 
Formula weight  448.48 
Temperature  100.00(10) K 
Wavelength  1.5418 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 5.1790(2) Å α= 94.342(3)°. 
 b = 5.4406(2) Å β= 93.910(3)°. 
 c = 19.2691(7) Å γ= 94.681(3)°. 
Volume 538.07(3) Å3 
Z 1 
Density (calculated) 1.384 Mg/m3 
Absorption coefficient 0.869 mm-1 
F(000) 238 
Crystal size 0.350 x 0.200 x 0.100 mm3 
Theta range for data collection 6.933 to 70.058°. 
Index ranges -6<=h<=6, -6<=k<=6, -23<=l<=23 
Reflections collected 5733 
Independent reflections 2026 [R(int) = 0.0159] 
Completeness to theta = 67.684° 98.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.84544 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2026 / 0 / 154 
Goodness-of-fit on F2 1.073 
Final R indices [I>2sigma(I)] R1 = 0.0339, wR2 = 0.0899 
R indices (all data) R1 = 0.0355, wR2 = 0.0911 
Extinction coefficient n/a 
Largest diff. peak and hole 0.290 and -0.169 e.Å-3 
 
 
Notes: The hydrogen atoms bonded to N(7) and O(8) were located in the electron density and their positions 
refined freely, with their isotropic thermal parameters based on the equivalent isotropic thermal parameter of the 
parent atom (Uiso(H) = 1.2(Ueq(N) and Uiso(H) = 1.5(Ueq(O)). All hydrogen atoms were fixed as riding models. 
__________________________________________________________________________________________ 
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Figure 3.40 shows the atom labelling and the hydrogen bonds present in the asymmetric unit 
of this cocrystal structure; it contains one pyrazinamide molecule per one half sebacic acid 
molecule linked by a strong hydrogen bond. 
 
Figure 3.40: The asymmetric unit of the crystal structure of pyrazinamide:sebacic acid (2:1) 
showing the atom numbering scheme. Strong hydrogen bonds are shown as dotted lines. 
Atom labels with a superscript denote the crystallographically equivalent half sebacic acid 
molecule. 
The basic supramolecular structure motif within the asymmetric unit (figure 3.40) is formed 
by one pyrazinamide molecule and one half sebacic acid molecule (that is located on an 
inversion centre to create the complete molecule). There is a strong acid-pyridine interaction 
O-H
…
N in which O(8) in the acid acts as a donor via H(8) to the pyridine nitrogen N(1); this 
is reinforced by a weak hydrogen bond C-H
…
O in which C(6) in the pyrazinamide acts as 
donor via H(6A) to O(9) in the sebacic acid. These combine to form a 22R (7) hydrogen bond 
ring. There is an N-H
….
N intra molecular hydrogen bond in the pyrazinamide molecule N-
H
…
N in which the amide nitrogen N(7A) acts as a donor via H(7A) to the pyridine nitrogen 
N(4) (as seen in the other  structures) which influences the planarity of the pyrazinamide 
molecule (table 3.16).  
Each pyrazinamide molecule is then linked to another through a complementary hydrogen 
bond N-H
….
O in which the amide nitrogen N(7) acts as a donor via H(7B) to the amide 
oxygen O(7) to form an complementary 
2
2R (8) pyrazinamide dimer rings. Finally, these units 
are linked together into an infinite chain through the sebacic acid lying on an inversion centre 
(figure 3.41). 
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Table 3.16: Intermolecular hydrogen bond distances (Å) and angles (
o
) within the 
pyrazinamide:sebacic acid. 
D-H-A                      d(D-H)              d(H
……
A)               d(D
……
A)                   <(DHA) 
N(7)-H(7A)
….
O(7)
iii 
N(7)-H(7B)
….
O(7)
iv 
N(7)-H(7A)
….
N(4)
 
O(8)-H(8)
….
N(1) 
C(2)-H(2A)
....
O(9)
ii 
C(3)-H(3A)
....
O(7)
ii
   
C(6)-H(6A)
….
O(9)       
0.86 
0.91 
0.86 
0.92 
0.95 
0.95 
0.95 
2.54 
1.97 
2.36 
1.79 
2.36 
2.54 
2.60 
3.178(13) 
2.887(14) 
2.738(13) 
2.714(13) 
3.247(15)  
3.383(14)   
3.285(14)                                            
130 
177 
106 
177 
154 
147 
129
Symmetry code: i) -x+3,-y+3,-z+1 ii) x-1,y-1,z  iii) x-1,y,z  iv) -x,-y+3,-z  
 
 
Figure 3.41: A view of the pyrazinamide:sebacic acid (2:1) cocrystal structure showing the 
acid-pyridine and pyrazinamide hydrogen bonded rings forming an infinite chain. Hydrogen 
bonds are shown as thin light blue lines. 
These hydrogen bonded chains are then linked to a neighbouring parallel chains through two 
additional weak C-H
...
O hydrogen bonds in which C(2) in pyrazinamide acts as a donor via 
H(2A) to O(9) in sebacic acid and C(3) in pyrazinamide acts as a donor via H(3A) to O(7) in 
the neighbouring pyrazinamide molecule (figure 3.42). This network brings the chains 
together to form an infinite molecular sheet. 
Finally these hydrogen bonded sheets interact with others above and below through a single 
strong N-H
…
O hydrogen bond in which N(7) in pyrazinamide acts as a donor via H(7A) to 
O(7) in the in the neighbouring pyrazinamide molecule (figure 3.43).  
All strong hydrogen bonding donor and acceptor sites are involved in the hydrogen-bonding 
network in this structure.  
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Figure 3.42: A view of the pyrazinamide:sebacic acid (2:1) cocrystal structure showing the 
infinite molecular sheet. 
 
Figure 3.43: A view of the pyrazinamide:sebacic acid (2:1) cocrystal structure showing the 
hydrogen bonded sheets through a single strong hydrogen bond. 
The bond lengths and torsion angles within the pyrazinamide:sebacic acid cocrystal are given 
in Table 3.17. The bond lengths C(7)-N(7) and C(7)-O(7) are 1.328(15) and 1.240(14) 
respectively and confirm the orientation of the amide group. In the acid, the bonds lengths 
C(8)-O(8) and C(8)-O(9) are 1.332(14) and 1.211(14) respectively, showing a clear 
distinction between the C=O and C-O(H) components of the carboxylic acid functional group, 
hence confirming that there is no proton transfer between the neutral components in this 
cocrystal structure. 
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The torsion angles within the pyrazinamide molecule N(4)-C(5)-C(7)-N(7) and C(6)-C(5)-
C(7)-N(7) are 10.93(16) and -168.66(11) respectively and show a slight deviation from 
planarity. The molecule is partially stabilized by the intramolecular N-H
….
N interaction 
which would result in a planar conformation, but other intermolecular interactions also effect 
this conformation and those formed by the amide group are most likely to cause distortion of 
the expected conformation. 
 
The torsion angles within the sebacic acid molecule O(8)-C(8)-C(9)-C(10) and O(9)-C(8)-
C(9)-C(10) are -173.30(10) and 7.27(18) and show a slight deviation from planarity and 
arises from interactions formed by the acid to pyridine acceptor. The other torsion angles 
show that overall the molecule is approximately planar and adopts the conformation expected 
in this type of diacid with an even chain length.    
 
Table 3.17: Selected intramolecular bond lengths and torsion angles within the pyrazinamide: 
sebacic acid (2:1) cocrystal. 
Pyrazinamide Bond Lengths       (Å)                    Acid Bond Lengths         (Å) 
C(7)-N(7) 
C(7)-O(7) 
1.328(15) 
1.240(14) 
C(8)-O(8) 
C(8)-O(9) 
1.332(14) 
1.211(14) 
Pyrazinamide Torsion Angles      (º) Acid Torsion Angles         (º) 
N(4)-C(5)-C(7)-N(7)  
N(4)-C(5)-C(7)-O(7)  
C(6)-C(5)-C(7)-O(7) 
C(6)-C(5)-C(7)-N(7)   
 10.93(16) 
-168.86(10) 
 11.54(17) 
-168.66(11) 
O(8)-C(8)-C(9)-C(10) 
O(9)-C(8)-C(9)-C(10) 
C(8)-C(9)-C(10)-C(11)
   
C(9)-C(10)-C(11)-C(12) 
C(10)-(11)-C(12)-C(12)
1
  
C(11)-C(12)-C(12)
1
-C(11)
1 
-173.30(10) 
 7.27(18) 
 173.33(10) 
-179.23(10) 
 178.63(12) 
 180.00 
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The synthesis of this pyrazinamide:sebacic acid (2:1) adduct was also attempted using 
different methods of synthesis and their X-ray powder diffraction patterns were compared 
with each other. The X-ray powder diffraction of the product obtained through solvent 
evaporation matches that obtained from solvent drop-grinding although there is more excess 
sebacic acid also present in the ground sample (figure 3.44). The crystal structure of 
pyrazinamide:sebacic acid (2:1) was determined at low temperature and hence some peak 
positions are shifted relative to the experimental room temperature data. The bulk powder 
patterns clearly show a match to the simulated single crystal pattern but there are also a 
number of differences that arise from the bulk sample being a mixture and the possible 
presence of preferred orientation.  
 
 
Figure 3.44: X-ray powder diffraction patterns of the products of pyrazinamide and sebacic 
acid crystallisation from methanol through different method of synthesis, the starting 
materials (pyrazinamide, sebacic acid), common pyrazinamide polymorphs and the simulated 
pattern from the single crystal structure. 
 
Anas. M. Al-Abachi                                                                                        Results                                                                                                               
 
 Page 88 
 
3.13   Pyrazinamide and isonicotinamide 
Pyrazinamide was crystallised with isonicotinamide using the solvent evaporation method 
with methanol used as the solvent to dissolve the starting materials in a 1:1 stoichiometric 
ratio. The new product formed was a white solid. The X-ray powder diffraction pattern of the 
product formed is different to that of the starting materials but when compared to the 
simulated patterns of previously published pyrazinamide polymorphs
76,83,97,98
, It can be seen 
form the figure 3.45 that the product contains a mixture of a small amount of the starting 
materials with the formation of an additional pyrazinamide polymorph (δ (PYRAZIN16))98. 
 
 
Figure 3.45: X-ray powder diffraction patterns of the product of pyrazinamide and 
isonicotinamide crystallisation from methanol, the starting materials (pyrazinamide, 
isonicotinamide) and common pyrazinamide polymorphs. 
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3.14   Pyrazinamide and nicotinamide 
Pyrazinamide was dissolved with nicotinamide using methanol as the solvent in a 1:1 
stoichiometric ratio and the solvent evaporation method used for crystallisation. The product 
formed was a white solid. The X-ray powder diffraction pattern of the product shows clearly 
that the product is a mixture of starting materials, predominantly nicotinamide. The figure 
4.46 also shows that the product also contains a small amount of polymorph (β 
(PYRAZIN18))
76
.  
 
 
Figure 4.46: X-ray powder diffraction patterns of the product of pyrazinamide and 
nicotinamide crystallization from methanol, the starting materials (pyrazinamide, 
nicotinamide) and common pyrazinamide polymorphs. 
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3.15   Pyrazinamide and histidine  
In this case, pyrazinamide was ground with histidine in a 1:1 starting stoichiometric ratio 
using the solvent drop grinding method for synthesis; some drops of methanol were used as 
the solvent for this process. Histidine is insoluble in alcohols and acids and therefore the 
solvent evaporation method was not used for synthesis here. The product formed was a white 
solid. The X-ray powder diffraction pattern of the product was compared with the powder 
patterns of the starting materials and confirmed that the product is a mixture of starting 
materials and that no new material has been formed (figure  4.47). 
 
Figure 4.47: X-ray powder diffraction pattern of the product of pyrazinamide and histidine 
using the solvent drop grinding method, the starting materials (pyrazinamide, histidine) and 
common pyrazinamide polymorphs. 
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3.16   Nicotinamide and isonicotinamide 
Nicotinamide was crystallised with isonicotinamide using methanol as the solvent with the 
components in a number of different stoichiometric ratios (1:1, 1:2 and 2:1). All new 
products were formed as white solids. The X-ray powder diffraction pattern of products 
formed confirms the formation of a new material in the 1:1 synthesis. This product is also 
formed in the 1:2 synthesis with excess isonicotinamide present (see peaks at 18º, 21º and 24º 
2-theta) , whereas in the 2:1 synthesis, the same product was formed in a mixture with excess 
nicotinamide present (see peaks at 15º,  25º and 27º 2-theta) (figure 4.48). 
 
 
Figure 4.48: X-ray powder diffraction patterns of the products of nicotinamide and 
isonicotinamide crystallisation from methanol from different stoichiometric ratios (1:1, 1:2, 
and 2:1) and the starting materials (nicotinamide, isonicotinamide). 
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3.17   Isonicotinamide and fumaric acid 
Isonicotinamide and fumaric acid were dissolved using methanol and crystallised from a 1:1 
starting stoichiometric ratio with the solvent evaporation method used for synthesis.  The new 
product formed was a white solid. The X-ray powder diffraction pattern of the material 
formed was different to that of the starting materials, confirming the formation of a new 
material. The pattern of this product was also compared with the simulated powder pattern of 
the previously published isonicotinamide:fumaric acid cocrystal
100
. It can be seen from figure 
4.49 that the product matches the published cocrystal structure, demonstrating the success of 
the synthesis approach used here. Although there is some peak shift present due to the 
simulated pattern being generated from a low temperature structure, it is clear that product is 
phase pure.  
 
Figure 4.49: X-ray powder diffraction patterns of the product of isonicotinamide and fumaric 
acid crystallisation from methanol, the starting materials (isonicotinamide, fumaric acid), 
and the simulated powder pattern from the published isonicotinamide:fumaric acid cocrystal 
structure. 
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3.18   L-dopamine and succinic acid 
L-dopamine was ground with succinic acid in a 1:1 starting stoichiometric ratio using the 
solvent drop grinding method for synthesis; some drops of methanol were used. L-dopamine 
is slightly soluble in water but insoluble in alcoholic slovents therefore the solvent 
evaporation method was not used for synthesis here. The product formed was a white solid. 
The X-ray powder diffraction pattern of product formed is clearly a match to a combination 
of the patterns of the starting materials, confirming that this is a mixture of the starting 
materials and there is no new material has been formed (figure 4.50 ). 
 
 
Figure 4.50: X-ray powder diffraction pattern of product of L-dopamine and succinic acid 
from grinding and the staring materials (l-dopamine, succinic acid). 
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Table 3.18: Summary of  new cocrystals formed. 
Combination   Product Polymorph Stoichio
metric 
ratio 
 
SX 
Structure 
Pyrazinamid:oxalic acid 
Pyrazinamide:oxamic acid 
Pyrazinamide:malonic acid 
 
 
Pyrazinamide:maleic acid 
Pyrazinamide:fumaric acid 
Pyrazinamide:succinic acid 
Pyrazinamide:glutaric acid 
 
 
Pyrazinamide:adipic acid 
 
Pyrazinamide:pimelic acid 
 
 
Pyrazinamide:subaric acid  
   
Pyrazinamide:azelaic acid 
Pyrazinamide:sebacic acid  
Pyrazinamide:isonicotinamide        
Pyrazinamide:nicotinamide 
Pyrazinamide:histidine 
Nicotinamide:Isonicotinamide 
 
Isonicotinamide:fumaric acid 
L-dopamine:succinic acid 
New product 
Mixture 
New product 
 
 
New product 
New product 
Mixture 
New product 
 
 
New product 
 
New product 
 
 
 
Mixture 
 
New product 
New product 
New product 
Mixture 
Mixture 
New product 
 
New product 
Mixture 
 
γ(PYRAZIN17) 
δ(PYRAZIN16), 
γ(PYRAZIN17) 
 
γ(PYRAZIN17) 
 
 
γ(PYRAZIN17) 
 
 
β (PYRAZIN18) 
 
α(PYRAZIN15, 
δ(PYRAZIN16 
 
 
 
α(PYRAZIN15) 
 
δ (PYRAZIN16) 
β (PYRAZIN18) 
 
1:1 
1:1 
1:1 
 
 
1:1 
1:1 
1:1 
1:1 
 
 
1:1 
 
1:1,1:2, 
2:1 
 
1:1 
 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1,1:2, 
2:1 
1:1 
1:1 
 
 
 
 
 
 
 
 
 
 
 
Cocrystal 
(1:1) 
 
Cocrystal 
(4:1) 
Cocrystal 
(1:1) 
 
 
Polymorph 
Cocrystal 
(2:1) 
 
Anas. M. Al-Abachi                                                                                         Conclusion                                                                                                               
 
 Page 95 
 
4.  Conclusion 
A number of cocrystals were synthesised from pyrazinamide with dicarboxylic acid (oxalic, 
oxamic, malonic, maleic, fumaric, succinic, glutaric, adipic, pimelic, subaric, azelaic and 
sebacic acid) using either slow solvent evaporation or solvent drop grinding methods and 
methanol, ethanol, propanol or ethyl acetate as a solvent in a different combination of 
stoichiometric ratios. Most of the products were formed employing methanol as the solvent 
while pyrazinamide:pimelic acid cocrystals were formed by using different solvents 
(methanol, ethanol, propanol or ethyl acetate) and all the products formed were of similar 
purity.  
1
H NMR spectroscopy confirmed that the cocrystals formed had stoichiometric ratios of  
pyrazinamide:oxalic acid (1:1), pyrazinamide:oxamic acid (1:1), pyrazinamide:fumaric (2:1), 
pyrazinamide:succinic acid (3:2), pyrazinamide:maleic acid (1:1), pyrazinamide:glutaric acid 
(1:1), pyrazinamide:adipic acid (2:3), pyrazinamide:pimelic acid (1:1), pyrazinamide:subaric 
acid (1:1), pyrazinamide: azelaic acid (1:1), pyrazinamide:sebacic acid (2:1), 
pyrazinamide:isonicotinamide (1:1), nicotinamide:isonicotinamide (1:1, 1:2 and 2:1) and 
isonicotinamide:fumaric acid(1:1).   
 X-ray powder diffraction confirmed the formation of new materials of pyrazinamide:oxalic 
acid, pyrazinamide:fumaric acid, pyrazinamide:maleic acid, pyrazinamie:malonic acid, 
pyrazinamide:glutaric acid, pyrazinamide:adipic acid, pyrazinamide:pimelic acid, 
pyrazinamide:azelaic acid, pyrazinamide:sebacic acid, pyrazinamide:isonicotinamide, 
isonicotinamide:nicotinamide and isonicotinamide:fumaric acid. X-ray powder diffraction 
indicated that pyrazinamide forms a mixture with oxamic acid, subaric acid, nicotinamide and 
histidine. It also indicated that the L-dopamine forms a mixture with succinic acid. The 
product was synthesised through the grinding method, probably due to L-dopamine being 
insoluble in most alcoholic solvents and therefore it was not possible to obtain a cocrystal of  
L-dopamine:succnic acid via the slow solvent evaporation method. 
The crystal structures of pyrazinamide:glutaric acid (1:1), pyrazinamide:adipic acid (4:1) 
pyrazinamide:pimelic acid (1:1), pyrazinamide:sebacic acid (2:1) and a polymorph of azelaic 
acid were determined by single crystal X-ray diffraction analysis. The crystal structure of 
pyrazinamide:glutaric acid (1:1) includes one molecule of pyrazinamide linked to one 
molecule of glutaric acid through acid-amide and acid-pyridine hydrogen bonds between the 
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two molecules forming an infinite chain. The single crystal pattern of the cocrystal product 
formed matched the simulated single crystal pattern of the previously published structure of 
pyrazinamide:glutaric acid (1:1)
90
. The crystal structure of pyrazinamide:adipic acid (4:1) 
includes two molecules of pyrazinamide linked to half a molecule of adipic acid. Again, this 
structure forms through acid-pyridine and amide-amide hydrogen bonds, forming an infinite 
chain. The crystal structure of pyrazinamide:pimelic acid (1:1) includes one molecule of 
pyrazinamide linked with one molecule of pimelic acid through acid-pyridine and acid-amide 
hydrogen bonds, forming an infinite chain. The crystal structure of pyrazinamide:sebacic acid 
(2:1) includes one molecule of pyrazinamide linked to half  a molecule of sebacic acid 
through acid-pyridine and amide-amide hydrogen bonds, forming a zigzag chain. The crystal 
structure of the polymorph of azelaic acid formed a chain through linked molecules of azelaic 
acid through acid-acid hydrogen bonds. 
Future work will investigate other physical properties of pyrazinamide cocrystals such as 
melting point, solubility, dissolution and bioavailability. Pyrazinamide may form cocrystals 
with other molecules or indeed other active drug ingredients and through drug-drug 
cocrystals may increase the therapeutic activity and efficacy of the drugs under consideration. 
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5.  Appendices  
 
Appendix   A:  
1
H NMR  spectrum 
A-1 : 
1
H NMR  pyrazinamide:maleic acid (1:1) 
A-2 : 
1
H NMR   pyrazinamide:isonicotinamide (1:1) 
A-3:
  1
H NMR pyrazinamide:nicotinamide (1:1) 
A-4:
  1
H NMR isonicotinamide:nicotinamide (1:1:) 
A-5:
  1
H NMR isonicotinamide:nicotinamide (1:2) 
A-6: 
1
H NMR isonicotinamide:fumaric acid
  
(1:1) 
Appendix   B:  CIF data file of cocrystal structures 
B-1 : Data_Pyrazinamide_Glutaric 
B-2: Data_Pyrazinamide_AdipicAcid 
B-3: Data_Pyrazinamide_PimelicAcid 
B-4: Data_Azelaic_Acid 
B-5: Data_Pyrazinamide_SebacicAcid 
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Appendix  A: 
1
H NMR  spectrum 
A-1:  
1
H NMR  pyrazinamide:maleic acid  
 
1
H NMR pyrazinamide: 7.84 (1H, s), 8.28 (1H, s), 8.73 (1H, t), 8.93(1H, d), 9.18(1H, d) 
1
H NMR maleic acid:    6.38 (2H, s)  
 
 A-2:
  1
H NMR pyrazinamide:isonicotinamide 
 
1
H NMR pyrazinamide: 7.84 (1H, s), 8.28 (1H, s), 8.73 (1H, t), 8.93(1H, d), 9.18(1H, d) 
1
H NMR Isonicotinamide:  7.76 (3H, dd), 8.27 (1H, s), 8.74 (2H, dd)   
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A-3:
  1
H NMR pyrazinamide:nicotinamide 
 
1
H NMR pyrazinamide: 7.89 (1H, s), 8.24 (1H, s), 8.72 (1H, t), 8.87 (1H, d), 9.02 (1H, d) 
1
H NMR nicotinamide:  7.51 (1H, q), 7.63(1H, s), 8.18 (2H, dt), 8.70 (1H,dd) , 9.05(1H,d)   
 
A-4:
  1
H NMR isonicotinamide:nicotinamide (1:1) 
 
1
H NMR isonicotinamide: 7.76 (3H, dd), 8.27 (1H, s), 8.74 (2H, dd)   
1
H NMR nicotinamide:  7.51 (1H, q), 7.63(1H, s), 8.18 (2H, dt), 8.70 (1H,dd) , 9.03(1H,d)   
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A-5:
  1
H NMR isonicotinamide:nicotinamide (1:2) 
 
1
H NMR isonicotinamide: 7.76 (3H, dd), 8.27 (1H, s), 8.74 (2H, dd)   
1
H NMR nicotinamide:  7.48 (1H, q), 7.61(5H, s), 8.18 (1H, dt), 8.70 (1H,dd) , 9.03(2H,dd)   
 
A-6: 
1
H NMR isonicotinamide:fumaric acid
   
 
1
H NMR isonicotinamide: 7.76 (3H, dd), 8.27 (1H, s), 8.74 (2H, dd)   
1
H NMR nicotinamide: 6.65 (2H, s) 
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Appendix B : CIF file data of crystal structures 
 
B-1: Data_Pyrazinamide_Glutaric 
_publ_section_comment 
; 
The crystal was a non-merohedral twin with the domains  
related by 180 degrees about the direct axis [0 0 1] 
and the refined percentage domain ratio being 64:36. 
; 
_audit_creation_method            SHELXL-97 
_chemical_name_systematic 
; 
 ? 
; 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety           
 'C5 H5 N3 O1, C5 H8 O4' 
_chemical_formula_sum 
 'C10 H13 N3 O5' 
_chemical_formula_weight          255.23 
loop_ 
 _atom_type_symbol 
 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0181   0.0091 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0311   0.0180 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0492   0.0322 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
_symmetry_cell_setting            Monoclinic 
_symmetry_space_group_name_H-M    'P 2(1)/c' 
  
loop_ 
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, y+1/2, -z+1/2' 
 '-x, -y, -z' 
 'x, -y-1/2, z-1/2' 
  
_cell_length_a                    11.3844(9) 
_cell_length_b                    4.8251(7) 
_cell_length_c                    21.9011(16) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  104.610(9) 
_cell_angle_gamma                 90.00 
_cell_volume                      1164.1(2) 
_cell_formula_units_Z             4 
_cell_measurement_temperature     100(2) 
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_cell_measurement_reflns_used     1614 
_cell_measurement_theta_min       4.1540 
_cell_measurement_theta_max       74.1980 
  
_exptl_crystal_description        Plate 
_exptl_crystal_colour             Colourless 
_exptl_crystal_size_max           0.15 
_exptl_crystal_size_mid           0.10 
_exptl_crystal_size_min           0.03 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.456 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              536 
_exptl_absorpt_coefficient_mu     1.012 
_exptl_absorpt_correction_type    Multi-scan 
_exptl_absorpt_correction_T_min   0.77183 
_exptl_absorpt_correction_T_max   1.00000 
_exptl_absorpt_process_details 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
Empirical absorption correction using spherical harmonics, 
 implemented in SCALE3 ABSPACK scaling algorithm. 
; 
_exptl_special_details 
; 
 ? 
; 
_diffrn_ambient_temperature 100.00(10)  
_diffrn_radiation_wavelength 1.5418 
_diffrn_radiation_type 'Cu K\a' 
_diffrn_radiation_source 'SuperNova (Cu) X-ray Source' 
_diffrn_radiation_monochromator 'mirror' 
_diffrn_measurement_device_type 'SuperNova, Dual, Cu at zero, Atlas' 
_diffrn_detector_area_resol_mean 5.1768 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             3397 
_diffrn_reflns_av_R_equivalents   0.0000 
_diffrn_reflns_av_sigmaI/netI     0.0256 
_diffrn_reflns_limit_h_min        -13 
_diffrn_reflns_limit_h_max        13 
_diffrn_reflns_limit_k_min        -5 
_diffrn_reflns_limit_k_max        5 
_diffrn_reflns_limit_l_min        -22 
_diffrn_reflns_limit_l_max        26 
_diffrn_reflns_theta_min          6.49 
_diffrn_reflns_theta_max          66.58 
_reflns_number_total              3397 
_reflns_number_gt                 2837 
_reflns_threshold_expression      >2\s(I) 
  
_computing_data_collection 
; 
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CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_cell_refinement 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_data_reduction 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 2008)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 2008)' 
_computing_molecular_graphics      
; 
OLEX2 (Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K, 
& Puschmann, H., 2009) 
; 
_computing_publication_material   'WinGX (Farrugia, 1999)' 
  
_refine_special_details 
; 
 Refinement of F^2^ against ALL reflections.  The weighted R-factor wR and 
 goodness of fit S are based on F^2^, conventional R-factors R are based 
 on F, with F set to zero for negative F^2^. The threshold expression of 
 F^2^ > 2\s(F^2^) is used only for calculating R-factors(gt) etc. and is 
 not relevant to the choice of reflections for refinement.  R-factors based 
 on F^2^ are statistically about twice as large as those based on F, and R- 
 factors based on ALL data will be even larger. 
;  
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
 'calc w=1/[\s^2^(Fo^2^)+(0.0675P)^2^+0.0460P] where P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      direct 
_atom_sites_solution_secondary    difmap 
_atom_sites_solution_hydrogens    geom 
_refine_ls_hydrogen_treatment     constr 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        ? 
_refine_ls_number_reflns          3397 
_refine_ls_number_parameters      166 
_refine_ls_number_restraints      0 
_refine_ls_R_factor_all           0.0491 
_refine_ls_R_factor_gt            0.0397 
_refine_ls_wR_factor_ref          0.1076 
_refine_ls_wR_factor_gt           0.1037 
_refine_ls_goodness_of_fit_ref    1.049 
_refine_ls_restrained_S_all       1.049 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
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loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_symmetry_multiplicity 
 _atom_site_calc_flag 
 _atom_site_refinement_flags 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
C2 C 0.89154(13) 2.0494(3) 0.05030(8) 0.0249(3) Uani 1 1 d . . . 
H2 H 0.9410 2.1893 0.0391 0.030 Uiso 1 1 calc R . . 
C3 C 0.82064(13) 1.8848(3) 0.00340(7) 0.0256(3) Uani 1 1 d . . . 
H3 H 0.8242 1.9129 -0.0390 0.031 Uiso 1 1 calc R . . 
C5 C 0.74684(13) 1.6590(3) 0.07678(7) 0.0194(3) Uani 1 1 d . . . 
C6 C 0.81945(13) 1.8188(3) 0.12416(7) 0.0206(3) Uani 1 1 d . . . 
H6 H 0.8176 1.7875 0.1667 0.025 Uiso 1 1 calc R . . 
C7 C 0.66383(12) 1.4434(3) 0.09198(7) 0.0188(3) Uani 1 1 d . . . 
N1 N 0.89194(11) 2.0156(3) 0.11122(6) 0.0226(3) Uani 1 1 d . . . 
N4 N 0.74770(11) 1.6886(3) 0.01577(6) 0.0227(3) Uani 1 1 d . . . 
N7 N 0.60145(11) 1.2946(2) 0.04418(6) 0.0205(3) Uani 1 1 d . . . 
H7A H 0.5520 1.1640 0.0507 0.025 Uiso 1 1 calc R . . 
H7B H 0.6093 1.3261 0.0058 0.025 Uiso 1 1 calc R . . 
O7 O 0.65787(9) 1.4118(2) 0.14771(4) 0.0218(2) Uani 1 1 d . . . 
C8 C 0.45077(12) 0.8820(3) 0.13900(6) 0.0190(3) Uani 1 1 d . . . 
C9 C 0.36751(13) 0.6981(3) 0.16330(7) 0.0208(3) Uani 1 1 d . . . 
H9A H 0.4158 0.5796 0.1974 0.025 Uiso 1 1 calc R . . 
H9B H 0.3233 0.5755 0.1289 0.025 Uiso 1 1 calc R . . 
C10 C 0.27577(13) 0.8666(3) 0.18878(7) 0.0217(3) Uani 1 1 d . . . 
H10A H 0.3204 0.9961 0.2216 0.026 Uiso 1 1 calc R . . 
H10B H 0.2252 0.9784 0.1540 0.026 Uiso 1 1 calc R . . 
C11 C 0.19339(14) 0.6850(3) 0.21685(7) 0.0233(3) Uani 1 1 d . . . 
H11A H 0.2447 0.5609 0.2486 0.028 Uiso 1 1 calc R . . 
H11B H 0.1473 0.8055 0.2391 0.028 Uiso 1 1 calc R . . 
C12 C 0.10484(13) 0.5108(3) 0.16998(7) 0.0213(3) Uani 1 1 d . . . 
O8 O 0.51735(10) 1.0470(2) 0.18238(5) 0.0251(3) Uani 1 1 d . . . 
H8 H 0.5595 1.1511 0.1656 0.038 Uiso 1 1 calc R . . 
O9 O 0.45676(9) 0.8842(2) 0.08404(5) 0.0241(3) Uani 1 1 d . . . 
O12 O 0.04475(9) 0.3386(2) 0.19860(5) 0.0264(3) Uani 1 1 d . . . 
H12 H -0.0011 0.2373 0.1716 0.040 Uiso 1 1 calc R . . 
O13 O 0.08886(9) 0.5219(2) 0.11311(5) 0.0271(3) Uani 1 1 d . . . 
  
loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
C2 0.0214(7) 0.0252(8) 0.0299(8) 0.0011(7) 0.0097(7) 0.0003(6) 
C3 0.0262(7) 0.0299(9) 0.0233(8) 0.0009(7) 0.0107(6) -0.0003(7) 
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C5 0.0194(7) 0.0196(8) 0.0197(7) 0.0007(6) 0.0057(6) 0.0047(6) 
C6 0.0207(7) 0.0213(8) 0.0207(7) -0.0018(6) 0.0065(6) 0.0024(6) 
C7 0.0184(6) 0.0201(8) 0.0186(7) -0.0005(6) 0.0056(6) 0.0027(6) 
N1 0.0198(6) 0.0232(7) 0.0258(7) -0.0029(5) 0.0074(5) 0.0006(5) 
N4 0.0227(6) 0.0274(7) 0.0186(7) -0.0005(5) 0.0065(5) -0.0005(5) 
N7 0.0234(6) 0.0236(7) 0.0149(6) -0.0022(5) 0.0055(5) -0.0041(5) 
O7 0.0251(5) 0.0256(6) 0.0148(5) -0.0012(4) 0.0048(4) -0.0029(4) 
C8 0.0190(7) 0.0204(8) 0.0166(7) -0.0008(6) 0.0026(6) 0.0027(6) 
C9 0.0238(8) 0.0223(8) 0.0164(7) -0.0014(6) 0.0055(6) -0.0001(6) 
C10 0.0247(7) 0.0213(8) 0.0204(7) -0.0024(6) 0.0081(6) -0.0038(6) 
C11 0.0247(7) 0.0279(8) 0.0187(7) -0.0033(7) 0.0080(6) -0.0035(6) 
C12 0.0175(7) 0.0244(8) 0.0234(8) 0.0003(6) 0.0077(6) 0.0016(6) 
O8 0.0292(6) 0.0312(6) 0.0158(5) -0.0046(5) 0.0073(4) -0.0098(5) 
O9 0.0293(6) 0.0285(6) 0.0151(5) -0.0036(4) 0.0067(4) -0.0067(5) 
O12 0.0269(6) 0.0285(6) 0.0247(6) -0.0041(5) 0.0080(5) -0.0085(5) 
O13 0.0252(5) 0.0362(7) 0.0192(6) -0.0034(5) 0.0041(4) -0.0047(5) 
  
_geom_special_details 
 All s.u.'s (except the s.u. in the dihedral angle between two l.s. planes) 
 are estimated using the full covariance matrix.  The cell s.u.'s are taken 
 into account individually in the estimation of s.u.'s in distances, angles 
 and torsion angles; correlations between s.u.'s in cell parameters are only 
 used when they are defined by crystal symmetry.  An approximate (isotropic) 
 treatment of cell s.u.'s is used for estimating s.u.'s involving l.s. planes. 
; 
  
loop_ 
 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
C2 N1 1.343(2) . ? 
C2 C3 1.385(2) . ? 
C2 H2 0.9500 . ? 
C3 N4 1.332(2) . ? 
C3 H3 0.9500 . ? 
C5 N4 1.346(2) . ? 
C5 C6 1.386(2) . ? 
C5 C7 1.498(2) . ? 
C6 N1 1.3345(19) . ? 
C6 H6 0.9500 . ? 
C7 O7 1.2488(17) . ? 
C7 N7 1.3192(19) . ? 
N7 H7A 0.8800 . ? 
N7 H7B 0.8800 . ? 
C8 O9 1.2227(18) . ? 
C8 O8 1.3221(17) . ? 
C8 C9 1.491(2) . ? 
C9 C10 1.535(2) . ? 
C9 H9A 0.9900 . ? 
C9 H9B 0.9900 . ? 
C10 C11 1.522(2) . ? 
C10 H10A 0.9900 . ? 
C10 H10B 0.9900 . ? 
C11 C12 1.501(2) . ? 
C11 H11A 0.9900 . ? 
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C11 H11B 0.9900 . ? 
C12 O13 1.2137(18) . ? 
C12 O12 1.3295(18) . ? 
O8 H8 0.8400 . ? 
O12 H12 0.8400 . ? 
 
loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
N1 C2 C3 121.50(14) . . ? 
N1 C2 H2 119.3 . . ? 
C3 C2 H2 119.3 . . ? 
N4 C3 C2 122.23(14) . . ? 
N4 C3 H3 118.9 . . ? 
C2 C3 H3 118.9 . . ? 
N4 C5 C6 122.13(14) . . ? 
N4 C5 C7 117.19(13) . . ? 
C6 C5 C7 120.68(13) . . ? 
N1 C6 C5 121.38(14) . . ? 
N1 C6 H6 119.3 . . ? 
C5 C6 H6 119.3 . . ? 
O7 C7 N7 123.91(14) . . ? 
O7 C7 C5 119.66(13) . . ? 
N7 C7 C5 116.43(13) . . ? 
C6 N1 C2 116.74(13) . . ? 
C3 N4 C5 116.01(13) . . ? 
C7 N7 H7A 120.0 . . ? 
C7 N7 H7B 120.0 . . ? 
H7A N7 H7B 120.0 . . ? 
O9 C8 O8 122.54(14) . . ? 
O9 C8 C9 123.72(13) . . ? 
O8 C8 C9 113.74(12) . . ? 
C8 C9 C10 111.51(12) . . ? 
C8 C9 H9A 109.3 . . ? 
C10 C9 H9A 109.3 . . ? 
C8 C9 H9B 109.3 . . ? 
C10 C9 H9B 109.3 . . ? 
H9A C9 H9B 108.0 . . ? 
C11 C10 C9 112.76(12) . . ? 
C11 C10 H10A 109.0 . . ? 
C9 C10 H10A 109.0 . . ? 
C11 C10 H10B 109.0 . . ? 
C9 C10 H10B 109.0 . . ? 
H10A C10 H10B 107.8 . . ? 
C12 C11 C10 114.96(12) . . ? 
C12 C11 H11A 108.5 . . ? 
C10 C11 H11A 108.5 . . ? 
C12 C11 H11B 108.5 . . ? 
C10 C11 H11B 108.5 . . ? 
H11A C11 H11B 107.5 . . ? 
O13 C12 O12 123.34(14) . . ? 
O13 C12 C11 125.31(14) . . ? 
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O12 C12 C11 111.35(13) . . ? 
C8 O8 H8 109.5 . . ? 
C12 O12 H12 109.5 . . ? 
loop_ 
 _geom_torsion_atom_site_label_1 
 _geom_torsion_atom_site_label_2 
 _geom_torsion_atom_site_label_3 
 _geom_torsion_atom_site_label_4 
 _geom_torsion 
 _geom_torsion_site_symmetry_1 
 _geom_torsion_site_symmetry_2 
 _geom_torsion_site_symmetry_3 
 _geom_torsion_site_symmetry_4 
 _geom_torsion_publ_flag 
N1 C2 C3 N4 1.2(2) . . . . ? 
N4 C5 C6 N1 1.7(2) . . . . ? 
C7 C5 C6 N1 -178.57(13) . . . . ? 
N4 C5 C7 O7 -178.55(13) . . . . ? 
C6 C5 C7 O7 1.7(2) . . . . ? 
N4 C5 C7 N7 2.1(2) . . . . ? 
C6 C5 C7 N7 -177.63(13) . . . . ? 
C5 C6 N1 C2 -0.4(2) . . . . ? 
C3 C2 N1 C6 -1.0(2) . . . . ? 
C2 C3 N4 C5 0.0(2) . . . . ? 
C6 C5 N4 C3 -1.4(2) . . . . ? 
C7 C5 N4 C3 178.87(13) . . . . ? 
O9 C8 C9 C10 -117.84(16) . . . . ? 
O8 C8 C9 C10 61.34(16) . . . . ? 
C8 C9 C10 C11 -177.22(12) . . . . ? 
C9 C10 C11 C12 -68.44(17) . . . . ? 
C10 C11 C12 O13 -6.1(2) . . . . ? 
C10 C11 C12 O12 173.80(12) . . . . ? 
  
loop_ 
 _geom_hbond_atom_site_label_D 
 _geom_hbond_atom_site_label_H 
 _geom_hbond_atom_site_label_A 
 _geom_hbond_distance_DH 
 _geom_hbond_distance_HA 
 _geom_hbond_distance_DA 
 _geom_hbond_angle_DHA 
 _geom_hbond_site_symmetry_A 
N7 H7A O9  0.88 1.98 2.8499(16) 168.1 . 
N7 H7B O9  0.88 2.17 2.8515(16) 133.6 3_675 
O8 H8 O7  0.84 1.79 2.6167(15) 166.5 . 
O12 H12 N1  0.84 1.89 2.7272(16) 178.3 1_435 
  
_diffrn_measured_fraction_theta_max    0.999 
_diffrn_reflns_theta_full              66.58 
_diffrn_measured_fraction_theta_full   0.999 
_refine_diff_density_max    0.179 
_refine_diff_density_min   -0.217 
_refine_diff_density_rms    0.048 
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B-2: Data_Pyrazinamide_AdipicAcid 
  
_audit_creation_method            SHELXL-97 
_chemical_name_systematic 
; 
 ? 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety           
 '4(C5 H5 N3 O), C6 H10 O4' 
_chemical_formula_sum 
 'C26 H30 N12 O8'  
_chemical_formula_weight          638.62 
 
loop_ 
 _atom_type_symbol 
 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0181   0.0091 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0311   0.0180 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0492   0.0322 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
_space_group_crystal_system       triclinic 
_space_group_IT_number            2 
_space_group_name_H-M_alt         'P -1' 
_space_group_name_Hall            '-P 1' 
  
_shelx_space_group_comment 
; 
The symmetry employed for this shelxl refinement is uniquely defined 
by the following loop, which should always be used as a source of 
symmetry information in preference to the above space-group names. 
They are only intended as comments. 
; 
  
loop_ 
 _space_group_symop_operation_xyz 
 'x, y, z' 
 '-x, -y, -z' 
_cell_length_a                    5.1814(8) 
_cell_length_b                    11.7163(16) 
_cell_length_c                    12.2250(14) 
_cell_angle_alpha                 74.708(11) 
_cell_angle_beta                  87.314(11) 
_cell_angle_gamma                 85.212(12) 
_cell_volume                      713.13(17) 
_cell_formula_units_Z             1 
_cell_measurement_temperature     100.00(10)  
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_cell_measurement_reflns_used     1781 
_cell_measurement_theta_min       3.8960 
_cell_measurement_theta_max       74.4610 
  
_exptl_crystal_description        Rod 
_exptl_crystal_colour             Colourless 
_exptl_crystal_density_meas       ?  
_exptl_crystal_density_method     ?               
_exptl_crystal_density_diffrn     1.487           
_exptl_crystal_F_000              334 
_exptl_transmission_factor_min    ?                                              
_exptl_transmission_factor_max    ?                                              
_exptl_crystal_size_max           0.200 
_exptl_crystal_size_mid           0.090 
_exptl_crystal_size_min           0.060 
_exptl_absorpt_coefficient_mu     0.963 
_shelx_estimated_absorpt_T_min    0.831 
_shelx_estimated_absorpt_T_max    0.944 
_exptl_absorpt_correction_type    Multi-scan 
_exptl_absorpt_correction_T_min   0.8308 
_exptl_absorpt_correction_T_max   0.9445 
_exptl_absorpt_process_details 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
Empirical absorption correction using spherical harmonics, 
 implemented in SCALE3 ABSPACK scaling algorithm. 
;  
  
_exptl_special_details 
; 
 ? 
 
_diffrn_ambient_temperature 100.00(10)  
_diffrn_radiation_wavelength 1.5418 
_diffrn_radiation_type 'Cu K\a' 
_diffrn_radiation_source 'SuperNova (Cu) X-ray Source' 
_diffrn_radiation_monochromator 'mirror' 
_diffrn_measurement_device_type 'SuperNova, Dual, Cu at zero, Atlas' 
_diffrn_detector_area_resol_mean 5.1768 
_diffrn_reflns_number             4178 
_diffrn_reflns_av_unetI/netI      0.0405 
_diffrn_reflns_av_R_equivalents   0.0348 
_diffrn_reflns_limit_h_min        -6 
_diffrn_reflns_limit_h_max        5 
_diffrn_reflns_limit_k_min        -13 
_diffrn_reflns_limit_k_max        14 
_diffrn_reflns_limit_l_min        -14 
_diffrn_reflns_limit_l_max        10 
_diffrn_reflns_theta_min          7.516 
_diffrn_reflns_theta_max          70.053 
_diffrn_reflns_theta_full         67.684 
_diffrn_measured_fraction_theta_max   0.982 
_diffrn_measured_fraction_theta_full  0.990 
_diffrn_reflns_Laue_measured_fraction_max    0.982 
_diffrn_reflns_Laue_measured_fraction_full   0.990 
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_diffrn_reflns_point_group_measured_fraction_max   0.982 
_diffrn_reflns_point_group_measured_fraction_full  0.990 
_reflns_number_total              2666 
_reflns_number_gt                 2197 
_reflns_threshold_expression      'I > 2\s(I)' 
_reflns_Friedel_coverage          0.000 
_reflns_Friedel_fraction_max      . 
_reflns_Friedel_fraction_full     . 
  
_reflns_special_details 
; 
 Reflections were merged by SHELXL according to the crystal 
 class for the calculation of statistics and refinement. 
  
 _reflns_Friedel_fraction is defined as the number of unique 
 Friedel pairs measured divided by the number that would be 
 possible theoretically, ignoring centric projections and 
 systematic absences. 
; 
 
_computing_data_collection  
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_cell_refinement 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_data_reduction 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 2008)' 
_computing_structure_refinement   'SHELXL-2013 (Sheldrick, 2013)' 
_computing_molecular_graphics      
; 
OLEX2 (Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K, 
& Puschmann, H., 2009) 
; 
_computing_publication_material   'WinGX (Farrugia, 1999)' 
_refine_special_details 
; 
 ? 
; 
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
'w=1/[\s^2^(Fo^2^)+(0.1155P)^2^+0.1109P] where P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      ? 
_atom_sites_solution_secondary    ? 
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_atom_sites_solution_hydrogens    mixed 
_refine_ls_hydrogen_treatment     mixed 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        . 
_refine_ls_number_reflns          2666 
_refine_ls_number_parameters      223 
_refine_ls_number_restraints      0 
_refine_ls_R_factor_all           0.0731 
_refine_ls_R_factor_gt            0.0623 
_refine_ls_wR_factor_ref          0.1780 
_refine_ls_wR_factor_gt           0.1642 
_refine_ls_goodness_of_fit_ref    1.050 
_refine_ls_restrained_S_all       1.050 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
  
 
loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_site_symmetry_order   
 _atom_site_calc_flag 
 _atom_site_refinement_flags_posn 
 _atom_site_refinement_flags_adp 
 _atom_site_refinement_flags_occupancy 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
C2A C 0.4085(4) 0.35859(19) -0.07386(19) 0.0263(5) Uani 1 1 d . . . . . 
H2A H 0.2676 0.4053 -0.1144 0.032 Uiso 1 1 calc R U . . . 
C3A C 0.5801(4) 0.29094(19) -0.12799(19) 0.0270(5) Uani 1 1 d . . . . . 
H3A H 0.5523 0.2923 -0.2046 0.032 Uiso 1 1 calc R U . . . 
C5A C 0.8115(4) 0.22510(18) 0.03340(18) 0.0235(5) Uani 1 1 d . . . . . 
C6A C 0.6400(4) 0.29184(18) 0.08805(18) 0.0245(5) Uani 1 1 d . . . . . 
H6A H 0.6662 0.2897 0.1650 0.029 Uiso 1 1 calc R U . . . 
C7A C 1.0351(4) 0.15261(18) 0.09798(18) 0.0239(5) Uani 1 1 d . . . . . 
N1A N 0.4400(4) 0.35846(15) 0.03390(16) 0.0251(4) Uani 1 1 d . . . . . 
N4A N 0.7817(3) 0.22463(16) -0.07480(15) 0.0250(4) Uani 1 1 d . . . . . 
N7A N 1.1931(4) 0.08911(16) 0.04328(16) 0.0249(4) Uani 1 1 d . . . . . 
H7A1 H 1.163(5) 0.093(2) -0.030(2) 0.034 Uiso 1 1 d . U . . . 
H7A2 H 1.327(6) 0.046(2) 0.087(2) 0.034 Uiso 1 1 d . U . . . 
O7A O 1.0634(3) 0.15611(14) 0.19676(13) 0.0284(4) Uani 1 1 d . . . . . 
C2B C 2.2314(4) -0.22531(19) 0.49135(19) 0.0263(5) Uani 1 1 d . . . . . 
H2B H 2.3622 -0.2679 0.5413 0.032 Uiso 1 1 calc R U . . . 
C3B C 2.0239(4) -0.16545(19) 0.53444(19) 0.0269(5) Uani 1 1 d . . . . . 
H3B H 2.0174 -0.1688 0.6130 0.032 Uiso 1 1 calc R U . . . 
C5B C 1.8543(4) -0.10190(18) 0.35921(18) 0.0233(5) Uani 1 1 d . . . . . 
C6B C 2.0611(4) -0.16248(19) 0.31587(18) 0.0260(5) Uani 1 1 d . . . . . 
H6B H 2.0670 -0.1597 0.2374 0.031 Uiso 1 1 calc R U . . . 
C7B C 1.6513(4) -0.02988(19) 0.27996(18) 0.0243(5) Uani 1 1 d . . . . . 
N1B N 2.2514(4) -0.22450(17) 0.38192(16) 0.0277(4) Uani 1 1 d . . . . . 
N4B N 1.8333(3) -0.10325(16) 0.46885(15) 0.0248(4) Uani 1 1 d . . . . . 
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N7B N 1.4875(4) 0.04159(17) 0.32306(17) 0.0287(5) Uani 1 1 d . . . . . 
H7B1 H 1.510(5) 0.042(2) 0.396(2) 0.033 Uiso 1 1 d . U . . . 
H7B2 H 1.355(6) 0.080(2) 0.279(2) 0.033 Uiso 1 1 d . U . . . 
O7B O 1.6442(3) -0.03823(13) 0.18110(12) 0.0271(4) Uani 1 1 d . . . . . 
C8 C 0.1943(4) 0.44251(18) 0.26678(18) 0.0244(5) Uani 1 1 d . . . . . 
C9 C 0.0075(4) 0.4960(2) 0.34221(18) 0.0261(5) Uani 1 1 d . . . . . 
H9A H -0.1603 0.4601 0.3468 0.031 Uiso 1 1 calc R U . . . 
H9B H -0.0231 0.5821 0.3069 0.031 Uiso 1 1 calc R U . . . 
C10 C 0.1036(4) 0.47780(19) 0.46206(18) 0.0260(5) Uani 1 1 d . . . . . 
H10A H 0.2611 0.5211 0.4588 0.031 Uiso 1 1 calc R U . . . 
H10B H 0.1506 0.3924 0.4953 0.031 Uiso 1 1 calc R U . . . 
O8 O 0.1055(3) 0.46106(14) 0.16325(13) 0.0288(4) Uani 1 1 d . . . . . 
O9 O 0.3997(3) 0.38959(15) 0.29721(14) 0.0341(4) Uani 1 1 d . . . . . 
H8 H 0.211(6) 0.432(3) 0.116(3) 0.051 Uiso 1 1 d . U . . . 
  
loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
C2A 0.0287(11) 0.0235(11) 0.0269(11) -0.0092(9) -0.0045(9) 0.0075(9) 
C3A 0.0305(11) 0.0289(11) 0.0230(10) -0.0115(9) -0.0050(9) 0.0073(9) 
C5A 0.0285(11) 0.0200(10) 0.0236(11) -0.0100(8) -0.0020(8) 0.0029(8) 
C6A 0.0291(10) 0.0228(11) 0.0228(10) -0.0100(8) -0.0023(8) 0.0053(8) 
C7A 0.0266(11) 0.0228(11) 0.0240(11) -0.0107(9) -0.0027(8) 0.0049(8) 
N1A 0.0264(9) 0.0224(9) 0.0270(10) -0.0096(7) -0.0002(7) 0.0061(7) 
N4A 0.0291(9) 0.0244(9) 0.0227(9) -0.0106(7) -0.0021(7) 0.0061(7) 
N7A 0.0277(9) 0.0262(9) 0.0216(9) -0.0107(7) -0.0045(7) 0.0096(7) 
O7A 0.0299(8) 0.0320(9) 0.0245(8) -0.0128(7) -0.0049(6) 0.0114(6) 
C2B 0.0289(11) 0.0237(11) 0.0270(11) -0.0091(9) -0.0046(9) 0.0044(8) 
C3B 0.0300(11) 0.0268(11) 0.0251(11) -0.0109(9) -0.0044(9) 0.0057(9) 
C5B 0.0286(11) 0.0204(10) 0.0228(11) -0.0103(8) -0.0016(8) 0.0026(8) 
C6B 0.0309(11) 0.0251(11) 0.0223(11) -0.0089(8) -0.0019(9) 0.0059(9) 
C7B 0.0280(11) 0.0235(11) 0.0230(10) -0.0103(8) -0.0028(8) 0.0034(8) 
N1B 0.0295(10) 0.0279(10) 0.0261(10) -0.0106(8) -0.0013(7) 0.0067(7) 
N4B 0.0294(9) 0.0238(9) 0.0232(9) -0.0111(7) -0.0031(7) 0.0047(7) 
N7B 0.0314(10) 0.0312(10) 0.0254(10) -0.0142(8) -0.0047(8) 0.0121(8) 
O7B 0.0305(8) 0.0305(8) 0.0216(8) -0.0116(6) -0.0036(6) 0.0084(6) 
C8 0.0270(10) 0.0243(11) 0.0227(11) -0.0097(8) -0.0024(8) 0.0066(8) 
C9 0.0278(11) 0.0276(11) 0.0249(11) -0.0131(9) -0.0032(8) 0.0081(9) 
C10 0.0272(11) 0.0255(11) 0.0271(11) -0.0128(9) -0.0016(9) 0.0071(9) 
O8 0.0303(8) 0.0332(9) 0.0251(8) -0.0158(7) -0.0042(6) 0.0147(7) 
O9 0.0297(8) 0.0421(10) 0.0324(9) -0.0182(7) -0.0048(7) 0.0156(7) 
  
_geom_special_details 
; 
 All esds (except the esd in the dihedral angle between two l.s. planes) 
 are estimated using the full covariance matrix.  The cell esds are taken 
 into account individually in the estimation of esds in distances, angles 
 and torsion angles; correlations between esds in cell parameters are only 
 used when they are defined by crystal symmetry.  An approximate (isotropic) 
 treatment of cell esds is used for estimating esds involving l.s. planes. 
; 
loop_ 
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 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
C2A N1A 1.335(3) . ? 
C2A C3A 1.400(3) . ? 
C2A H2A 0.9500 . ? 
C3A N4A 1.334(3) . ? 
C3A H3A 0.9500 . ? 
C5A N4A 1.340(3) . ? 
C5A C6A 1.397(3) . ? 
C5A C7A 1.502(3) . ? 
C6A N1A 1.333(3) . ? 
C6A H6A 0.9500 . ? 
C7A O7A 1.235(2) . ? 
C7A N7A 1.334(3) . ? 
N7A H7A1 0.90(3) . ? 
N7A H7A2 0.92(3) . ? 
C2B N1B 1.335(3) . ? 
C2B C3B 1.393(3) . ? 
C2B H2B 0.9500 . ? 
C3B N4B 1.340(3) . ? 
C3B H3B 0.9500 . ? 
C5B N4B 1.336(3) . ? 
C5B C6B 1.397(3) . ? 
C5B C7B 1.508(3) . ? 
C6B N1B 1.341(3) . ? 
C6B H6B 0.9500 . ? 
C7B O7B 1.240(2) . ? 
C7B N7B 1.331(3) . ? 
N7B H7B1 0.91(3) . ? 
N7B H7B2 0.91(3) . ? 
C8 O9 1.209(3) . ? 
C8 O8 1.324(3) . ? 
C8 C9 1.516(3) . ? 
C9 C10 1.525(3) . ? 
C9 H9A 0.9900 . ? 
C9 H9B 0.9900 . ? 
C10 C10 1.534(4) 2_566 ? 
C10 H10A 0.9900 . ? 
C10 H10B 0.9900 . ? 
O8 H8 0.89(3) . ? 
  
loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
N1A C2A C3A 120.97(19) . . ? 
N1A C2A H2A 119.5 . . ? 
C3A C2A H2A 119.5 . . ? 
N4A C3A C2A 121.71(19) . . ? 
N4A C3A H3A 119.1 . . ? 
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C2A C3A H3A 119.1 . . ? 
N4A C5A C6A 121.71(19) . . ? 
N4A C5A C7A 119.48(17) . . ? 
C6A C5A C7A 118.81(18) . . ? 
N1A C6A C5A 121.00(19) . . ? 
N1A C6A H6A 119.5 . . ? 
C5A C6A H6A 119.5 . . ? 
O7A C7A N7A 124.22(19) . . ? 
O7A C7A C5A 118.73(17) . . ? 
N7A C7A C5A 117.05(18) . . ? 
C6A N1A C2A 117.78(17) . . ? 
C3A N4A C5A 116.84(17) . . ? 
C7A N7A H7A1 119.0(18) . . ? 
C7A N7A H7A2 113.7(17) . . ? 
H7A1 N7A H7A2 127(2) . . ? 
N1B C2B C3B 121.8(2) . . ? 
N1B C2B H2B 119.1 . . ? 
C3B C2B H2B 119.1 . . ? 
N4B C3B C2B 122.3(2) . . ? 
N4B C3B H3B 118.9 . . ? 
C2B C3B H3B 118.9 . . ? 
N4B C5B C6B 122.02(19) . . ? 
N4B C5B C7B 118.55(18) . . ? 
C6B C5B C7B 119.41(18) . . ? 
N1B C6B C5B 121.83(19) . . ? 
N1B C6B H6B 119.1 . . ? 
C5B C6B H6B 119.1 . . ? 
O7B C7B N7B 123.74(19) . . ? 
O7B C7B C5B 120.52(18) . . ? 
N7B C7B C5B 115.73(18) . . ? 
C2B N1B C6B 116.19(18) . . ? 
C5B N4B C3B 115.88(18) . . ? 
C7B N7B H7B1 117.0(17) . . ? 
C7B N7B H7B2 117.2(17) . . ? 
H7B1 N7B H7B2 126(2) . . ? 
O9 C8 O8 123.99(18) . . ? 
O9 C8 C9 124.2(2) . . ? 
O8 C8 C9 111.82(17) . . ? 
C8 C9 C10 113.57(17) . . ? 
C8 C9 H9A 108.9 . . ? 
C10 C9 H9A 108.9 . . ? 
C8 C9 H9B 108.9 . . ? 
C10 C9 H9B 108.9 . . ? 
H9A C9 H9B 107.7 . . ? 
C9 C10 C10 111.3(2) . 2_566 ? 
C9 C10 H10A 109.4 . . ? 
C10 C10 H10A 109.4 2_566 . ? 
C9 C10 H10B 109.4 . . ? 
C10 C10 H10B 109.4 2_566 . ? 
H10A C10 H10B 108.0 . . ? 
C8 O8 H8 115(2) . . ? 
  
loop_ 
 _geom_torsion_atom_site_label_1 
 _geom_torsion_atom_site_label_2 
 _geom_torsion_atom_site_label_3 
 _geom_torsion_atom_site_label_4 
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 _geom_torsion 
 _geom_torsion_site_symmetry_1 
 _geom_torsion_site_symmetry_2 
 _geom_torsion_site_symmetry_3 
 _geom_torsion_site_symmetry_4 
 _geom_torsion_publ_flag 
N1A C2A C3A N4A -0.4(4) . . . . ? 
N4A C5A C6A N1A -0.4(3) . . . . ? 
C7A C5A C6A N1A 179.36(19) . . . . ? 
N4A C5A C7A O7A 178.3(2) . . . . ? 
C6A C5A C7A O7A -1.4(3) . . . . ? 
N4A C5A C7A N7A -0.9(3) . . . . ? 
C6A C5A C7A N7A 179.3(2) . . . . ? 
C5A C6A N1A C2A 0.4(3) . . . . ? 
C3A C2A N1A C6A 0.0(3) . . . . ? 
C2A C3A N4A C5A 0.4(3) . . . . ? 
C6A C5A N4A C3A 0.0(3) . . . . ? 
C7A C5A N4A C3A -179.8(2) . . . . ? 
N1B C2B C3B N4B -0.3(4) . . . . ? 
N4B C5B C6B N1B -0.6(4) . . . . ? 
C7B C5B C6B N1B 177.7(2) . . . . ? 
N4B C5B C7B O7B -170.6(2) . . . . ? 
C6B C5B C7B O7B 11.0(3) . . . . ? 
N4B C5B C7B N7B 9.9(3) . . . . ? 
C6B C5B C7B N7B -168.5(2) . . . . ? 
C3B C2B N1B C6B 0.2(3) . . . . ? 
C5B C6B N1B C2B 0.2(3) . . . . ? 
C6B C5B N4B C3B 0.5(3) . . . . ? 
C7B C5B N4B C3B -177.81(19) . . . . ? 
C2B C3B N4B C5B -0.1(3) . . . . ? 
O9 C8 C9 C10 0.5(3) . . . . ? 
O8 C8 C9 C10 -179.37(19) . . . . ? 
C8 C9 C10 C10 -174.2(2) . . . 2_566 ? 
  
loop_ 
 _geom_hbond_atom_site_label_D  
 _geom_hbond_atom_site_label_H  
 _geom_hbond_atom_site_label_A  
 _geom_hbond_distance_DH  
 _geom_hbond_distance_HA  
 _geom_hbond_distance_DA  
 _geom_hbond_angle_DHA  
 _geom_hbond_site_symmetry_A  
N7A H7A1 O7B  0.90(3) 2.28(3) 3.025(2) 140(2) 2_855 
N7A H7A2 O7B  0.92(3) 2.08(3) 2.998(2) 175(2) . 
N7B H7B2 O7A  0.91(3) 1.88(3) 2.783(2) 176(2) . 
N7B H7B1 N4B  0.91(3) 2.56(3) 3.183(3) 127(2) 2_856 
O8 H8 N1A  0.89(3) 1.82(3) 2.711(2) 173(3) . 
  
_refine_diff_density_max    0.353 
_refine_diff_density_min   -0.368 
_refine_diff_density_rms    0.091 
 
_shelxl_version_number 2013-4 
 
_shelx_res_file 
; 
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TITL Pyrazinamide_AdipicAcid_(1)1_1 in P-1 #2 
CELL  1.54184   5.1814  11.7163  12.2250   74.708   87.314   85.212 
ZERR     1.00   0.0008   0.0016   0.0014    0.011    0.011    0.012 
 
TITL Pyrazinamide_AdipicAcid_(1)1_1 in P-1 
REM P-1 (#2 in standard setting) 
CELL 1.54184   5.181357  11.716258  12.225045  74.7082  87.3141  85.2121 
ZERR    2.00   0.000790   0.001554   0.001360   0.0106   0.0110   0.0117 
LATT  1 
SFAC C H N O 
UNIT 22.00 30.00 6.00 10.00 
TREF 
HKLF 4 
END 
 
        
 
B-3: Data_Pyrazinamide_PimelicAcid 
  
_audit_creation_method            SHELXL-97 
_chemical_name_systematic 
; 
 ? 
; 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum 
 'C12 H17 N3 O5' 
_chemical_formula_weight          283.29 
  
loop_ 
 _atom_type_symbol 
 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0061   0.0033 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
_symmetry_cell_setting            Triclinic 
_symmetry_space_group_name_H-M    'P -1' 
  
loop_ 
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, -y, -z' 
  
_cell_length_a                    5.3302(4) 
_cell_length_b                    8.4201(6) 
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_cell_length_c                    15.5321(11) 
_cell_angle_alpha                 89.478(7) 
_cell_angle_beta                  82.760(7) 
_cell_angle_gamma                 71.840(6) 
_cell_volume                      656.75(9) 
_cell_formula_units_Z             2 
_cell_measurement_temperature     100(2) 
_cell_measurement_reflns_used     0 
_cell_measurement_theta_min       2.5 
_cell_measurement_theta_max       27.5 
  
_exptl_crystal_description        Plate 
_exptl_crystal_colour             Colourless 
_exptl_crystal_size_max           0.42 
_exptl_crystal_size_mid           0.16 
_exptl_crystal_size_min           0.02 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.433 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              300 
_exptl_absorpt_coefficient_mu     0.113 
_exptl_absorpt_correction_type          'Multi-scan' 
_exptl_absorpt_correction_T_max         1.000 
_exptl_absorpt_correction_T_min         0.791 
_exptl_absorpt_process_details     
; 
CrystalClear-SM Expert 3.1 b26 (Rigaku, 2012) 
; 
  
_exptl_special_details 
; 
 ? 
; 
  
_diffrn_ambient_temperature       100(2) 
_diffrn_radiation_wavelength      0.71075 
_diffrn_radiation_type            MoK\a 
_diffrn_source                          'Rotating Anode' 
_diffrn_radiation_monochromator         'Graphite Monochromator' 
_diffrn_measurement_specimen_support    'MiTeGen' 
_diffrn_detector                        'CCD' 
_diffrn_measurement_device 
; 
AFC12 (Right): Kappa 3 circle 
; 
_diffrn_measurement_device_type 
; 
Rigaku Saturn724+ (2x2 bin mode) 
; 
_diffrn_detector_area_resol_mean        28.5714 
_diffrn_measurement_method              'profile data from \w-scans' 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             7308 
_diffrn_reflns_av_R_equivalents   0.0290 
Anas. M. Al-Abachi                                                                                 Appendices                                                                                                               
 Page 124 
 
_diffrn_reflns_av_sigmaI/netI     0.0228 
_diffrn_reflns_limit_h_min        -6 
_diffrn_reflns_limit_h_max        6 
_diffrn_reflns_limit_k_min        -10 
_diffrn_reflns_limit_k_max        10 
_diffrn_reflns_limit_l_min        -20 
_diffrn_reflns_limit_l_max        20 
_diffrn_reflns_theta_min          3.73 
_diffrn_reflns_theta_max          27.48 
_reflns_number_total              2979 
_reflns_number_gt                 2697 
_reflns_threshold_expression      >2\s(I) 
  
_computing_data_collection 
; 
CrystalClear-SM Expert 3.1 b26 (Rigaku, 2012) 
; 
_computing_cell_refinement 
; 
CrystalClear-SM Expert 3.1 b26 (Rigaku, 2012) 
; 
_computing_data_reduction 
; 
CrystalClear-SM Expert 3.1 b26 (Rigaku, 2012) 
; 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 2008)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 2008)' 
_computing_molecular_graphics      
; 
OLEX2 (Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K, 
& Puschmann, H., 2009) 
; 
_computing_publication_material   'WinGX (Farrugia, 1999)' 
  
_refine_special_details 
; 
 Refinement of F^2^ against ALL reflections.  The weighted R-factor wR and 
 goodness of fit S are based on F^2^, conventional R-factors R are based 
 on F, with F set to zero for negative F^2^. The threshold expression of 
 F^2^ > 2\s(F^2^) is used only for calculating R-factors(gt) etc. and is 
 not relevant to the choice of reflections for refinement.  R-factors based 
 on F^2^ are statistically about twice as large as those based on F, and R- 
 factors based on ALL data will be even larger. 
; 
  
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
 'calc w=1/[\s^2^(Fo^2^)+(0.0572P)^2^+0.1477P] where P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      direct 
_atom_sites_solution_secondary    difmap 
_atom_sites_solution_hydrogens    geom 
_refine_ls_hydrogen_treatment     constr 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        ? 
_refine_ls_number_reflns          2979 
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_refine_ls_number_parameters      183 
_refine_ls_number_restraints      0 
_refine_ls_R_factor_all           0.0381 
_refine_ls_R_factor_gt            0.0350 
_refine_ls_wR_factor_ref          0.1010 
_refine_ls_wR_factor_gt           0.0984 
_refine_ls_goodness_of_fit_ref    1.062 
_refine_ls_restrained_S_all       1.062 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
  
loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_symmetry_multiplicity 
 _atom_site_calc_flag 
 _atom_site_refinement_flags 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
C2 C 0.1996(2) 0.74419(13) 0.06798(7) 0.0191(2) Uani 1 1 d . . . 
H2 H 0.1590 0.8029 0.0164 0.023 Uiso 1 1 calc R . . 
C3 C -0.0048(2) 0.75477(13) 0.13515(7) 0.0190(2) Uani 1 1 d . . . 
H3 H -0.1818 0.8185 0.1277 0.023 Uiso 1 1 calc R . . 
C5 C 0.29496(19) 0.59084(11) 0.21663(6) 0.0151(2) Uani 1 1 d . . . 
C6 C 0.5000(2) 0.57605(12) 0.14905(7) 0.0166(2) Uani 1 1 d . . . 
H6 H 0.6764 0.5103 0.1561 0.020 Uiso 1 1 calc R . . 
C7 C 0.3575(2) 0.51222(12) 0.30214(6) 0.0160(2) Uani 1 1 d . . . 
N1 N 0.45164(17) 0.65344(11) 0.07417(6) 0.01757(19) Uani 1 1 d . . . 
N4 N 0.04111(17) 0.67780(11) 0.20971(6) 0.01756(19) Uani 1 1 d . . . 
N7 N 0.15084(18) 0.52093(11) 0.36128(6) 0.0211(2) Uani 1 1 d . . . 
H7A H 0.1766 0.4781 0.4125 0.025 Uiso 1 1 calc R . . 
H7B H -0.0121 0.5695 0.3493 0.025 Uiso 1 1 calc R . . 
O7 O 0.59382(14) 0.44627(10) 0.31319(5) 0.02045(18) Uani 1 1 d . . . 
C8 C 0.7003(2) 0.79984(13) -0.11307(6) 0.0170(2) Uani 1 1 d . . . 
C9 C 0.8954(2) 0.82530(13) -0.18699(7) 0.0185(2) Uani 1 1 d . . . 
H9A H 0.9673 0.7211 -0.2233 0.022 Uiso 1 1 calc R . . 
H9B H 1.0461 0.8454 -0.1626 0.022 Uiso 1 1 calc R . . 
C10 C 0.7777(2) 0.96990(13) -0.24476(6) 0.0173(2) Uani 1 1 d . . . 
H10A H 0.9253 0.9949 -0.2818 0.021 Uiso 1 1 calc R . . 
H10B H 0.6809 1.0704 -0.2074 0.021 Uiso 1 1 calc R . . 
C11 C 0.5880(2) 0.93678(12) -0.30307(6) 0.0175(2) Uani 1 1 d . . . 
H11A H 0.4393 0.9125 -0.2664 0.021 Uiso 1 1 calc R . . 
H11B H 0.6841 0.8366 -0.3408 0.021 Uiso 1 1 calc R . . 
C12 C 0.4742(2) 1.08466(13) -0.36022(6) 0.0176(2) Uani 1 1 d . . . 
H12A H 0.3269 1.0661 -0.3874 0.021 Uiso 1 1 calc R . . 
H12B H 0.3999 1.1881 -0.3233 0.021 Uiso 1 1 calc R . . 
C13 C 0.6836(2) 1.10813(13) -0.43110(6) 0.0180(2) Uani 1 1 d . . . 
H13A H 0.8219 1.1369 -0.4034 0.022 Uiso 1 1 calc R . . 
H13B H 0.7704 1.0006 -0.4638 0.022 Uiso 1 1 calc R . . 
C14 C 0.5754(2) 1.24171(13) -0.49419(6) 0.0169(2) Uani 1 1 d . . . 
O8 O 0.81265(15) 0.66873(9) -0.06626(5) 0.02025(18) Uani 1 1 d . . . 
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H8 H 0.7033 0.6622 -0.0235 0.030 Uiso 1 1 calc R . . 
O9 O 0.47061(15) 0.88701(10) -0.09651(5) 0.0265(2) Uani 1 1 d . . . 
O14 O 0.75951(15) 1.24772(10) -0.55884(5) 0.02310(19) Uani 1 1 d . . . 
H14 H 0.6895 1.3171 -0.5949 0.035 Uiso 1 1 calc R . . 
O15 O 0.34542(15) 1.33214(10) -0.48753(5) 0.02399(19) Uani 1 1 d . . . 
  
loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
C2 0.0210(5) 0.0204(5) 0.0180(5) 0.0050(4) -0.0053(4) -0.0082(4) 
C3 0.0158(5) 0.0191(5) 0.0227(5) 0.0039(4) -0.0049(4) -0.0054(4) 
C5 0.0163(5) 0.0124(4) 0.0168(5) 0.0015(3) -0.0015(4) -0.0052(4) 
C6 0.0164(5) 0.0151(5) 0.0179(5) 0.0013(4) -0.0014(4) -0.0046(4) 
C7 0.0179(5) 0.0124(4) 0.0164(5) 0.0013(3) -0.0004(4) -0.0037(4) 
N1 0.0187(4) 0.0181(4) 0.0165(4) 0.0023(3) -0.0018(3) -0.0069(3) 
N4 0.0165(4) 0.0166(4) 0.0195(4) 0.0023(3) -0.0011(3) -0.0054(3) 
N7 0.0171(4) 0.0225(4) 0.0188(4) 0.0068(3) 0.0017(3) -0.0008(3) 
O7 0.0168(4) 0.0237(4) 0.0191(4) 0.0067(3) -0.0014(3) -0.0044(3) 
C8 0.0183(5) 0.0177(5) 0.0155(5) 0.0027(4) -0.0035(4) -0.0059(4) 
C9 0.0152(5) 0.0210(5) 0.0179(5) 0.0050(4) -0.0016(4) -0.0039(4) 
C10 0.0174(5) 0.0182(5) 0.0169(5) 0.0046(4) -0.0020(4) -0.0066(4) 
C11 0.0193(5) 0.0178(5) 0.0163(5) 0.0040(4) -0.0027(4) -0.0072(4) 
C12 0.0147(5) 0.0198(5) 0.0164(5) 0.0036(4) -0.0008(4) -0.0034(4) 
C13 0.0166(5) 0.0185(5) 0.0167(5) 0.0049(4) -0.0010(4) -0.0028(4) 
C14 0.0171(5) 0.0174(5) 0.0160(5) 0.0015(4) -0.0014(4) -0.0054(4) 
O8 0.0198(4) 0.0207(4) 0.0180(4) 0.0067(3) -0.0007(3) -0.0038(3) 
O9 0.0188(4) 0.0308(4) 0.0233(4) 0.0096(3) 0.0024(3) -0.0003(3) 
O14 0.0179(4) 0.0269(4) 0.0203(4) 0.0108(3) 0.0008(3) -0.0025(3) 
O15 0.0187(4) 0.0255(4) 0.0208(4) 0.0075(3) 0.0011(3) 0.0015(3) 
  
_geom_special_details 
; 
 All s.u.'s (except the s.u. in the dihedral angle between two l.s. planes) 
 are estimated using the full covariance matrix.  The cell s.u.'s are taken 
 into account individually in the estimation of s.u.'s in distances, angles 
 and torsion angles; correlations between s.u.'s in cell parameters are only 
 used when they are defined by crystal symmetry.  An approximate (isotropic) 
 treatment of cell s.u.'s is used for estimating s.u.'s involving l.s. planes. 
; 
  
loop_ 
 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
C2 N1 1.3377(13) . ? 
C2 C3 1.3922(14) . ? 
C2 H2 0.9500 . ? 
C3 N4 1.3342(13) . ? 
C3 H3 0.9500 . ? 
C5 N4 1.3402(13) . ? 
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C5 C6 1.3928(14) . ? 
C5 C7 1.5070(13) . ? 
C6 N1 1.3419(13) . ? 
C6 H6 0.9500 . ? 
C7 O7 1.2414(12) . ? 
C7 N7 1.3261(13) . ? 
N7 H7A 0.8800 . ? 
N7 H7B 0.8800 . ? 
C8 O9 1.2116(13) . ? 
C8 O8 1.3375(12) . ? 
C8 C9 1.5095(14) . ? 
C9 C10 1.5255(13) . ? 
C9 H9A 0.9900 . ? 
C9 H9B 0.9900 . ? 
C10 C11 1.5269(14) . ? 
C10 H10A 0.9900 . ? 
C10 H10B 0.9900 . ? 
C11 C12 1.5333(13) . ? 
C11 H11A 0.9900 . ? 
C11 H11B 0.9900 . ? 
C12 C13 1.5234(14) . ? 
C12 H12A 0.9900 . ? 
C12 H12B 0.9900 . ? 
C13 C14 1.5086(13) . ? 
C13 H13A 0.9900 . ? 
C13 H13B 0.9900 . ? 
C14 O15 1.2167(13) . ? 
C14 O14 1.3251(12) . ? 
O8 H8 0.8400 . ? 
O14 H14 0.8400 . ? 
  
loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
N1 C2 C3 121.69(9) . . ? 
N1 C2 H2 119.2 . . ? 
C3 C2 H2 119.2 . . ? 
N4 C3 C2 121.80(9) . . ? 
N4 C3 H3 119.1 . . ? 
C2 C3 H3 119.1 . . ? 
N4 C5 C6 122.31(9) . . ? 
N4 C5 C7 117.89(9) . . ? 
C6 C5 C7 119.76(9) . . ? 
N1 C6 C5 120.87(9) . . ? 
N1 C6 H6 119.6 . . ? 
C5 C6 H6 119.6 . . ? 
O7 C7 N7 124.55(9) . . ? 
O7 C7 C5 119.04(9) . . ? 
N7 C7 C5 116.40(9) . . ? 
C2 N1 C6 116.94(9) . . ? 
C3 N4 C5 116.35(9) . . ? 
C7 N7 H7A 120.0 . . ? 
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C7 N7 H7B 120.0 . . ? 
H7A N7 H7B 120.0 . . ? 
O9 C8 O8 123.25(9) . . ? 
O9 C8 C9 125.09(9) . . ? 
O8 C8 C9 111.66(8) . . ? 
C8 C9 C10 114.37(8) . . ? 
C8 C9 H9A 108.7 . . ? 
C10 C9 H9A 108.7 . . ? 
C8 C9 H9B 108.7 . . ? 
C10 C9 H9B 108.7 . . ? 
H9A C9 H9B 107.6 . . ? 
C9 C10 C11 114.24(8) . . ? 
C9 C10 H10A 108.7 . . ? 
C11 C10 H10A 108.7 . . ? 
C9 C10 H10B 108.7 . . ? 
C11 C10 H10B 108.7 . . ? 
H10A C10 H10B 107.6 . . ? 
C10 C11 C12 112.74(8) . . ? 
C10 C11 H11A 109.0 . . ? 
C12 C11 H11A 109.0 . . ? 
C10 C11 H11B 109.0 . . ? 
C12 C11 H11B 109.0 . . ? 
H11A C11 H11B 107.8 . . ? 
C13 C12 C11 112.32(8) . . ? 
C13 C12 H12A 109.1 . . ? 
C11 C12 H12A 109.1 . . ? 
C13 C12 H12B 109.1 . . ? 
C11 C12 H12B 109.1 . . ? 
H12A C12 H12B 107.9 . . ? 
C14 C13 C12 114.21(8) . . ? 
C14 C13 H13A 108.7 . . ? 
C12 C13 H13A 108.7 . . ? 
C14 C13 H13B 108.7 . . ? 
C12 C13 H13B 108.7 . . ? 
H13A C13 H13B 107.6 . . ? 
O15 C14 O14 123.66(9) . . ? 
O15 C14 C13 124.27(9) . . ? 
O14 C14 C13 112.06(8) . . ? 
C8 O8 H8 109.5 . . ? 
C14 O14 H14 109.5 . . ? 
  
loop_ 
 _geom_torsion_atom_site_label_1 
 _geom_torsion_atom_site_label_2 
 _geom_torsion_atom_site_label_3 
 _geom_torsion_atom_site_label_4 
 _geom_torsion 
 _geom_torsion_site_symmetry_1 
 _geom_torsion_site_symmetry_2 
 _geom_torsion_site_symmetry_3 
 _geom_torsion_site_symmetry_4 
 _geom_torsion_publ_flag 
N1 C2 C3 N4 1.39(16) . . . . ? 
N4 C5 C6 N1 1.96(15) . . . . ? 
C7 C5 C6 N1 -175.91(9) . . . . ? 
N4 C5 C7 O7 -172.48(9) . . . . ? 
C6 C5 C7 O7 5.48(14) . . . . ? 
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N4 C5 C7 N7 6.76(13) . . . . ? 
C6 C5 C7 N7 -175.28(9) . . . . ? 
C3 C2 N1 C6 -1.56(15) . . . . ? 
C5 C6 N1 C2 -0.03(14) . . . . ? 
C2 C3 N4 C5 0.49(14) . . . . ? 
C6 C5 N4 C3 -2.11(14) . . . . ? 
C7 C5 N4 C3 175.79(9) . . . . ? 
O9 C8 C9 C10 -2.54(15) . . . . ? 
O8 C8 C9 C10 178.24(8) . . . . ? 
C8 C9 C10 C11 -72.02(11) . . . . ? 
C9 C10 C11 C12 -179.92(8) . . . . ? 
C10 C11 C12 C13 70.18(11) . . . . ? 
C11 C12 C13 C14 174.49(8) . . . . ? 
C12 C13 C14 O15 4.55(15) . . . . ? 
C12 C13 C14 O14 -174.50(9) . . . . ? 
  
loop_ 
 _geom_hbond_atom_site_label_D 
 _geom_hbond_atom_site_label_H 
 _geom_hbond_atom_site_label_A 
 _geom_hbond_distance_DH 
 _geom_hbond_distance_HA 
 _geom_hbond_distance_DA 
 _geom_hbond_angle_DHA 
 _geom_hbond_site_symmetry_A 
N7 H7A O15  0.88 2.09 2.9385(12) 162.5 1_546 
N7 H7B O15  0.88 2.57 3.0116(12) 111.9 2_575 
O8 H8 N1  0.84 1.91 2.7510(12) 178.6 . 
O14 H14 O7  0.84 1.81 2.6433(11) 169.2 1_564 
  
_diffrn_measured_fraction_theta_max    0.993 
_diffrn_reflns_theta_full              27.48 
_diffrn_measured_fraction_theta_full   0.993 
_refine_diff_density_max    0.404 
_refine_diff_density_min   -0.207 
_refine_diff_density_rms    0.046 
 
 
 
 
B-4: Data_Azelaic_Acid 
  
_audit_creation_method            SHELXL-2013 
_chemical_name_systematic 
; 
 ? 
; 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety           
 'C9 H16 O4' 
_chemical_formula_sum 
 'C9 H16 O4'  
_chemical_formula_weight          188.22 
 
loop_ 
 _atom_type_symbol 
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 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0181   0.0091 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0492   0.0322 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
_space_group_crystal_system       monoclinic 
_space_group_IT_number            14 
_space_group_name_H-M_alt         'P 21/c' 
_space_group_name_Hall            '-P 2ybc' 
  
_shelx_space_group_comment 
; 
The symmetry employed for this shelxl refinement is uniquely defined 
by the following loop, which should always be used as a source of 
symmetry information in preference to the above space-group names. 
They are only intended as comments. 
; 
  
loop_ 
 _space_group_symop_operation_xyz 
 'x, y, z' 
 '-x, y+1/2, -z+1/2' 
 '-x, -y, -z' 
 'x, -y-1/2, z-1/2' 
  
_cell_length_a                    5.4938(2) 
_cell_length_b                    9.4418(3) 
_cell_length_c                    18.8258(6) 
_cell_angle_alpha                 90 
_cell_angle_beta                  95.673(3) 
_cell_angle_gamma                 90 
_cell_volume                      971.74(6) 
_cell_formula_units_Z             4 
_cell_measurement_temperature   100.00(10)  
_cell_measurement_reflns_used   2039 
_cell_measurement_theta_min     4.7030 
_cell_measurement_theta_max     74.1230 
  
_exptl_crystal_description        Slab 
_exptl_crystal_colour             Colourless 
_exptl_crystal_density_meas       ?  
_exptl_crystal_density_method     ?               
_exptl_crystal_density_diffrn     1.287           
_exptl_crystal_F_000              408 
_exptl_transmission_factor_min    ?                                              
_exptl_transmission_factor_max    ?                                              
_exptl_crystal_size_max           0.140 
_exptl_crystal_size_mid           0.130 
_exptl_crystal_size_min           0.030 
_exptl_absorpt_coefficient_mu     0.838 
_shelx_estimated_absorpt_T_min    0.892 
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_shelx_estimated_absorpt_T_max    0.975 
_exptl_absorpt_correction_T_min                   0.89788 
_exptl_absorpt_correction_T_max                   1.00000 
_exptl_absorpt_correction_type            'multi-scan' 
_exptl_absorpt_process_details 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
Empirical absorption correction using spherical harmonics, 
 implemented in SCALE3 ABSPACK scaling algorithm. 
; 
  
_exptl_special_details 
; 
 ? 
; 
  
_diffrn_ambient_temperature 100.00(10)  
_diffrn_radiation_wavelength 1.5418 
_diffrn_radiation_type 'Cu K\a' 
_diffrn_radiation_source 'SuperNova (Cu) X-ray Source' 
_diffrn_radiation_monochromator 'mirror' 
_diffrn_measurement_device_type 'SuperNova, Dual, Cu at zero, Atlas' 
_diffrn_detector_area_resol_mean 5.1768 
_diffrn_reflns_number             3622 
_diffrn_reflns_av_unetI/netI      0.0257 
_diffrn_reflns_av_R_equivalents   0.0182 
_diffrn_reflns_limit_h_min        -6 
_diffrn_reflns_limit_h_max        6 
_diffrn_reflns_limit_k_min        -10 
_diffrn_reflns_limit_k_max        11 
_diffrn_reflns_limit_l_min        -22 
_diffrn_reflns_limit_l_max        21 
_diffrn_reflns_theta_min          6.657 
_diffrn_reflns_theta_max          74.248 
_diffrn_reflns_theta_full         67.684 
_diffrn_measured_fraction_theta_max   0.969 
_diffrn_measured_fraction_theta_full  0.997 
_diffrn_reflns_Laue_measured_fraction_max    0.969 
_diffrn_reflns_Laue_measured_fraction_full   0.997 
_diffrn_reflns_point_group_measured_fraction_max   0.969 
_diffrn_reflns_point_group_measured_fraction_full  0.997 
_reflns_number_total              1922 
_reflns_number_gt                 1726 
_reflns_threshold_expression      'I > 2\s(I)' 
_reflns_Friedel_coverage          0.000 
_reflns_Friedel_fraction_max      . 
_reflns_Friedel_fraction_full     . 
  
_reflns_special_details 
; 
 Reflections were merged by SHELXL according to the crystal 
 class for the calculation of statistics and refinement. 
  
 _reflns_Friedel_fraction is defined as the number of unique 
 Friedel pairs measured divided by the number that would be 
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 possible theoretically, ignoring centric projections and 
 systematic absences. 
; 
  
_computing_data_collection 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_cell_refinement 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_data_reduction 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_structure_solution     'SHELXS-2013 (Sheldrick, 2013)' 
_computing_structure_refinement   'SHELXL-2013 (Sheldrick, 2013)' 
_computing_molecular_graphics      
; 
OLEX2 (Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K, 
& Puschmann, H., 2009) 
; 
_computing_publication_material   'WinGX (Farrugia, 1999)' 
  
_refine_special_details 
; 
 ? 
; 
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
'w=1/[\s^2^(Fo^2^)+(0.0458P)^2^+0.7566P] where P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      ? 
_atom_sites_solution_secondary    ? 
_atom_sites_solution_hydrogens    mixed 
_refine_ls_hydrogen_treatment     mixed 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        . 
_refine_ls_number_reflns          1922 
_refine_ls_number_parameters      126 
_refine_ls_number_restraints      0 
_refine_ls_R_factor_all           0.0480 
_refine_ls_R_factor_gt            0.0430 
_refine_ls_wR_factor_ref          0.1287 
_refine_ls_wR_factor_gt           0.1254 
_refine_ls_goodness_of_fit_ref    1.171 
_refine_ls_restrained_S_all       1.171 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
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loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_site_symmetry_order   
 _atom_site_calc_flag 
 _atom_site_refinement_flags_posn 
 _atom_site_refinement_flags_adp 
 _atom_site_refinement_flags_occupancy 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
C1 C -0.2214(3) 0.4162(2) 0.05512(9) 0.0174(4) Uani 1 1 d . . . . . 
C2 C -0.0183(3) 0.3432(2) 0.09975(9) 0.0182(4) Uani 1 1 d . . . . . 
H2A H 0.0734 0.2841 0.0681 0.022 Uiso 1 1 calc R U . . . 
H2B H -0.0909 0.2789 0.1334 0.022 Uiso 1 1 calc R U . . . 
C3 C 0.1616(3) 0.44099(19) 0.14230(9) 0.0174(4) Uani 1 1 d . . . . . 
H3A H 0.0709 0.5066 0.1711 0.021 Uiso 1 1 calc R U . . . 
H3B H 0.2501 0.4983 0.1091 0.021 Uiso 1 1 calc R U . . . 
C4 C 0.3453(3) 0.3563(2) 0.19155(9) 0.0183(4) Uani 1 1 d . . . . . 
H4A H 0.2549 0.2994 0.2244 0.022 Uiso 1 1 calc R U . . . 
H4B H 0.4324 0.2897 0.1623 0.022 Uiso 1 1 calc R U . . . 
C5 C 0.5336(3) 0.4472(2) 0.23560(9) 0.0181(4) Uani 1 1 d . . . . . 
H5A H 0.4476 0.5200 0.2616 0.022 Uiso 1 1 calc R U . . . 
H5B H 0.6365 0.4967 0.2031 0.022 Uiso 1 1 calc R U . . . 
C6 C 0.6976(3) 0.35978(19) 0.28923(9) 0.0188(4) Uani 1 1 d . . . . . 
H6A H 0.5937 0.3104 0.3215 0.023 Uiso 1 1 calc R U . . . 
H6B H 0.7818 0.2866 0.2630 0.023 Uiso 1 1 calc R U . . . 
C7 C 0.8895(3) 0.44712(19) 0.33420(9) 0.0173(4) Uani 1 1 d . . . . . 
H7A H 0.8099 0.5298 0.3545 0.021 Uiso 1 1 calc R U . . . 
H7B H 1.0123 0.4828 0.3035 0.021 Uiso 1 1 calc R U . . . 
C8 C 1.0170(3) 0.3582(2) 0.39464(10) 0.0213(4) Uani 1 1 d . . . . . 
H8A H 0.8917 0.3250 0.4252 0.026 Uiso 1 1 calc R U . . . 
H8B H 1.0870 0.2733 0.3734 0.026 Uiso 1 1 calc R U . . . 
C9 C 1.2166(3) 0.42989(19) 0.44144(9) 0.0172(4) Uani 1 1 d . . . . . 
O1 O -0.3709(2) 0.32655(14) 0.01868(7) 0.0239(3) Uani 1 1 d . . . . . 
H1 H -0.496(6) 0.372(4) -0.0052(16) 0.059(9) Uiso 1 1 d . . . . . 
O2 O -0.2510(2) 0.54463(14) 0.05291(7) 0.0238(3) Uani 1 1 d . . . . . 
O9 O 1.3510(2) 0.51934(15) 0.40831(7) 0.0242(3) Uani 1 1 d . . . . . 
H9 H 1.483(6) 0.548(3) 0.4406(15) 0.053(8) Uiso 1 1 d . . . . . 
O10 O 1.2566(2) 0.40404(15) 0.50543(6) 0.0226(3) Uani 1 1 d . . . . . 
 
 
loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
C1 0.0159(8) 0.0196(9) 0.0160(8) -0.0005(7) -0.0012(6) -0.0023(7) 
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C2 0.0170(8) 0.0183(9) 0.0184(8) -0.0010(7) -0.0034(6) 0.0009(7) 
C3 0.0146(8) 0.0185(9) 0.0183(8) -0.0004(7) -0.0028(6) 0.0001(7) 
C4 0.0157(8) 0.0193(9) 0.0189(8) -0.0005(7) -0.0036(6) 0.0010(7) 
C5 0.0154(8) 0.0196(9) 0.0185(8) -0.0007(7) -0.0033(6) 0.0002(7) 
C6 0.0178(8) 0.0179(9) 0.0195(8) -0.0008(7) -0.0045(7) 0.0000(7) 
C7 0.0160(8) 0.0169(8) 0.0181(8) 0.0007(7) -0.0034(6) -0.0007(7) 
C8 0.0200(9) 0.0192(9) 0.0228(9) 0.0018(7) -0.0072(7) -0.0024(7) 
C9 0.0157(8) 0.0150(8) 0.0203(8) -0.0001(7) -0.0008(6) 0.0012(6) 
O1 0.0210(7) 0.0187(7) 0.0295(7) -0.0014(5) -0.0109(5) -0.0004(5) 
O2 0.0220(7) 0.0181(7) 0.0289(7) 0.0000(5) -0.0091(5) 0.0004(5) 
O9 0.0212(7) 0.0309(8) 0.0191(6) 0.0019(5) -0.0044(5) -0.0096(6) 
O10 0.0206(6) 0.0272(7) 0.0185(6) 0.0036(5) -0.0057(5) -0.0035(6) 
  
_geom_special_details 
; 
 All esds (except the esd in the dihedral angle between two l.s. planes) 
 are estimated using the full covariance matrix.  The cell esds are taken 
 into account individually in the estimation of esds in distances, angles 
 and torsion angles; correlations between esds in cell parameters are only 
 used when they are defined by crystal symmetry.  An approximate (isotropic) 
 treatment of cell esds is used for estimating esds involving l.s. planes. 
; 
  
loop_ 
 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
C1 O2 1.223(2) . ? 
C1 O1 1.323(2) . ? 
C1 C2 1.497(2) . ? 
C2 C3 1.521(2) . ? 
C2 H2A 0.9900 . ? 
C2 H2B 0.9900 . ? 
C3 C4 1.527(2) . ? 
C3 H3A 0.9900 . ? 
C3 H3B 0.9900 . ? 
C4 C5 1.525(2) . ? 
C4 H4A 0.9900 . ? 
C4 H4B 0.9900 . ? 
C5 C6 1.527(2) . ? 
C5 H5A 0.9900 . ? 
C5 H5B 0.9900 . ? 
C6 C7 1.527(2) . ? 
C6 H6A 0.9900 . ? 
C6 H6B 0.9900 . ? 
C7 C8 1.527(2) . ? 
C7 H7A 0.9900 . ? 
C7 H7B 0.9900 . ? 
C8 C9 1.499(2) . ? 
C8 H8A 0.9900 . ? 
C8 H8B 0.9900 . ? 
C9 O10 1.228(2) . ? 
C9 O9 1.318(2) . ? 
O1 H1 0.89(3) . ? 
O9 H9 0.94(3) . ? 
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loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
O2 C1 O1 122.90(16) . . ? 
O2 C1 C2 124.36(16) . . ? 
O1 C1 C2 112.72(15) . . ? 
C1 C2 C3 115.18(15) . . ? 
C1 C2 H2A 108.5 . . ? 
C3 C2 H2A 108.5 . . ? 
C1 C2 H2B 108.5 . . ? 
C3 C2 H2B 108.5 . . ? 
H2A C2 H2B 107.5 . . ? 
C2 C3 C4 110.98(15) . . ? 
C2 C3 H3A 109.4 . . ? 
C4 C3 H3A 109.4 . . ? 
C2 C3 H3B 109.4 . . ? 
C4 C3 H3B 109.4 . . ? 
H3A C3 H3B 108.0 . . ? 
C5 C4 C3 114.07(15) . . ? 
C5 C4 H4A 108.7 . . ? 
C3 C4 H4A 108.7 . . ? 
C5 C4 H4B 108.7 . . ? 
C3 C4 H4B 108.7 . . ? 
H4A C4 H4B 107.6 . . ? 
C4 C5 C6 112.31(15) . . ? 
C4 C5 H5A 109.1 . . ? 
C6 C5 H5A 109.1 . . ? 
C4 C5 H5B 109.1 . . ? 
C6 C5 H5B 109.1 . . ? 
H5A C5 H5B 107.9 . . ? 
C7 C6 C5 113.86(15) . . ? 
C7 C6 H6A 108.8 . . ? 
C5 C6 H6A 108.8 . . ? 
C7 C6 H6B 108.8 . . ? 
C5 C6 H6B 108.8 . . ? 
H6A C6 H6B 107.7 . . ? 
C6 C7 C8 110.91(14) . . ? 
C6 C7 H7A 109.5 . . ? 
C8 C7 H7A 109.5 . . ? 
C6 C7 H7B 109.5 . . ? 
C8 C7 H7B 109.5 . . ? 
H7A C7 H7B 108.0 . . ? 
C9 C8 C7 116.41(15) . . ? 
C9 C8 H8A 108.2 . . ? 
C7 C8 H8A 108.2 . . ? 
C9 C8 H8B 108.2 . . ? 
C7 C8 H8B 108.2 . . ? 
H8A C8 H8B 107.3 . . ? 
O10 C9 O9 122.51(16) . . ? 
O10 C9 C8 122.46(16) . . ? 
O9 C9 C8 115.00(15) . . ? 
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C1 O1 H1 111(2) . . ? 
C9 O9 H9 108.3(18) . . ? 
  
loop_ 
 _geom_torsion_atom_site_label_1 
 _geom_torsion_atom_site_label_2 
 _geom_torsion_atom_site_label_3 
 _geom_torsion_atom_site_label_4 
 _geom_torsion 
 _geom_torsion_site_symmetry_1 
 _geom_torsion_site_symmetry_2 
 _geom_torsion_site_symmetry_3 
 _geom_torsion_site_symmetry_4 
 _geom_torsion_publ_flag 
O2 C1 C2 C3 -1.8(3) . . . . ? 
O1 C1 C2 C3 179.34(14) . . . . ? 
C1 C2 C3 C4 174.23(14) . . . . ? 
C2 C3 C4 C5 179.47(14) . . . . ? 
C3 C4 C5 C6 174.38(14) . . . . ? 
C4 C5 C6 C7 179.76(15) . . . . ? 
C5 C6 C7 C8 170.42(15) . . . . ? 
C6 C7 C8 C9 177.87(15) . . . . ? 
C7 C8 C9 O10 145.95(18) . . . . ? 
C7 C8 C9 O9 -36.1(2) . . . . ? 
  
loop_ 
 _geom_hbond_atom_site_label_D  
 _geom_hbond_atom_site_label_H  
 _geom_hbond_atom_site_label_A  
 _geom_hbond_distance_DH  
 _geom_hbond_distance_HA  
 _geom_hbond_distance_DA  
 _geom_hbond_angle_DHA  
 _geom_hbond_site_symmetry_A  
O1 H1 O2  0.89(3) 1.76(3) 2.6566(18) 177(3) 3_465 
O9 H9 O10  0.94(3) 1.73(3) 2.6673(17) 175(3) 3_866 
  
_refine_diff_density_max    0.288 
_refine_diff_density_min   -0.224 
_refine_diff_density_rms    0.050 
 
_shelxl_version_number 2013-4 
 
_shelx_res_file 
; 
TITL AzelaicAcid in P21/c #14 
CELL  1.54184   5.4938   9.4418  18.8258   90.000   95.673   90.000 
ZERR     4.00   0.0002   0.0003   0.0006    0.000    0.003    0.000 
LATT   1 
SYMM  - X, 1/2 + Y, 1/2 - Z 
SFAC  C    H    O 
UNIT  36   64   16 
MERG   2 
SHEL 7 0.80 
EQIV $1 -x-1, -y+1, -z 
HTAB O1 O2_$1 
EQIV $2 -x+3, -y+1, -z+1 
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HTAB O9 O10_$2 
FMAP   2 
PLAN    5 
SIZE     0.030   0.130   0.140 
ACTA 
BOND   $H 
CONF 
L.S.  20 
TEMP  -173.00 
WGHT    0.045800    0.756600 
FVAR       7.64177 
C1    1   -0.221437    0.416236    0.055116    11.00000    0.01589    0.01962 = 
         0.01601   -0.00047   -0.00121   -0.00225 
C2    1   -0.018275    0.343218    0.099748    11.00000    0.01695    0.01828 = 
         0.01843   -0.00101   -0.00342    0.00091 
AFIX  23 
H2A   2    0.073374    0.284093    0.068072    11.00000   -1.20000 
H2B   2   -0.090851    0.278866    0.133426    11.00000   -1.20000 
AFIX   0 
C3    1    0.161566    0.440991    0.142304    11.00000    0.01456    0.01852 = 
         0.01832   -0.00039   -0.00284    0.00012 
AFIX  23 
H3A   2    0.070912    0.506610    0.171142    11.00000   -1.20000 
H3B   2    0.250077    0.498269    0.109086    11.00000   -1.20000 
AFIX   0 
C4    1    0.345325    0.356325    0.191547    11.00000    0.01567    0.01928 = 
         0.01888   -0.00053   -0.00358    0.00103 
AFIX  23 
H4A   2    0.254855    0.299370    0.224424    11.00000   -1.20000 
H4B   2    0.432369    0.289720    0.162268    11.00000   -1.20000 
AFIX   0 
C5    1    0.533615    0.447189    0.235596    11.00000    0.01535    0.01958 = 
         0.01851   -0.00072   -0.00331    0.00017 
AFIX  23 
H5A   2    0.447605    0.519979    0.261555    11.00000   -1.20000 
H5B   2    0.636520    0.496678    0.203119    11.00000   -1.20000 
AFIX   0 
C6    1    0.697588    0.359777    0.289235    11.00000    0.01777    0.01786 = 
         0.01955   -0.00078   -0.00449    0.00003 
AFIX  23 
H6A   2    0.593746    0.310445    0.321509    11.00000   -1.20000 
H6B   2    0.781825    0.286588    0.263035    11.00000   -1.20000 
AFIX   0 
C7    1    0.889494    0.447115    0.334201    11.00000    0.01602    0.01689 = 
         0.01811    0.00072   -0.00340   -0.00066 
AFIX  23 
H7A   2    0.809930    0.529810    0.354522    11.00000   -1.20000 
H7B   2    1.012321    0.482788    0.303493    11.00000   -1.20000 
AFIX   0 
C8    1    1.017014    0.358205    0.394644    11.00000    0.01998    0.01917 = 
         0.02280    0.00182   -0.00718   -0.00239 
AFIX  23 
H8A   2    0.891715    0.325044    0.425160    11.00000   -1.20000 
H8B   2    1.086978    0.273317    0.373422    11.00000   -1.20000 
AFIX   0 
C9    1    1.216646    0.429893    0.441442    11.00000    0.01571    0.01504 = 
         0.02027   -0.00013   -0.00078    0.00124 
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O1    3   -0.370911    0.326549    0.018681    11.00000    0.02099    0.01867 = 
         0.02947   -0.00136   -0.01094   -0.00038 
O2    3   -0.250979    0.544627    0.052907    11.00000    0.02201    0.01814 = 
         0.02894    0.00001   -0.00912    0.00043 
O9    3    1.350991    0.519341    0.408314    11.00000    0.02118    0.03095 = 
         0.01907    0.00190   -0.00444   -0.00957 
O10   3    1.256631    0.404039    0.505435    11.00000    0.02062    0.02717 = 
         0.01849    0.00365   -0.00571   -0.00349 
H1    2   -0.495599    0.372344   -0.005179    11.00000    0.05883 
H9    2    1.482825    0.548358    0.440562    11.00000    0.05280 
HKLF    4 
 
REM  AzelaicAcid in P21/c #14 
REM R1 =  0.0430 for    1726 Fo > 4sig(Fo)  and  0.0480 for all    1922 data 
REM    126 parameters refined using      0 restraints 
 
END 
 
 
 
 
B-5: Data_Pyrazinamide_SebacicAcid 
  
_audit_creation_method            SHELXL-97 
_chemical_name_systematic 
; 
 ? 
; 
_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety           
 '2(C5 H5 N3 O), C10 H18 O4' 
_chemical_formula_sum 
 'C20 H28 N6 O6'  
_chemical_formula_weight          448.48 
 
loop_ 
 _atom_type_symbol 
 _atom_type_description 
 _atom_type_scat_dispersion_real 
 _atom_type_scat_dispersion_imag 
 _atom_type_scat_source 
 'C'  'C'   0.0181   0.0091 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0311   0.0180 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0492   0.0322 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
_space_group_crystal_system       triclinic 
_space_group_IT_number            2 
_space_group_name_H-M_alt         'P -1' 
_space_group_name_Hall            '-P 1' 
  
_shelx_space_group_comment 
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; 
The symmetry employed for this shelxl refinement is uniquely defined 
by the following loop, which should always be used as a source of 
symmetry information in preference to the above space-group names. 
They are only intended as comments. 
; 
  
loop_ 
 _space_group_symop_operation_xyz 
 'x, y, z' 
 '-x, -y, -z' 
  
_cell_length_a                    5.1790(2) 
_cell_length_b                    5.4406(2) 
_cell_length_c                    19.2691(7) 
_cell_angle_alpha                 94.342(3) 
_cell_angle_beta                  93.910(3) 
_cell_angle_gamma                 94.681(3) 
_cell_volume                      538.07(3) 
_cell_formula_units_Z             1 
_cell_measurement_temperature   100.00(10)  
_cell_measurement_reflns_used   4287 
_cell_measurement_theta_min     4.6040 
_cell_measurement_theta_max     73.7000 
  
_exptl_crystal_description        Block 
_exptl_crystal_colour             'Pale Yellow' 
_exptl_crystal_density_meas       ?  
_exptl_crystal_density_method     ?               
_exptl_crystal_density_diffrn     1.384           
_exptl_crystal_F_000              238 
_exptl_transmission_factor_min    ?                                              
_exptl_transmission_factor_max    ?                                              
_exptl_crystal_size_max           0.350 
_exptl_crystal_size_mid           0.200 
_exptl_crystal_size_min           0.100 
_exptl_absorpt_coefficient_mu     0.869 
_shelx_estimated_absorpt_T_min    0.751 
_shelx_estimated_absorpt_T_max    0.918 
_exptl_absorpt_correction_T_min                   0.84544 
_exptl_absorpt_correction_T_max                   1.00000 
_exptl_absorpt_correction_type            'multi-scan' 
_exptl_absorpt_process_details 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
Empirical absorption correction using spherical harmonics, 
 implemented in SCALE3 ABSPACK scaling algorithm. 
; 
  
_exptl_special_details 
; 
 ? 
; 
  
_diffrn_ambient_temperature 100.00(10)  
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_diffrn_radiation_wavelength 1.5418 
_diffrn_radiation_type 'Cu K\a' 
_diffrn_radiation_source 'SuperNova (Cu) X-ray Source' 
_diffrn_radiation_monochromator 'mirror' 
_diffrn_measurement_device_type 'SuperNova, Dual, Cu at zero, Atlas' 
_diffrn_detector_area_resol_mean 5.1768 
_diffrn_reflns_number             5733 
_diffrn_reflns_av_unetI/netI      0.0159 
_diffrn_reflns_av_R_equivalents   0.0159 
_diffrn_reflns_limit_h_min        -6 
_diffrn_reflns_limit_h_max        6 
_diffrn_reflns_limit_k_min        -6 
_diffrn_reflns_limit_k_max        6 
_diffrn_reflns_limit_l_min        -23 
_diffrn_reflns_limit_l_max        23 
_diffrn_reflns_theta_min          6.933 
_diffrn_reflns_theta_max          70.058 
_diffrn_reflns_theta_full         67.684 
_diffrn_measured_fraction_theta_max   0.984 
_diffrn_measured_fraction_theta_full  0.989 
_diffrn_reflns_Laue_measured_fraction_max    0.984 
_diffrn_reflns_Laue_measured_fraction_full   0.989 
_diffrn_reflns_point_group_measured_fraction_max   0.984 
_diffrn_reflns_point_group_measured_fraction_full  0.989 
_reflns_number_total              2026 
_reflns_number_gt                 1902 
_reflns_threshold_expression      'I > 2\s(I)' 
_reflns_Friedel_coverage          0.000 
_reflns_Friedel_fraction_max      . 
_reflns_Friedel_fraction_full     . 
  
_reflns_special_details 
; 
 Reflections were merged by SHELXL according to the crystal 
 class for the calculation of statistics and refinement. 
  
 _reflns_Friedel_fraction is defined as the number of unique 
 Friedel pairs measured divided by the number that would be 
 possible theoretically, ignoring centric projections and 
 systematic absences. 
; 
  
_computing_data_collection 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_cell_refinement 
; 
CrysAlisPro, Agilent Technologies, 
Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_data_reduction 
; 
CrysAlisPro, Agilent Technologies, 
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Version 1.171.36.28 (release 01-02-2013 CrysAlis171 .NET) 
(compiled Feb  1 2013,16:14:44) 
; 
_computing_structure_solution     'SHELXS-2013 (Sheldrick, 2013)' 
_computing_structure_refinement   'SHELXL-2013 (Sheldrick, 2013)' 
_computing_molecular_graphics      
; 
OLEX2 (Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K, 
& Puschmann, H., 2009) 
; 
_computing_publication_material   'WinGX (Farrugia, 1999)' 
  
_refine_special_details 
; 
 ? 
; 
_refine_ls_structure_factor_coef  Fsqd 
_refine_ls_matrix_type            full 
_refine_ls_weighting_scheme       calc 
_refine_ls_weighting_details 
'w=1/[\s^2^(Fo^2^)+(0.0448P)^2^+0.1746P] where P=(Fo^2^+2Fc^2^)/3' 
_atom_sites_solution_primary      ? 
_atom_sites_solution_secondary    ? 
_atom_sites_solution_hydrogens    mixed 
_refine_ls_hydrogen_treatment     mixed 
_refine_ls_extinction_method      none 
_refine_ls_extinction_coef        . 
_refine_ls_number_reflns          2026 
_refine_ls_number_parameters      154 
_refine_ls_number_restraints      0 
_refine_ls_R_factor_all           0.0355 
_refine_ls_R_factor_gt            0.0339 
_refine_ls_wR_factor_ref          0.0911 
_refine_ls_wR_factor_gt           0.0899 
_refine_ls_goodness_of_fit_ref    1.073 
_refine_ls_restrained_S_all       1.073 
_refine_ls_shift/su_max           0.000 
_refine_ls_shift/su_mean          0.000 
  
loop_ 
 _atom_site_label 
 _atom_site_type_symbol 
 _atom_site_fract_x 
 _atom_site_fract_y 
 _atom_site_fract_z 
 _atom_site_U_iso_or_equiv 
 _atom_site_adp_type 
 _atom_site_occupancy 
 _atom_site_site_symmetry_order   
 _atom_site_calc_flag 
 _atom_site_refinement_flags_posn 
 _atom_site_refinement_flags_adp 
 _atom_site_refinement_flags_occupancy 
 _atom_site_disorder_assembly 
 _atom_site_disorder_group 
C2 C -0.1144(2) 0.6643(2) 0.20111(6) 0.0238(3) Uani 1 1 d . . . . . 
H2A H -0.1355 0.5330 0.2306 0.029 Uiso 1 1 calc R U . . . 
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C3 C -0.3091(2) 0.6919(2) 0.14948(6) 0.0241(3) Uani 1 1 d . . . . . 
H3A H -0.4607 0.5795 0.1451 0.029 Uiso 1 1 calc R U . . . 
C5 C -0.0699(2) 1.0212(2) 0.11408(6) 0.0208(3) Uani 1 1 d . . . . . 
C6 C 0.1245(2) 0.9977(2) 0.16610(6) 0.0228(3) Uani 1 1 d . . . . . 
H6A H 0.2759 1.1104 0.1705 0.027 Uiso 1 1 calc R U . . . 
C7 C -0.0348(2) 1.2224(2) 0.06542(6) 0.0210(3) Uani 1 1 d . . . . . 
N1 N 0.10188(19) 0.81926(19) 0.21000(5) 0.0237(2) Uani 1 1 d . . . . . 
N4 N -0.28994(19) 0.87068(19) 0.10596(5) 0.0230(2) Uani 1 1 d . . . . . 
N7 N -0.2433(2) 1.2627(2) 0.02522(5) 0.0243(2) Uani 1 1 d . . . . . 
H7A H -0.390(3) 1.182(3) 0.0321(8) 0.029 Uiso 1 1 d . U . . . 
H7B H -0.228(3) 1.387(3) -0.0036(8) 0.029 Uiso 1 1 d . U . . . 
O7 O 0.18104(15) 1.33865(16) 0.06464(4) 0.0265(2) Uani 1 1 d . . . . . 
C8 C 0.6488(2) 1.0352(2) 0.31551(6) 0.0224(3) Uani 1 1 d . . . . . 
C9 C 0.8526(2) 1.0475(2) 0.37557(6) 0.0246(3) Uani 1 1 d . . . . . 
H9A H 0.9513 0.8998 0.3700 0.029 Uiso 1 1 calc R U . . . 
H9B H 0.7635 1.0377 0.4193 0.029 Uiso 1 1 calc R U . . . 
C10 C 1.0450(2) 1.2761(2) 0.38383(6) 0.0233(3) Uani 1 1 d . . . . . 
H10A H 0.9496 1.4266 0.3848 0.028 Uiso 1 1 calc R U . . . 
H10B H 1.1536 1.2770 0.3435 0.028 Uiso 1 1 calc R U . . . 
C11 C 1.2187(2) 1.2783(2) 0.45125(6) 0.0233(3) Uani 1 1 d . . . . . 
H11A H 1.1070 1.2722 0.4909 0.028 Uiso 1 1 calc R U . . . 
H11B H 1.3122 1.1266 0.4495 0.028 Uiso 1 1 calc R U . . . 
C12 C 1.4175(2) 1.5017(2) 0.46547(6) 0.0240(3) Uani 1 1 d . . . . . 
H12A H 1.3257 1.6544 0.4665 0.029 Uiso 1 1 calc R U . . . 
H12B H 1.5336 1.5061 0.4268 0.029 Uiso 1 1 calc R U . . . 
O8 O 0.47398(17) 0.84256(16) 0.31714(4) 0.0271(2) Uani 1 1 d . . . . . 
H8 H 0.351(3) 0.836(3) 0.2796(9) 0.041 Uiso 1 1 d . U . . . 
O9 O 0.64349(17) 1.17980(16) 0.27073(4) 0.0282(2) Uani 1 1 d . . . . . 
  
loop_ 
 _atom_site_aniso_label 
 _atom_site_aniso_U_11 
 _atom_site_aniso_U_22 
 _atom_site_aniso_U_33 
 _atom_site_aniso_U_23 
 _atom_site_aniso_U_13 
 _atom_site_aniso_U_12 
C2 0.0255(6) 0.0215(6) 0.0245(6) 0.0053(5) 0.0029(5) -0.0019(5) 
C3 0.0224(6) 0.0220(6) 0.0272(6) 0.0024(5) 0.0030(5) -0.0048(5) 
C5 0.0196(5) 0.0219(6) 0.0207(5) 0.0026(4) 0.0013(4) -0.0005(4) 
C6 0.0193(6) 0.0246(6) 0.0240(6) 0.0061(5) -0.0002(4) -0.0032(4) 
C7 0.0203(6) 0.0222(6) 0.0200(5) 0.0028(5) 0.0000(4) -0.0013(4) 
N1 0.0230(5) 0.0241(5) 0.0237(5) 0.0069(4) -0.0007(4) -0.0016(4) 
N4 0.0207(5) 0.0236(5) 0.0238(5) 0.0025(4) -0.0004(4) -0.0028(4) 
N7 0.0205(5) 0.0264(5) 0.0251(5) 0.0088(4) -0.0042(4) -0.0040(4) 
O7 0.0198(4) 0.0309(5) 0.0286(4) 0.0125(4) -0.0021(3) -0.0043(3) 
C8 0.0223(6) 0.0213(6) 0.0234(6) 0.0043(5) 0.0017(4) -0.0014(4) 
C9 0.0236(6) 0.0244(6) 0.0250(6) 0.0058(5) -0.0017(5) -0.0025(5) 
C10 0.0214(6) 0.0241(6) 0.0239(6) 0.0048(5) -0.0013(4) -0.0013(5) 
C11 0.0209(6) 0.0236(6) 0.0249(6) 0.0049(5) -0.0012(5) -0.0009(5) 
C12 0.0209(6) 0.0237(6) 0.0270(6) 0.0055(5) -0.0014(5) -0.0008(5) 
O8 0.0257(5) 0.0287(5) 0.0253(4) 0.0101(4) -0.0057(3) -0.0077(3) 
O9 0.0293(5) 0.0271(5) 0.0275(5) 0.0106(4) -0.0041(3) -0.0048(4) 
  
_geom_special_details 
; 
 All esds (except the esd in the dihedral angle between two l.s. planes) 
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 are estimated using the full covariance matrix.  The cell esds are taken 
 into account individually in the estimation of esds in distances, angles 
 and torsion angles; correlations between esds in cell parameters are only 
 used when they are defined by crystal symmetry.  An approximate (isotropic) 
 treatment of cell esds is used for estimating esds involving l.s. planes. 
; 
  
loop_ 
 _geom_bond_atom_site_label_1 
 _geom_bond_atom_site_label_2 
 _geom_bond_distance 
 _geom_bond_site_symmetry_2 
 _geom_bond_publ_flag 
C2 N1 1.3387(15) . ? 
C2 C3 1.3925(17) . ? 
C2 H2A 0.9500 . ? 
C3 N4 1.3336(16) . ? 
C3 H3A 0.9500 . ? 
C5 N4 1.3408(15) . ? 
C5 C6 1.3919(16) . ? 
C5 C7 1.5020(16) . ? 
C6 N1 1.3385(15) . ? 
C6 H6A 0.9500 . ? 
C7 O7 1.2403(14) . ? 
C7 N7 1.3283(15) . ? 
N7 H7A 0.869(16) . ? 
N7 H7B 0.912(16) . ? 
C8 O9 1.2114(14) . ? 
C8 O8 1.3317(14) . ? 
C8 C9 1.5058(16) . ? 
C9 C10 1.5203(16) . ? 
C9 H9A 0.9900 . ? 
C9 H9B 0.9900 . ? 
C10 C11 1.5275(15) . ? 
C10 H10A 0.9900 . ? 
C10 H10B 0.9900 . ? 
C11 C12 1.5227(16) . ? 
C11 H11A 0.9900 . ? 
C11 H11B 0.9900 . ? 
C12 C12 1.534(2) 2_886 ? 
C12 H12A 0.9900 . ? 
C12 H12B 0.9900 . ? 
O8 H8 0.926(18) . ? 
  
loop_ 
 _geom_angle_atom_site_label_1 
 _geom_angle_atom_site_label_2 
 _geom_angle_atom_site_label_3 
 _geom_angle 
 _geom_angle_site_symmetry_1 
 _geom_angle_site_symmetry_3 
 _geom_angle_publ_flag 
N1 C2 C3 121.30(11) . . ? 
N1 C2 H2A 119.4 . . ? 
C3 C2 H2A 119.4 . . ? 
N4 C3 C2 122.25(11) . . ? 
N4 C3 H3A 118.9 . . ? 
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C2 C3 H3A 118.9 . . ? 
N4 C5 C6 122.21(11) . . ? 
N4 C5 C7 118.44(10) . . ? 
C6 C5 C7 119.35(10) . . ? 
N1 C6 C5 121.18(11) . . ? 
N1 C6 H6A 119.4 . . ? 
C5 C6 H6A 119.4 . . ? 
O7 C7 N7 124.17(11) . . ? 
O7 C7 C5 119.54(10) . . ? 
N7 C7 C5 116.28(10) . . ? 
C2 N1 C6 116.96(10) . . ? 
C3 N4 C5 116.07(10) . . ? 
C7 N7 H7A 117.7(10) . . ? 
C7 N7 H7B 117.8(9) . . ? 
H7A N7 H7B 124.0(14) . . ? 
O9 C8 O8 123.66(11) . . ? 
O9 C8 C9 124.88(11) . . ? 
O8 C8 C9 111.46(10) . . ? 
C8 C9 C10 116.09(10) . . ? 
C8 C9 H9A 108.3 . . ? 
C10 C9 H9A 108.3 . . ? 
C8 C9 H9B 108.3 . . ? 
C10 C9 H9B 108.3 . . ? 
H9A C9 H9B 107.4 . . ? 
C9 C10 C11 110.31(9) . . ? 
C9 C10 H10A 109.6 . . ? 
C11 C10 H10A 109.6 . . ? 
C9 C10 H10B 109.6 . . ? 
C11 C10 H10B 109.6 . . ? 
H10A C10 H10B 108.1 . . ? 
C12 C11 C10 114.89(10) . . ? 
C12 C11 H11A 108.5 . . ? 
C10 C11 H11A 108.5 . . ? 
C12 C11 H11B 108.5 . . ? 
C10 C11 H11B 108.5 . . ? 
H11A C11 H11B 107.5 . . ? 
C11 C12 C12 112.86(12) . 2_886 ? 
C11 C12 H12A 109.0 . . ? 
C12 C12 H12A 109.0 2_886 . ? 
C11 C12 H12B 109.0 . . ? 
C12 C12 H12B 109.0 2_886 . ? 
H12A C12 H12B 107.8 . . ? 
C8 O8 H8 110.5(10) . . ? 
  
loop_ 
 _geom_torsion_atom_site_label_1 
 _geom_torsion_atom_site_label_2 
 _geom_torsion_atom_site_label_3 
 _geom_torsion_atom_site_label_4 
 _geom_torsion 
 _geom_torsion_site_symmetry_1 
 _geom_torsion_site_symmetry_2 
 _geom_torsion_site_symmetry_3 
 _geom_torsion_site_symmetry_4 
 _geom_torsion_publ_flag 
N1 C2 C3 N4 0.73(19) . . . . ? 
N4 C5 C6 N1 1.16(18) . . . . ? 
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C7 C5 C6 N1 -179.25(10) . . . . ? 
N4 C5 C7 O7 -168.86(10) . . . . ? 
C6 C5 C7 O7 11.54(17) . . . . ? 
N4 C5 C7 N7 10.94(16) . . . . ? 
C6 C5 C7 N7 -168.66(11) . . . . ? 
C3 C2 N1 C6 -1.43(17) . . . . ? 
C5 C6 N1 C2 0.53(17) . . . . ? 
C2 C3 N4 C5 0.92(17) . . . . ? 
C6 C5 N4 C3 -1.83(17) . . . . ? 
C7 C5 N4 C3 178.58(10) . . . . ? 
O9 C8 C9 C10 7.25(18) . . . . ? 
O8 C8 C9 C10 -173.30(10) . . . . ? 
C8 C9 C10 C11 173.33(10) . . . . ? 
C9 C10 C11 C12 -179.22(10) . . . . ? 
C10 C11 C12 C12 178.63(12) . . . 2_886 ? 
  
loop_ 
 _geom_hbond_atom_site_label_D  
 _geom_hbond_atom_site_label_H  
 _geom_hbond_atom_site_label_A  
 _geom_hbond_distance_DH  
 _geom_hbond_distance_HA  
 _geom_hbond_distance_DA  
 _geom_hbond_angle_DHA  
 _geom_hbond_site_symmetry_A  
C2 H2A O9  0.95 2.36 3.2476(15) 154.6 1_445 
C3 H3A O7  0.95 2.54 3.3833(14) 147.5 1_445 
C6 H6A O9  0.95 2.60 3.2855(14) 129.2 . 
N7 H7A O7  0.869(16) 2.546(15) 3.1780(13) 130.4(12) 1_455 
N7 H7B O7  0.912(16) 1.976(17) 2.8874(14) 177.8(14) 2_585 
O8 H8 N1  0.926(18) 1.790(18) 2.7147(13) 177.1(15) . 
  
_refine_diff_density_max    0.290 
_refine_diff_density_min   -0.169 
_refine_diff_density_rms    0.035 
 
_shelxl_version_number 2013-4 
 
_shelx_res_file 
; 
TITL Pyrazinamide_SebacicAcid_(1)1_1 in P-1 #2 
CELL  1.54184   5.1790   5.4406  19.2691   94.342   93.910   94.681 
ZERR     1.00   0.0002   0.0002   0.0007    0.003    0.003    0.003 
LATT   1 
SFAC  C    H    N    O 
UNIT  20   28   6    6 
MERG   2 
SHEL 7 0.82 
EQIV $1 x-1, y-1, z 
HTAB C2 O9_$1 
HTAB C3 O7_$1 
HTAB C6 O9 
EQIV $2 x-1, y, z 
HTAB N7 O7_$2 
EQIV $3 -x, -y+3, -z 
HTAB N7 O7_$3 
HTAB O8 N1 
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FMAP   2 
PLAN    5 
SIZE     0.100   0.200   0.350 
ACTA 
HTAB    2.00000 
BOND   $H 
CONF 
L.S.  10 
TEMP  -173.00 
WGHT    0.044800    0.174600 
FVAR      20.93984 
MOLE    1 
C2    1   -0.114387    0.664334    0.201111    11.00000    0.02550    0.02149 = 
         0.02449    0.00530    0.00288   -0.00187 
AFIX  43 
H2A   2   -0.135463    0.533021    0.230604    11.00000   -1.20000 
AFIX   0 
C3    1   -0.309058    0.691879    0.149481    11.00000    0.02235    0.02196 = 
         0.02716    0.00241    0.00296   -0.00478 
AFIX  43 
H3A   2   -0.460669    0.579461    0.145113    11.00000   -1.20000 
AFIX   0 
C5    1   -0.069916    1.021221    0.114083    11.00000    0.01963    0.02193 = 
         0.02067    0.00259    0.00128   -0.00050 
C6    1    0.124482    0.997739    0.166102    11.00000    0.01925    0.02462 = 
         0.02401    0.00612   -0.00024   -0.00323 
AFIX  43 
H6A   2    0.275906    1.110401    0.170526    11.00000   -1.20000 
AFIX   0 
C7    1   -0.034791    1.222371    0.065423    11.00000    0.02035    0.02224 = 
         0.01996    0.00282   -0.00001   -0.00132 
N1    3    0.101881    0.819262    0.210002    11.00000    0.02304    0.02407 = 
         0.02370    0.00689   -0.00073   -0.00160 
N4    3   -0.289940    0.870678    0.105958    11.00000    0.02068    0.02362 = 
         0.02381    0.00249   -0.00037   -0.00279 
N7    3   -0.243266    1.262682    0.025220    11.00000    0.02052    0.02640 = 
         0.02510    0.00883   -0.00416   -0.00398 
H7A   2   -0.389798    1.181818    0.032096    11.00000   -1.20000 
H7B   2   -0.227910    1.387486   -0.003633    11.00000   -1.20000 
O7    4    0.181041    1.338650    0.064636    11.00000    0.01979    0.03086 = 
         0.02864    0.01254   -0.00211   -0.00430 
MOLE    2 
C8    1    0.648838    1.035200    0.315513    11.00000    0.02230    0.02129 = 
         0.02343    0.00425    0.00171   -0.00141 
C9    1    0.852592    1.047508    0.375569    11.00000    0.02365    0.02438 = 
         0.02499    0.00579   -0.00168   -0.00253 
AFIX  23 
H9A   2    0.951338    0.899816    0.370036    11.00000   -1.20000 
H9B   2    0.763516    1.037717    0.419257    11.00000   -1.20000 
AFIX   0 
C10   1    1.045045    1.276088    0.383834    11.00000    0.02136    0.02406 = 
         0.02389    0.00482   -0.00129   -0.00127 
AFIX  23 
H10A  2    0.949618    1.426595    0.384833    11.00000   -1.20000 
H10B  2    1.153560    1.276966    0.343484    11.00000   -1.20000 
AFIX   0 
C11   1    1.218741    1.278346    0.451246    11.00000    0.02089    0.02358 = 
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         0.02487    0.00492   -0.00123   -0.00088 
AFIX  23 
H11A  2    1.106997    1.272174    0.490874    11.00000   -1.20000 
H11B  2    1.312182    1.126605    0.449454    11.00000   -1.20000 
AFIX   0 
C12   1    1.417521    1.501704    0.465470    11.00000    0.02091    0.02371 = 
         0.02703    0.00546   -0.00139   -0.00083 
AFIX  23 
H12A  2    1.325676    1.654401    0.466538    11.00000   -1.20000 
H12B  2    1.533620    1.506091    0.426756    11.00000   -1.20000 
AFIX   0 
O8    4    0.473981    0.842556    0.317137    11.00000    0.02570    0.02872 = 
         0.02526    0.01014   -0.00567   -0.00773 
H8    2    0.351258    0.836381    0.279643    11.00000   -1.50000 
O9    4    0.643488    1.179803    0.270729    11.00000    0.02926    0.02709 = 
         0.02755    0.01056   -0.00409   -0.00483 
HKLF    4 
 
REM  Pyrazinamide_SebacicAcid_(1)1_1 in P-1 #2 
REM R1 =  0.0339 for    1902 Fo > 4sig(Fo)  and  0.0355 for all    2026 data 
REM    154 parameters refined using      0 restraints 
 
END 
 
 
 
 
 
 
 
 
 
 
